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ABSTRACT 
 
Individuals often display a wide variety of phenotypic responses to drug treatment, in terms 
of both efficacy and side effects. Part of this variation appears to have an individual genetic 
basis which is not well understood. It is well established in the literature that most traits, 
including drug response, are not controlled by a single gene, but rather arise from multiple loci 
known as quantitative trait loci (QTL). This thesis investigated the genetic basis of individual 
variability of response to two antifungal agents whose targets are known—namely benomyl 
(an industrial fungicide) and ketoconazole (a medicinal fungicide). A collection of 33 
Saccharomyces cerevisiae yeast strains, sourced from the Saccharomyces Genome 
Resequencing Project (SGRP, Sanger Institute) was used to model individuals as these strains 
carry natural variation in terms of single nucleotide polymorphisms (SNPs) akin to human 
individuals. 
 
Drug response measurements using serial spot dilution and high-throughput 384-colony 
robotic pinning screens were used to select four SGRP strains on the basis of drug resistance 
or sensitivity relative to the laboratory strain BY. These were L-1374 that was sensitive to 
benomyl compared to BY; UWOPS87-2421 that was resistant to benomyl compared to BY; 
Y12 that was sensitive to ketoconazole compared to BY; DBVPG6044 that was resistant 
ketoconazole compared to BY. The four strains described were crossed individually with the 
BY laboratory strain and the resultant diploids were sporulated to obtain meiotic recombinant 
offspring. Spores were then subjected ten cycles of intercrossing in order to obtain advanced 
intercross lines (AILs); these contain reduced linkage disequilibrium between marker and trait 
genomic position and act to refine the localising potential of the QTL.  The segregant offspring 
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produced following the setup of AIL were subjected to studies to investigate the heritability of 
drug response to intermediate and high dose of benomyl or ketoconazole. It was concluded that 
in each of the crosses trialled, the drug response was a multigenic trait. Furthermore, the broad 
sense heritability estimates were high (L-1374×BY: H2 = 0.91 and 0.92 for response to 75 µM 
and 137.5 µM benomyl respectively; UWOPS87-2421×BY: H2 = 0.75 and 0.87 for response 
to 150 µM and 250 µM benomyl; Y12×BY: H2 = 0.9 and 0.88 for response to 60 µM and 100 
µM ketoconazole). This indicates that most of the variance seen in drug response arises due to 
genetic variance. Additionally, the relative drug sensitivity in each of the crosses trialled was 
found to be either a dominant trait (either partially or fully so). 
 
Finally QTL mapping through next generation sequencing bulk segregant analysis (NGS-BSA) 
confirmed the multigenic nature of the drug response in the selected strains. The effect of 
intermediate versus high dose drug treatment revealed that the QTL network is largely 
conserved between treatment regimens (L-1374×BY cross: three and five QTL upon treatment 
with 30 µM and 50 µM benomyl respectively; UWOPS87-2421×BY cross: nine and 18 QTL 
upon treatment with 45 µM and 80 µM of benomyl; Y12×BY cross: 41 and 56 QTL for 
response to 11.5 µM and 15 µM of ketoconazole; DBVPG6044×BY cross: 12 and 10 QTL for 
the response to 25 µM and 65 µM ketoconazole). In order to investigate the contribution of 
individual variation to drug response, the QTL network of the sensitive and the resistant strain 
for each drug were compared. It was revealed that although there is a conserved core of QTL 
for response to benomyl and ketoconazole respectively, the individual strains possess a 
considerable number of strain-specific QTL. This suggested that individual variation may 
indeed play a significant role in drug response. Analysis of the top-ranking QTL (in terms of 
LOD score) for each of the four strains revealed that each of them harboured genes that have 
literature-supported relationships to their relevant drug.  
III 
 
 
This thesis presents a significant contribution to existing literature in terms of elucidating 
the QTL network underlying individual response to benomyl and ketoconazole. The findings 
from this study have practical potential to provide improved insight into factors that can 
produce antifungal resistance (a growing and significant clinical problem). Furthermore, it 
provides insight into better therapeutic regimens that can improve medicinal treatment for 
individuals. 
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Δ Deletion  
 
 
 1 
 
Chapter 1: General Introduction 
 
1.1. Drug response—variation amongst individuals and the need for a 
new study paradigm 
Individuals often undergo a wide variety of responses to drug treatment. Drugs belonging 
to different therapeutic classes have been shown to vary extensively in their efficacy rates 
(Davidson et al., 1997; Spear et al., 2001). In addition to efficacy, individuals vary in terms of 
adverse reactions to drugs (Edwards & Aronson, 2000), which poses a significant healthcare 
problem (Lu, 1998; Pirmohamed & Park, 2001; Spear et al., 2001; Wilke et al., 2007). In the 
US (with similar statistics in other parts of the world), serious drug adverse reactions account 
for over 6% of hospitalisations, with over 100, 000 cases of fatal drug reactions (Lazarou et al., 
1998; Wilke et al., 2007). A large portion of this differential response has a genetic basis, as 
evidenced by twin heritability studies (Vesell, 1989),   and drug responses correlating with 
various mutations and polymorphisms in genes encoding drug targets and related processes 
(Meyer, 2000; Shastry, 2005; Spear et al., 2001; Wilke et al., 2007). Drug response is known 
to vary between individuals on a genetic level and the study of it through genetic means 
underpins the field of pharmacogenetics/genomics (Antman et al., 2012; Meyer, 2004; Nebert 
& Menon, 2001). While adverse reactions can be related to the mechanism of action of the 
drug, a smaller but significant portion of these are idiosyncratic, and difficult to predict based 
on previous knowledge but can have grave health consequences and higher mortality than the 
majority of adverse drug reactions (Pirmohamed et al., 2001; Wilke et al., 2007). An example 
is drug-induced liver injury that arises with a wide range of drug classes (from antibiotics to 
anti-inflammatories  (Wilke et al., 2007)). This suggests that the field of individual drug 
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response warrants further study in order to identify risk factors that can lead to adverse drug 
reactions and achieve optimal treatment for patients  
 
Traditional drug development programs are very costly (bringing a drug to market is 
estimated to cost more than US$1.8 billion (Paul et al., 2010)) and typically focus on developing 
drugs against a single target. However such drug development programs are not only costly  but 
are plagued by high attrition rates due to inadequate efficacy or intolerable side-effects  
suggesting that such single target approaches may not be enough for development of safe and 
effective drugs (Hopkins, 2008; Schadt et al., 2009). Analysis of the mode of action of salicylate 
is a prime example of a successful drug showing that assumption of a single target for a drug 
may not be justified as it acts on a network of targets (Figure 1.1). 
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Many highly-effective drugs on the market today are known to exert their action through 
several cellular targets—so-called “network pharmacology” or “polypharmacology” (Hopkins, 
2008; Imming et al., 2006; Keiser et al., 2009; Overington et al., 2006).  Like many phenotypes, 
drug responses are resistant to environmental perturbation. Such phenotypic stability is 
explained by underlying genetic interaction networks where disruption of a network node can 
be compensated by functional interaction by other member genes (Figure 1.2) (Huang, 2002, 
2004). 
 
  
Pathway Indirect effects on inflammation
Figure 1.1: Network pharmacology of the non-steroidal anti-inflammatory agent salicylate. While 
salycyclate is known as a “COX-2 inhibitor”, it also mediates its anti-inflammatory and analgesic 
effects through interactions with multiple pathways, such as NF-κB and MAPK. From (Huang, 
2002). 
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While the study of genetics was pioneered by Mendel’s idea of a single gene for a single 
trait, it has been shown since then that heredity is more complex than a matter of “either/or”.  It 
is well established that most inherited traits—for example sporulation efficiency in yeast 
(Deutschbauer & Davis, 2005) or height in humans (Lango Allen et al., 2010)—are quantitative, 
meaning they display and are controlled by multiple genetic loci. Even traits that have been 
traditionally been considered “single gene traits” often turn out to be modified by additional 
loci (Cutting, 2010; Nadeau, 2001) and the same principle of modifier loci may therefore apply 
to individual drug response, even when a drug is presumed to act through a single major target. 
However, mapping these multiple loci (which are known as quantitative trait loci or QTL) 
presents significant challenges—it cannot be done by the genetic analysis of single-genes 
Figure 1.2: A genetic interaction diagram of the hub genes ARP2, ARP40, BBC1, BIM1, BNI1, RAD27 
and SGS1, showing the network of compensatory genes. From (Boone et al., 2007). 
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strategies. Other approaches using prior knowledge to study  “candidate genes”   have not been 
effective for this purpose (Mackay et al., 2009) and do not account for traits that are mostly 
polygenic. Therefore, a study to map the DNA sequence basis of individual drug response will 
require a means to survey the whole genome in an unbiased manner. 
 
1.2. The genetics of quantitative traits 
 
Quantitative traits display a non-discrete, continuous phenotype (Figure 1.3) and are not 
fundamentally different from single gene traits (also known as Mendelian traits)—rather, the 
QTL follow Mendelian principles of inheritance (Burns, 1980; Falconer & Mackay, 1996a). 
However, a combination of factors such as multiple allelic combination of heterogeneous loci 
giving rise to the same phenotype, epistasis (interaction between genetic loci), environmental 
variance, and the variable and often small contribution of each locus leads to lack of distinction 
between phenotypic classes, thus producing the continuous phenotype characteristic of 
quantitative traits. A common assumption is that if the QTL underlying a phenotype act in an 
additive manner, the distribution of the phenotype will approach a normal distribution 
(depending on the number of underlying QTL) (Kruglyak & Lander, 1995). QTL can influence 
either the phenotype mean, phenotype variance, or a combination of both (Mackay et al., 2009). 
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variance 
Figure 1.3: A theoretical example of a quantitative trait. 
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The field of quantitative genetics was established by Ronald Fisher in 1918 (Nelson et al., 
2013), but the relative lag in development of molecular biology meant that there was a lack of 
tools for studying the molecular mechanisms of such traits until the 1980s (Mackay et al., 2009; 
Nelson et al., 2013). However since then the field has developed immensely. Quantitative 
genetic ideas have been instrumental in agriculture and selective breeding programmes in order 
to maximise traits of interest (Georges et al., 1995)  and they have provided invaluable insight 
for medicine to study the genetics of disease susceptibility (Manolio et al., 2009). Such ideas 
have answered questions about the fundamentals of what makes us who we are, from height 
and weight to intelligence levels (Lango Allen et al., 2010; Posthuma et al., 2005; Rankinen et 
al., 2006). A particular boon of quantitative genetic studies has been the fact that they often 
uncover causative loci that had no previously known relationship to the phenotype under 
investigation and thus greatly expand our knowledge of the molecular mechanisms of the 
organism (Mackay et al., 2009). Furthermore, variants in non-coding parts of the genome can 
make significant trait contribution (Glazier et al., 2002) adding emphasis to the need for  taking 
an unbiased genomic approach to understanding the molecular basis of trait variation. However 
despite its broad utility, the quantitative genetics field still has shortcomings in that few traits 
have been dissected fully in terms of finding all or even most of the QTL that account for a 
trait of interest. In addition, progressing from a locus (which may span hundreds of genes 
including the causal gene) to a causative genetic variant has been a persistent challenge in QTL 
studies (Flint & Mott, 2001). 
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1.2.1. Architecture of a phenotype 
Fisher proposed that the continuous phenotype variance of quantitative traits arises as a 
result of an infinitesimal model, where a very large number of loci each make a miniscule 
contribution towards the phenotype (Nelson et al., 2013). However, actual dissection of 
quantitative traits has shown this to be inaccurate: while multiple loci are indeed involved, their 
numbers are limited and their contribution to the overall phenotype is variable (Barton & 
Keightley, 2002; Mackay, 2001; Nelson et al., 2013).. Generally, there tend to be few loci of 
large effect and a large number of loci with small effect  
 
Is it genetic? 
Natural traits are not solely produced by genetics—they are the result of genes, environment, 
sex, and any possible interaction between those. Therefore, when looking at a variant 
phenotype, it first has to be determined how much of that variance has a genetic basis—that is, 
how much of the variance is heritable (Visscher et al., 2008; Wray & Visscher, 2008). The total 
variance of a phenotype can be described as: 
 
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒
= 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑑𝑢𝑒 𝑡𝑜 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 + 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑑𝑢𝑒 𝑡𝑜 𝑒𝑛𝑣𝑖𝑟𝑜𝑛𝑚𝑒𝑛𝑡
+ 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑑𝑢𝑒 𝑡𝑜 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 × 𝑒𝑛𝑣𝑖𝑟𝑜𝑛𝑚𝑒𝑛𝑡 
 
 
In a controlled experiment, the environment is kept constant and any variance caused by 
interaction between genotype and environment is cancelled out. In such cases, the broad sense 
heritability (H2; the total genetic contribution to the phenotype) can be defined: 
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𝐻2 =  
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑑𝑢𝑒 𝑡𝑜 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒
 
 
Broad sense heritability includes all contributing genetic effects—the additive effects of 
individual alleles (which is often the point of interest) as well as any dominance or epistatic 
effects. Therefore, to tease apart only the contribution of additive effects to the variance of the 
phenotype, narrow sense heritability (h2) can be defined: 
 
ℎ2 =
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑑𝑢𝑒 𝑡𝑜 𝑎𝑑𝑑𝑖𝑡𝑖𝑣𝑒 𝑒𝑓𝑓𝑒𝑐𝑡𝑠
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒
 
 
Heritability estimates range from zero to one. Heritability can only be estimated, because it 
is impossible to directly measure the amount of phenotypic variance due to either environment 
or genotype—it is only possible to measure the phenotype itself. Such estimates can thus be 
performed by controlling or eliminating one of the variables in the phenotype variance 
equation. For example, by having all study subjects in an identical environment, variance due 
to environment becomes zero.   Heritability can be estimated from relatedness, which can be 
assessed from identity-by-descent between siblings (Ritland, 2000; Visscher et al., 2006) or 
inferred from genetic marker-and phenotype similarities in groups of apparently unrelated 
individuals (Barton et al., 2002) . A number of ways exist of calculating heritability, such as 
through breeding response or through phenotype regression calculations between individuals 
of known relation such as parent-offspring pairs, full or half siblings or correlation between 
identical and fraternal twins (Visscher et al., 2008). Producing an estimate of heritability is 
usually the first step in a quantitative trait study as it determines whether the phenotype of 
interest can be studied by genetic means and if it can, what should be the scale of the study in 
order to investigate its genetic basis. 
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Methods for finding QTL 
Owing to the inherent nature of QTL no single locus alone contributes to the total phenotype 
i.e. no single locus has complete penetrance. An allele achieves complete “penetrance” when 
100% of individuals in a population have the allele displaying the phenotype. Classical 
methods used to map genes responsible for Mendelian traits (such as mutagenesis screens or 
positional cloning) are inadequate for pinning down the genetic basis of quantitative traits (Flint 
et al., 2001). Therefore, rigorous approaches for finding QTL demand that all QTL contributing 
to a phenotype of interest are identified simultaneously. Such approaches  rely on finding a 
statistically significant association between phenotype and genotype within a genetically 
heterogeneous population, known as the mapping population, that shows variance in the 
phenotype of interest (Falconer et al., 1996a; Mackay et al., 2009). It is not feasible to fully 
sequence the genomes of all the individuals in a mapping population, which can be several 
hundred to tens of thousands of individuals, in order to genotype them. Therefore, genotypic 
linkage studies are chiefly done by identifying genetic markers that are distributed evenly 
throughout the genome thence finding with which markers the phenotype of interest segregates 
with them. These days such genetic markers are usually single nucleotide polymorphisms 
(SNPs), but can also be insertion or deletion polymorphisms (indels), simple sequence repeats 
(microsatellites), or restriction fragment length polymorphisms (RFLPs) which are readily 
identifiable by PCR or gel sizing methodologies. The principle underlying QTL mapping is 
that upon meiotic recombination (either through generating crosses between inbred lines, or 
through historical recombination; described below), the markers of known position in the 
genome, will not associate with the QTL phenotypes (of unknown position) unless the markers 
are close to the genomic position of  the QTL. An underlying assumption of detecting such 
linkage is that the relevant marker and the QTL are in linkage disequilibrium (LD) i.e. do not 
General Introduction 
 
10 
 
segregate away from each other in multiple meiotic generations. The location and phenotypic 
contribution of the QTL can therefore be deduced by testing which markers exhibit a significant 
association with the phenotype under study. As this methodology can only resolve regions of 
the genome that contain a QTL (which may extend over hundreds of kilobases, and contain 
hundreds of genes), further fine-scale mapping is necessary. This may lead to resolving the 
QTL to the level of a causal quantitative trait nucleotide (QTN), giving a better understanding 
of the genetic basis of the phenotype (as discussed below) (Abiola et al., 2003; Flint et al., 
2001; Mackay et al., 2009). 
 
Linkage-based mapping of QTL 
Linkage-based mapping is a highly effective method for identifying causal loci for a 
phenotype. It relies on crossings between two parental populations, genetically and 
phenotypically different from each other, each of which carries polymorphic genetic markers 
distributed throughout the genome (Broman, 2001; Mackay et al., 2009; Miles & Wayne, 
2008). If the parents come from inbred lines subsequent genetic analysis is simpler because 
each marker site will have alleles homozygous to parent 1 or parent 2 (note that in the context 
of genetic markers, the term “allele” just denotes any genetic difference, such as an SNP; the 
marker alleles do not have to lie within a gene or have any phenotypic consequence).   While 
classical linkage-based QTL studies use organisms in which controlled crosses can be made, 
such investigation may also be made in humans (or other organisms not amenable to such 
manipulation) through the use of pedigree information. When controlled crosses are used,   
intercrosses (F2 genotypes) or backcrosses (BC1 genotypes) may be applied where each 
strategy has its own set of advantages and becomes part of different experimental designs.  
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A number of statistical methods can be used to establish significant marker-trait linkage 
(Broman, 2001; Doerge, 2002). The simplest is a single-marker test (t-test or ANOVA), 
performed independently at each marker. The shortcoming of this is that while it detects 
significant linkage, it fails to distinguish whether that is due to a closely-associated QTL or a 
more distant QTL with a greater effect and thus cannot localise a QTL sufficiently. To 
overcome this, interval mapping methods have been developed (Lander & Botstein, 1989). 
Simple interval mapping tests calculates potential marker-trait association at set recombination 
fractions from markers (usually every 0.1 centiMorgans; (cM)) between two markers (Balding, 
2006) to maximise the estimate of the genetic effect of an allele of interest.  Such mapping 
plots the output as a logarithm of odds (LOD) score along the tested genomic positions 
determining both the magnitude of the effect of the QTL and its position. A LOD score is a 
logarithmic ratio of the odds that the given marker-trait data occurs given a QTL is present (at 
the putative position) to the odds that the same data occurs given that there is no QTL present 
there (LOD=𝑙𝑜𝑔10
𝑃(𝑑𝑎𝑡𝑎 | 𝑄𝑇𝐿 𝑝𝑟𝑒𝑠𝑒𝑛𝑡)
𝑃 (𝑑𝑎𝑡𝑎 | 𝑛𝑜 𝑄𝑇𝐿)
). The LOD score is used to select a detection 
significance threshold, either based on a generic cut-off (3 is often used for these purposes, 
corresponding to a significance level of p < 0.001 of a QTL being present at the position being 
tested) or tailored to the particular experiment using permutation testing. A QTL is considered 
to lie within a certain confidence interval surrounding a peak on the LOD plot. However, simple 
interval mapping assumes the presence of a single QTL between markers and is deficient at 
resolving broad QTL peaks. An extension of this method is composite interval mapping, which 
includes information about surrounding QTL and is better suited for resolving linked or 
interacting QTL. 
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The basic concept of a linkage-based QTL mapping experiment, illustrated using an 
intercross between two inbred lines, is described in Figure 1.4. 
 
 
 
  
1. Cross parental inbred lines (usually divergent in the phenotype of interest). A genetic 
map of the markers must be present for positional mapping. 
Phenotype Genotype 
Genetic markers, 
allelic between parents. 
POSITION KNOWN. 
QTL contributing to 
increased body weight. 
POSITION UNKNOWN. 
M1 
P1 P2 
M1 M2 M3 M4 M2 M3 M4 
Body weight 
Parental 
population 1 (P1) 
Parental 
population 2 (P2) 
2. Produce F1 hybrid of intermediate phenotype. 
Body weight 
Hybrid offspring 
F1 
M1 M2 M3 M4 
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3. Create either intercrosses between F1 individuals (F2), or backcrosses to either one 
of the parents (BC1 or BC2). This cross results in offspring containing a mixture of 
recombinant genomic portions from P1 and P2. Example shown for generation of 
F2. 
Body weight 
Intercross offspring 
F2 
M1 M2 M3 M4 
Individual 1 
M1 M2 M3 M4 
Ind. 
2 
M1 M2 M3 M4 
Ind. 
3 
M1 M2 M3 M4 
Ind. 
5 
Ind. 
6 
M1 M2 M3 M4 
Ind. 
4 
M1 M2 M3 M4 
Note: F2 individuals inherit either two, one, or no alleles of the QTL contributing to body weight 
increased variance in phenotype distribution compared to P1 and P2 individuals. 
4. Genotype each marker, to determine parent of origin of that genomic region. Sort the 
mapping population by genotype at each marker and record phenotypes of each 
individual. Carry out statistical tests, to determine whether there is statistically 
significant association between a particular genotype, and the phenotype in 
question—i.e. find loci where the phenotype segregates with the genotype. The 
phenotype difference between marker genotypes should increase the nearer a marker 
lies to the true QTL (but is also affected by the magnitude of the QTL 
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Association mapping for QTL 
Another technique for identifying QTL is association mapping. Association mapping also 
relies on genotyping of markers distributed throughout the genome, but unlike linkage-based 
studies, association mapping studies do not rely on inbred lines but rather use natural outbred 
populations, which have undergone many generations of historical recombination  minimising 
linkage disequilibrium as for example between a QTL and genetic markers (Mackay et al., 
2009). Association mapping is therefore of great use particularly in organisms that are not 
amenable to genetic manipulation, such as inbred lines, or in humans, or when no pedigree 
information is available. The principle of association mapping relies on finding a statistically 
significant association between a causative genetic locus (or more commonly a genetic marker 
linked to the allele of the locus that contributes to the phenotype) and a phenotype difference 
between two groups—one displaying the phenotype of interest (“cases”) and  a group without 
the phenotype (“controls”). These studies range from highly focused candidate polymorphisms 
5. Plot statistical significance of linkage of marker to phenotype (denoted here as “LOD 
score”; explained below) along the genetic map to determine the QTL map position. 
Such significance of linkage can be determined through single marker analysis 
(black diamonds), simple interval mapping (blue line) or composite interval mapping 
(green line).  
(Doerge, 2002) 
Threshold of significance 
for detecting QTL 
 
Figure 1.4: Overview of the premise of linkage-based QTL mapping. (Broman, 2001; Doerge, 2002; Mackay 
et al., 2009) 
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or genes studies  which may or may not be turn out to be involved in a phenotype, to the all-
encompassing genome-wide association studies (GWAS), which expand the search to the 
whole genome in an unbiased manner (Balding, 2006). In each case, the magnitude of the effect 
of the locus allele on the trait is estimated through an odds ratio—the ratio of the odds that the 
trait is present in individuals that carry that allele to the odds of the trait being present in 
individuals without that allele at any particular point in the genome (Clarke et al., 2011). The 
premise of an association study is illustrated in Figure 1.5. 
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Figure 1.5: Overview of the premise of association studies for detecting QTL for type I diabetes. Adapted 
from (Mackay et al., 2009) 
 
Association mapping depends on the idea of common disease-common variant (Gibson & 
Muse, 2009).  An association will only be detected if the causative allele is present at a 
relatively high frequency in the case group; rare alleles (i.e. ones with a frequency of less than 
Mating and 
recombination over 
multiple generations 
M1 M2 M3 M4 
QTL contributing to 
type I diabetes 
Individual 6 
M1 M2 M3 M4 
Individual 3 
Individual 2 
Individual 1 
Individual 4 
Individual 5 
Initial haplotypes 
Individual 1 
Individual 3 
Individual 5 
M1 M2 M3 M4 
Individual 6 
Individual 2 
Individual 4 
M1 M2 M3 M4 
Segregate mapping population into individuals displaying 
the phenotype of interest, and a matched control pool that 
doesn’t display the phenotype. 
Individuals with type I diabetes 
(cases)  
Unaffected control individuals 
Genotype both populations at each marker; 
Identify markers that are significantly over-
represented the phenotype of interest population—i.e. 
find loci where the phenotype associates with the 
genotype. 
Chromosomal position 
-l
o
g
1
0
(P
) 
General Introduction 
 
17 
 
5% in the population) are unlikely to be detected (Balding, 2006). The premise behind this is 
that widespread diseases (or other common, non-disease phenotypes, such as height) are caused 
by numerous causative alleles, which all act in an additive manner to contribute to the 
phenotype. Because these alleles often  each add only small contributions, such studies  require 
very high numbers of individuals—in the order of a minimum of 500, to thousands—in order 
to have enough statistical power to detect causative loci (Gibson et al., 2009; Lewis & Knight, 
2012). Additionally, association studies can be hampered by a variety of issues that can either 
lead to true associations going undetected, or spurious false associations appearing as 
significant. Missing genotypes, genotyping error (such as through deficiencies on SNP 
microarray chips, the major method for genotyping individuals today), or insufficient 
distinction in phenotype between case and control groups can lead to false negatives. On the 
other end of the spectrum, underlying population stratification (i.e. different allele frequencies 
between the two groups, which do not actually contribute to the phenotype) which can occur if 
the case and control populations have not been matched genetically, can lead to false positives.  
 
 
1.2.2. Methods for genotyping 
Until the major molecular biology advances in the 1970s and 1980s allowed DNA-level 
genotyping, the study of quantitative traits was largely limited to those that had linkage to some 
visible or measurable phenotype (Chial, 2008). However, since the 1980s a number of 
techniques have been developed—such as RFLP analysis (Lander et al., 1989) or high-
resolution DNA melting analysis (Reed et al., 2007)—that allowed precise molecular 
genotyping and allowed a vast expansion of the study of quantitative genetics. A particularly 
valuable development was that of genotyping microarrays, which allowed easy and high-
throughput genotyping of individuals—although the major limitation with these is that 
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genotyping was largely restricted to the particular SNPs represented on commercially available 
arrays (Gresham et al., 2008). While array-based genotyping is still widely used, the recent 
advances in next-generation sequencing (NGS) have made considerable contribution to the 
field of genotyping. Methods such as genotyping-by-sequencing (GBS) or restriction site-
associated DNA sequencing (RAD-Seq) have allowed direct and tailorable genotyping 
(Jamann et al., 2015). Furthermore, the falling costs of NGS (van Dijk et al., 2014) now make 
whole-genome sequencing possible even for small laboratories and have greatly enhanced the 
ability to find high-density high-quality genomic markers. Genotyping using NGS is discussed 
in greater detail in Chapter 5.  
 
Making sense of the QTL—narrowing down to causative variants 
Owing to limitations in terms of genotyping and obtainable sample numbers, an initial “first 
pass” scan of the genome will produce candidate QTL—however, these QTL may not be 
informative in themselves as they may cover a large area 10 cM or around 2 000 average sized 
genes in the case of humans. This may be because of insufficient segregating progeny to narrow 
down the QTL peak or an insufficiently dense marker map (Abiola et al., 2003; Flint et al., 
2001; Glazier et al., 2002). Therefore, further work usually needs to be done to narrow down 
the QTL in order to identify a quantitative trait gene (QTG) or better, a quantitative trait 
nucleotide (QTN). The first step in such refinement is additional fine scale mapping using an 
increased number of progeny and markers.  Refined analysis becomes feasible at this point, as 
only the narrowed-down candidate region is examined instead of the entire genome in order to 
achieve a more manageable QTL region of around 1 cM or where it becomes practicable to test 
each gene or genetic variant individually. Selection of candidate genes based on function or 
association between trait and polymorphisms in coding/regulatory regions becomes more 
justifiable. Additional evidence can be gathered based on mRNA or protein expression levels 
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(Mackay et al., 2009). However, the best formal proof of a causal QTG or QTN is through 
allelic exchange or introgression of the locus into another strain and observation of a change in 
phenotype. To this end, methods such as reciprocal hemizygocity analysis have been developed 
to test the contribution of candidate gene alleles to the phenotype (Liti & Louis, 2012; 
Steinmetz et al., 2002).   
 
 
1.2.3. Addressing limitations in QTL mapping 
There are a number of limitations of a QTL study. First are factors that kerb the power of a 
study (“power” in this context means the chance of detecting a QTL). This is usually directly 
related to the size of the mapping population—greater populations have greater power, as QTL 
of moderate to small effect have a greater chance of being detected. However, the genotyping 
costs associated with increased population size eventually become prohibitive. Therefore, as a 
trade-off between the two factors, mapping populations of several hundred individuals or 
greater are generally considered acceptable, as while being reasonably economical, this size 
also allows detection of QTL that only contribute 5% to the phenotype (Broman, 2001). One 
promising alternative to such limitations is bulk segregant analysis (BSA). BSA (described in 
greater detail in Chapter 5) depends on grouping individuals based on whether they express the 
phenotype of interest or not and then genotyping them en masse allowing for vastly increased 
numbers of individuals to be assayed. In BSA, the presumption is that any marker that is 
significantly associated with the phenotype will be over-represented in the “phenotype 
positive” pool compared to the control pool (Schlotterer et al., 2014). 
 
While linkage disequilibrium between markers and QTL position is advantageous when it 
comes to coarse mapping, that is not the case when one is performing fine mapping.   High LD   
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usually seen in inbred lines used for QTL studies makes it impossible to narrow the candidate 
region. LD may be reduced by increasing the number of recombination events sampled such 
as through creation of advanced intercross lines (AILs) between parental inbred strains through 
repeated rounds of random intercrossing (Darvasi & Soller, 1995). This has been shown to be 
highly effective for narrowing the confidence interval of the putative QTL and improving 
resolution of its location (Parts et al., 2011). AIL approaches are used in this dissertation and 
are discussed further in Chapter 4. 
 
QTL structure also presents a potential issue for detection. A repeated finding is the 
occurrence of linked QTL (Figure 1.6). Occasionally, QTL of similar effect on the trait are 
found grouped together into a “super-QTL” on the chromosome; this is not so much of a 
problem because fine mapping can resolve them into distinct loci. What does pose a problem 
is the linkage of QTL of opposite effect—if marker density is sparse, these will group as a 
single QTL and the likelihood of detecting them will be reduced or non-existent. Possible 
solutions to this would be either genotyping more markers or decreasing the amount of LD, 
such as through creation of AILs. This is also discussed in greater detail in Chapter 4.  
 
Figure 1.6: Confounding effects of linked QTL. Genotyping an insufficient number of markers (black tick 
marks) could lead to (A) linked small-effect QTL acting in the same direction being detected as a single 
large-effect QTL or (B) linked QTL acting in opposite directions going undetected. Additional markers 
(red tick marks) would be required to resolve these effects. 
 
Which QTL are able to be found is limited by the starting genetic variation in the founder 
strains. For instance, if a locus isn’t polymorphic between the parental strains in a cross, 
naturally it will never get detected—even if it can contribute to the phenotype. Therefore, one 
A B 
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must be careful when drawing conclusions based on studies with limited starting genetic 
diversity, or ones that use a single parental cross. Studies in yeast have illustrated genetic 
heterogeneity—a QTN found responsible for a trait in one set of parents did not have the same 
effect in other genetic backgrounds (Deutschbauer et al., 2005; Gerke et al., 2006; Sinha et al., 
2006; Steinmetz et al., 2002). Furthermore, examining multiple parental strains when studying 
a phenotype has reaped a significantly higher number of QTL than in any single cross (Cubillos 
et al., 2011; Ehrenreich et al., 2012) and multiparental mating strategies have highlighted a 
similar advantage from incorporating information from multiple strains into a single 
experiment (Cubillos et al., 2013; Treusch et al., 2015). Another factor that may affect variable 
QTL detection between strains is due to the masking effect from major-effect loci that may be 
present in some strains but not others; it has been shown that eliminating or controlling for the 
presence of major-effect QTL can aid detection of minor-effect QTL (Kim & Fay, 2009; Sinha 
et al., 2008). 
 
1.3. Saccharomyces cerevisiae and the power of yeast genetics 
1.3.1. Yeast as a model organism 
The budding yeast Saccharomyces cerevisiae has long been a genetic model organism of 
choice not only thanks to its close association with humans throughout history, but also owing 
to several appealing aspects of its biology. Yeast is an experimentally tractable, non-hazardous 
organism with simple survival requirements and a mere 90 minute doubling time making it 
ideal for laboratory work. It has been a leading genetic model organism for over 70 years 
(Barnett, 2007). It was the first eukaryote to undergo transformation with plasmids (Hinnen et 
al., 1978), to have its genome sequenced (Goffeau et al., 1996) and have a genome-wide 
deletion mutant array (DMA) constructed (Giaever et al., 2002; Winzeler et al., 1999). It is 
likely to remain an excelent model system for several reasons. Its amenability to homologous 
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recombination has led to the development of PCR-mediated gene disruption, which dispensed 
with the requirement to clone genes and improved the ability to study genes of unknown 
function (Baudin et al., 1993; Lorenz et al., 1995). Yeast can exist as either a haploid 
(possessing either the MATa or the MATα mating type) or a diploid (where cells of opposite 
mating type fuse to give MATa/α cells) (Figure 1.7 A). Most natural isolate strains are 
homothallic due to the presence of the HO locus, which encodes a site-specific endonuclease 
that allows mating type switching in haploid cells (mechanism illustrated in Figure 1.7.B). As 
a model organism, presence of the HO locus  precludes  stable haploid lines because during 
mitotic proliferation the mother cell switches mating and mates with its progeny to reconstitute 
a MATa/α diploid (Herskowitz, 1988). However, inactivation of the HO locus (such as through 
a null mutation, as is the case with most laboratory strains) eliminates this phenomenon, and 
makes cells heterothallic. This allows for controlled intercrosses and the option to study genes 
either in haploids (so that effects of recessive mutations can be examined) or diploids (where 
dominance effects or interactions in a hybrid background or complementation may be studied). 
Furthermore, yeast has a small (~12Mb) and exon-rich yeast genome  with genes representing 
over 70% of genomic material (Sherman, 2002). These properties facilitate genomic 
approaches, such as whole-genome sequencing analysis or the construction of genomic 
resources (like the DMA, which consists of individual null deletions of ~80% of the genome, 
each replaced by an antibiotic resistance marker) (Botstein & Fink, 2011; Duina et al., 2014). 
It is the best characterised eukaryotic genome to date and has a world-wide active scientific 
community and has centralised analytical resources (Saccharomyces Genome Database, SGD 
(Cherry et al., 2012)).  
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Figure 1.7: Life cycle and mating type switching in Saccharomyces cerevisiae.  
A. Life cycle of Saccharomyces cerevisiae. Heterothallic haploid cells can propagate as stable lines through 
mitotic division. Proximity of a haploid of the opposite mating type can lead to a mating event and formation 
of a MATa/α diploid, which likewise can grow asexually. Encountering carbon or nitrogen limiting 
conditions triggers sporulation—the meiotic conversion of a diploid cell to four haploid spores enclosed in 
an ascus (sporulation sac). Spores exist in a vegetative state until favourable conditions arise, when they 
germinate and resume growth. Diagram from (Duina et al., 2014). 
B. Mating type switching in homothallic yeast. Mating type is determined by the cassette expressed at the 
MAT locus on chromosome three (green). Additionally, yeast carry silent mating type cassettes at the HML 
(α genes) and HMR (a genes). The Ho endonuclease creates a double strand break at the MAT locus. This 
is followed by a gene conversion event which puts the sequence of the opposite mating type in the MAT 
locus. Illustrated is the conversion of MATa to MATα. 
 
 
Yeast serves as an attractive model of a general eukaryotic cell, as 30% of its genes are 
homologous to human disease-related genes (Foury, 1997), and its essential cellular 
mechanisms show good conservation to other systems. Information gained in yeast allows 
formulation of specific hypotheses seeking similar mechanisms in mammalian cells serving as 
a filter for these more costly and genetically less tractable systems. This approach has been 
successful for multiple yeast-based studies, whose findings have provided information on 
disease progression and treatment in humans (Couplan et al., 2011; Fishel et al., 1993; 
Munkacsi et al., 2011; Parsons et al., 2006; Pearce et al., 1999). Furthermore, natural isolate 
yeast strains have been reported to contain similar levels of genetic variation to human 
individuals (Dowell et al., 2010), and can thus be used as a proxy for human individuals in 
studies of drug response, a key point in this dissertation. 
A 
HMR (a) MATa HML (α) Chrm 3 
HML (α) HMR (a) 
HO 
HMR (a) MATα HML (α) 
B 
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1.3.2. Natural genetic variation in Saccharomyces cerevisiae 
Saccharomyces cerevisiae is abundant all over the world and is found in a wide variety of 
niches, ranging from strains domesticated for brewing and baking purposes to wild isolates 
(Fay & Benavides, 2005; Liti et al., 2009; Schacherer et al., 2009). Despite this, a vast bulk of 
yeast research has been carried out in the laboratory strain S288C—a progenitor of the EM93 
strain isolated from Californian rotting figs by Emil Mrak in 1938 (Mortimer & Johnston, 
1986). The establishment of S288C as a pioneer in yeast research is due to its natural 
heterothallism, lack of flocculence in liquid growth and simple nutritional requirements. Its 
ubiquity led to further developments in this background, such as the introduction of 
auxotrophic markers and antibiotic resistance cassettes generating the widely used BY 
laboratory strains (Brachmann et al., 1998; Winston et al., 1995) also genome sequencing and 
creation of the DMA, which established S288C as the “reference strain” in the literature. 
However, findings based on a single genetic background carry limitations. S288C carries 
mitochondrial defects due to a mutation in HAP1 (Sherman, 2002) and has an extremely high 
rate of petite colony formation that are produced by cells which have lost their mitochondrial 
genome  (Dimitrov et al., 2009). It also has a low sporulation rate (Deutschbauer et al., 2005) 
which is a drawback and high transposon content (Liti et al., 2009) compared to most other 
yeast strains. Moreover, population genomic studies have shown S288C to be a genetic and 
phenotypic outlier compared to the majority of other yeast strains (Strope et al., 2015; 
Warringer et al., 2011). This places in question how applicable findings solely from this strain 
are to general biology.  
 
Starting from 2005, there has been an increased drive to study natural genomic variation in 
diverse populations of Saccharomyces cerevisiae. In particular, the development of next-
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generation sequencing (NGS) techniques and dropping costs of sequencing have greatly aided 
genomic exploration (Metzker, 2010). Whole-genome sequencing of non-S288C strains 
uncovered the presence of multiple inversions, translocations, copy number variants (CNVs) 
and non-reference open reading frames (ORFs)—for example, 34 new genes in EC1118 (the 
most widely used wine strain worldwide) involved in metabolism and sugar and nitrogen 
transport, which may contribute to its fermentative abilities (Engel & Cherry, 2013). There 
have also been a number of population genetic studies to describe diversity between different 
strains (Aa et al., 2006; Ayoub et al., 2006; Ben-Ari et al., 2005; Fay et al., 2005). The first 
attempt to capture species-wide variation involved microarray scanning of the genomes of a 
compendium of diverse strains against S288C and detected almost two million SNPs and 
almost 4000 deletions (Schacherer et al., 2007; Schacherer et al., 2009). These findings support 
the need to expand beyond the reference strain and to encapsulate a greater degree of yeast 
population genomic resources in order to paint a more representative picture of phenotypes. 
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1.3.3. Saccharomyces Genome Resequencing Project (SGRP) 
A major insight into species-wide genomic variation was provided by the Saccharomyces 
Genome Resequencing Project (SGRP) which aimed to characterise the extent of genomic 
variation in S. cerevisiae in order to identify genetic lineages and to ascertain the influence of 
human activity on the population structure of yeast species (Liti et al., 2009). The 33 S. 
cerevisiae strains examined in this work came from sources ranging from lab strains, clinical 
isolates, food and fermentation applications as well as natural isolates from a wide range of 
geographical locations (Figure 1.8). 
 
 
Most of these strains have been modified through the introduction of an Δho null deletion 
to make them heterothallic and thus amenable to genetic studies (Cubillos et al., 2009). The 
characteristics of this collection are described in greater detail in Chapter 3. 
  
Figure 1.8: Phylogenetic tree of S. cerevisiae isolates 
used in SGRP. Adapted from (Liti et al., 2009) 
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1.3.4. Investigation of quantitative traits in yeast 
Saccharomyces cerevisiae has been at the forefront of studies of the genetic basis of 
quantitative traits. The first single study to go from the initial QTL screen to causative genes 
was one investigating the genetic basis of differential heat tolerance between a yeast lab strain 
(S96) and a clinical isolate strain  YJM789  (Steinmetz et al., 2002). Yeast have also been 
amenable to fine-scale dissections of QTL down to causative nucleotides or quantitative trait 
nucleotides (QTN), on a level that’s unparalleled in other species (Ben-Ari et al., 2006; 
Deutschbauer et al., 2005; Diezmann & Dietrich, 2011; Steinmetz et al., 2002). Expression 
QTL (eQTL) and protein QTL (pQTL) have been described, which are QTL that underlie 
heritable variation in gene transcript and protein levels respectively (Albert et al., 2014; Brem 
& Kruglyak, 2005; Brem et al., 2002; Foss et al., 2007).  Importantly, Ehrenreich et al. 
developed the idea of extreme QTL (X-QTL)—a form of bulk segregant analysis (BSA) which 
takes advantage of yeast high-throughput culturing and phenotyping techniques in order to 
work with extremely large numbers of meiotic segregants,  on the order of 107 individuals  
(Ehrenreich et al., 2010). This and other BSA approaches have proven fruitful because of their 
economical genotyping and increased power through the use of pooled populations (Ehrenreich 
et al., 2012; Ehrenreich et al., 2010; Segrè et al., 2006; Swinnen, Schaerlaekens, et al., 2012; 
Wenger et al., 2010).  
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1.4. Studying drug response as a quantitative trait 
A range of studies has explored individual drug response in a genome-wide manner in a 
variety of systems (Avsaroglu et al., 2007; Brown et al., 2014; Martinelli-Boneschi et al., 
2013). The current study will only summarise what has been done in that respect in yeast using 
different genetic backgrounds in lieu of individual variation. 
 
1.4.1. Individual basis of drug response—studies in yeast 
A large contribution to pharmacogenomics in yeast has been gained from the BY×RM cross 
(between the RM11 wine strain and the BY laboratory strain) (Ehrenreich et al., 2009). 
Perlstein et al. used this cross to uncover 124 QTL to a library of 100 chemically diverse 
compounds (Perlstein et al., 2007) while the increased detection power of large mapping 
populations was illustrated by Bloom et al. and Ehrenreich et al. using similarly diverse panels 
of small molecules (using a 46 and 17 member chemical library respectively) (Bloom et al., 
2013; Ehrenreich et al., 2010). Using diverse genetic backgrounds in order to sample from a 
broader range of genetic loci proved fruitful as it revealed a wide range of novel QTL, even to 
previously-investigated compounds (Cubillos et al., 2011; Ehrenreich et al., 2012; Kim & Fay, 
2007; Kim et al., 2009). 
 
In order to study drug response as a quantitative trait, the current dissertation sought to 
investigate the genetic basis of natural drug response from the yeast of the SGRP collection of 
wild type yeast. To this end, two antifungal agents—benomyl and ketoconazole—were selected 
on the basis of two criteria. Firstly both have known, well-characterised targets, which allowed 
to characterise the response of the SGRP strains as a target-derived or as an off-target effect. 
Secondly, both drugs are medically or economically significant. The benzimidazoles (of which 
General Introduction 
 
29 
 
benomyl is a member) play a significant role both as agricultural fungicides, anthelmintics and 
anti-cancer treatments and the azoles are the most widely used clinical antifungals. 
 
1.4.2. Mechanism of action of drugs used in this study 
Benomyl 
Benomyl belongs to the benzimidazole class of compounds. It was released by DuPont and has 
been used from 1968 to 2001 as an agricultural fungicide (Amos, 2011; WHO). However, it 
was removed from the market due to concerns regarding its toxicological effects on humans 
(including developmental, reproductive and carcinogenic effects) (US Environmental 
Protection Agency (EPA)). In aqueous conditions benomyl hydrolyses to its active metabolite 
carbendazim which is thought to confer most of its antifungal activity. It is also an 
anthelminthic (Figure 1.9)  (Actor et al., 1967).  Its primary mode of action is as a microtubule 
depolymerizing agent. It binds to β-tubulin and interferes with the dynamic behaviour of 
microtubules.  
 
Figure 1.9: Chemical structure of benomyl (A) and its main metabolite carbendazim (B). 
 
Microtubules are highly conserved structures in all eukaryotes and consist of α and β 
subunits, which dimerize 1:1 in a particular orientation and form the tubule’s cylindrical 
structure, with a plus end carrying β subunits (bound to hydrolysable GTP) and a minus end 
that has the α subunits exposed (Jordan & Wilson, 2004). Saccharomyces cerevisiae only has 
A B 
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a single β-tubulin gene (TUB2) and two α-tubulins (namely the paralogs TUB1 and TUB3, 
which have 90% homology and interchangeable functionality) (Winsor & Schiebel, 1997). The 
correct functioning of microtubules is critically dependent on their highly dynamic 
behaviour—they need to be able to rapidly grow and shorten over a distance of micrometres in 
order to carry out their role in probing for chromosomes, lining them up along the equatorial 
plane during metaphase and separating them in anaphase. Microtubule depolymerizing agents 
such as benomyl (but also the clinically used anti-gout drug colchicine and the anti-cancer class 
of Vinca alkaloids) inhibit microtubule polymerization behaviour and dynamics, but can cause 
a change in microtubule mass when used in high concentrations (through the action of the loss 
of microtubule subunits and depolymerisation of the structure). Their primary anti-mitotic 
action is thought to occur at the lower doses, at which they inhibit the dynamic behaviour of 
microtubules prior to a corresponding change in polymer mass occurring. The inhibition of 
dynamicity obliterates the function of microtubules (Jordan et al., 2004; Singh et al., 2008). 
 
Yeast microtubules are involved in the nuclear aspects of cell division and the ensuing 
movement of chromosomes by nuclear microtubules in the formation of mitotic spindles and 
the nuclear envelope controlled by cytoplasmic microtubules (Stearns, 1990; Winsor et al., 
1997). Benomyl can interfere at a number of steps where microtubules are involved. Nuclear 
microtubules are needed for correct mitotic spindle formation and its attachment to 
chromosomes through the kinetochore. The correct attachment and appropriate chromosome 
(or chromatid) segregation are assessed by the spindle checkpoint and cell cycle progression 
checkpoints. Mutations in a number of genes involved in these processes leads to benomyl 
sensitivity (Hardwick & Murray, 1995; Kawashima et al., 2011; Pan & Chen, 2004; Poddar et 
al., 1999; Wysocka et al., 2004). Furthermore, impaired nuclear migration also leads to 
benomyl sensitivity (Berlin et al., 1990; Fujiwara et al., 1999; Schwartz et al., 1997). Growth 
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inhibition is usually caused by a mitotic block, aberrant exit from mitosis and eventual 
apoptotic destruction (Davidse, 1986; Thomas et al., 1985) (Jordan et al., 2004; Rathinasamy 
& Panda, 2006). 
Ketoconazole 
Fungal infections are estimated to affect up to 25% of the human population and cause 
significant morbidity and mortality (Brown et al., 2012). There is an estimated mortality of 1.5-
2 million deaths per annum, yet few new drugs are coming onto the market (Denning & 
Bromley, 2015). There is also an increasing incidence of antifungal resistance. The azoles are 
a class of antifungals that constitute one of the frontline treatments for clinical mycoses and 
ketoconazole is one of those important front-line drugs. Their primary mechanism of action is 
through inhibition of 14 α-demethylation of lanosterol in the ergosterol biosynthesis pathway 
(Kathiravan et al., 2012; Lupetti et al., 2002; 2003). Azoles fall into two general classes based 
on the structure of the azole ring (Figure 1.10).  
 
Figure 1.10: Examples of azoles of the imidazole (A) and triazole (B) classes. The active azole moiety is 
circled.  
 
The older imidazole class was first developed in the 1980s and includes ketoconazole—the 
first broad spectrum azole on the market. The imidazole class was followed by the triazole 
class, which includes fluconazole and other structurally related molecules. 
A B 
Ketoconazole Fluconazole 
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The primary target of azoles is cytochrome P450 lanosterol 14 α-demethylase whose activity 
they inhibit (also known as Erg11p or Cyp51p). This enzyme normally acts in the ergosterol 
biosynthesis pathway by oxidatively removing the 14 α-methyl moiety of lanosterol (Figure 
1.11).  
Figure 1.11: 14α-demethylation of lanosterol activity that is specifically inhibited by azoles (three sequential 
monooxidations by cytochrome P450 lanosterol 14 α-demethylase). Structures from http://www.ymdb.ca/ 
 
Erg11p contains an iron protoporphyrin at its active site, which azoles bind to via orientation 
of the nitrogen atom on the azole ring to the iron atom of Erg11p. The rest of the azole molecule 
binds to the surroundings of the Erg11p active site, with the binding orientation being specific 
to different azoles. There may also be additional interactions between the aromatic rings of the 
azole and the aromatic groups of phenylalanine on Cyp51p (Phe 233 or 235 in Candida 
albicans Cyp51p) (Lamb et al., 1999; Odds et al., 2003). 
 
The growth-inhibitory activity of azoles results from depletion of the ergosterol end product 
and build-up of ergosterol pathway intermediates. This leads to changes in membrane 
properties, including a loss in integrity and fluidity, and disruption of membrane-associated 
proteins. Specifically, the inhibition of C14α demethylase leads to the built up squalene 
precursor being converted to the toxic 14α-methyl-3,6-diol  through the action of sterol Δ5,6-
desaturase (encoded by ERG3).  (Kathiravan et al., 2012; Lamb et al., 1999; Lupetti et al., 
2002). Studies of clinical isolates of fluconazole-resistant C. albicans, and azole-resistant S. 
Lanosterol 14α-demethylase 
Lanosterol 4,4-dimethyl-5α-cholesta-8,14,24-trien-3β-ol 
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cerevisiae strains have indicated that the build-up of 14α-methyl-3,6-diol is growth inhibitory 
due to its disruption of membrane phospholipids by virtue of its extra hydroxide group (Figure 
1.12). The additional build-up of 14α-methylated sterol intermediates also leads to inhibition 
of 14α-demethylation of lanosterol. Finally, azole treatment leads to accumulation of toxic 
ketosteroids (Marichal et al., 1999).  
 
Figure 1.12: Depiction of normal ergosterol-membrane interaction (A) and disruption of membrane 
interaction caused by 14α-methyl-3,6-diol (B). The sterols are depicted in blue. Adapted from (Lamb et al., 
1999). 
 
Further mechanisms that can contribute to off-target effects of both benomyl and 
ketoconazole are discussed in greater detail in Chapter 5. 
 
1.5. Study aim and research design 
 
1.5.1. Study aim 
This study aimed to investigate the genetic basis of individual variation in drug response 
using natural strains of Saccharomyces cerevisiae as a model for individuals, with an emphasis 
on looking for causes of off-target effects. To achieve this, the set of 33 strains from the 
Saccharomyces Genome Resequencing Project (henceforth referred to as the SGRP strains) 
was used and tested their growth response to two well-known antifungals with characterised 
cellular targets: benomyl and ketoconazole. The strains show a continuous range of drug 
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response phenotypes in terms of either resistance or sensitivity to each of the drugs.  The 
hypothesis of this dissertation is that multiple genetic loci, that are not the target of the drug, 
underlie drug sensitivity or drug resistance either qualitatively or quantitatively. Since the 
strains show variability of response to the drugs it must be one or the other.  Identifying these 
loci should provide understanding of what factors can lead to off-target effects of drugs. The 
investigation was split up into three main objectives, as follows: 
 
1. Phenotype test selected Saccharomyces Genome Resequencing Project (SGRP) strains 
for resistance or sensitivity against the two drugs in this study (benomyl and 
ketoconazole) by dose-response assay. Explore the potential role of “obvious 
candidates” (such as the primary drug target) and factors that could contribute to general 
drug response (such as members of the pleiotropic drug resistance system). Select one 
sensitive and one resistant strain to benomyl and ketoconazole each for further in-depth 
study.  
 
2. Determine the heritability of the drug response phenotypes in the selected strains of 
interest using information from meiotic segregant offspring from intercrosses between 
strains of interest and the control laboratory strain. In order to create the intercrosses of 
interest, the two parental strains were subjected to ten rounds of random mating and 
sporulation to create advanced intercross lines (AILs). The aim of creating AILs is to 
reduce linkage disequilibrium between the two parental strains in order to refine the 
QTL interval for the final aim.  
 
3. Create a high-density genetic map and use linkage-based mapping to identify 
quantitative trait loci (QTL) that segregate with the resistance or sensitivity phenotypes. 
The identification of QTL will be performed using next-generation sequencing bulk 
segregant analysis (NGS-BSA). 
 
The following two pages show a graphical representation of the dissertation experimental 
design.  
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1.5.2. Research design 
 
 
 
Continued on next page. 
 
 
Ketoconazole Benomyl 
Dose response testing against benomyl and ketoconazole 
Based on each set of 33 dose responses from each drug, select strains for further study that 
display the most extreme phenotype (in terms of either resistance or sensitivity) 
SGRP4 
SGRP1 
SGRP3 
SGRP5 
SGRP2 
SGRP collection—33 strains 
BY (control) 
… 
AIM 1: Phenotype the SGRP collection in terms of resistance or sensitivity to benomyl and ketoconazole 
relative to the BY control strain. Based on these, select four strains (one resistant and one sensitive to 
benomyl and ketoconazole each) for further study. 
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AIM 2: Study the heritability of the drug response phenotypes in the four selected strains of interest. The 
particular aspects of heritability to be studied are estimates of broad sense heritability, estimates of the 
number of loci responsible for the respective drug response phenotype of each strain, a measure of 
transgressive segregation and finally an estimate of whether drug response was dominant or recessive. 
BY (control) SGRP1 (drug 
resistant strain) 
x 
Determine whether drug response phenotype is heritable.  
Drug resistance 
10 rounds of random mating and sporulation to 
create advanced intercross lines (AILs) 
Haploid recombinant F10 progeny 
AIM 3: Map the QTL responsible for the drug response phenotype of interest in each respective strain 
using next-generation sequencing bulk segregant analysis (NGS BSA). This method relies on using drug 
response as a selectable phenotype for phenotypic enrichment. As “drug sensitivity” cannot be selected, 
the QTL underlying the phenotype of the two sensitive strain were mapped by using the relative 
resistance of the BY control strain as the selected trait. 
Create drug resistant and 
control populations 
Extract gDNA 
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CHROMOSOMAL LOCATION 
0.5 
1.0 
0.0 
QTL 
Perform whole-genome Illumina sequencing; map reads to reference genome and derive allelic 
frequencies at each marker position between parental strains 
After determining markers (SNPs) between parental strains, genotype a pooled 
population of segregant offspring through NGS-BSA; identify QTL that underlie the drug 
response phenotype 
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Chapter 2: Materials and Methods 
 
2.1. Sourcing information 
All reagents, consumables and equipment used in this study are listed in this Section. All 
sourcing information is listed in this Section instead of being described in the body of the text. 
 
2.1.1. Reagents used 
All reagents and their respective sourcing information are listed in Table 2.1. 
Table 2.1: Reagents used in this study. 
1kb Plus DNA Ladder  Life Technologies, Auckland, NZ 
Acid-washed glass beads  (0.45-
0.52mm) 
dnature Ltd, Gisbourne, NZ 
Agar 
Life Technologies, Auckland, NZ or Formedium, 
Norfolk, UK 
Agarose, low electroendosmosis 
(LE) 
medi'Ray, Auckland, NZ 
Amino acid powder stocks 
Sigma Aldrich, Auckland, NZ or Formedium, Norfolk, 
UK 
Ampicillin AppliChem, Darmstadt, Germany 
Benomyl Sigma Aldrich New Zealand Ltd, Auckland, NZ  
Boric acid 
Thermo Fisher Scientific New Zealand Ltd, North 
Shore City, NZ 
Bromophenol blue Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Chloroform Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Dithiothreitol, DTT Sigma Aldrich New Zealand Ltd, Auckland, NZ 
DMSO Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Deoxynucleotide (dNTP) mix 
Thermo Fisher Scientific New Zealand Ltd, North 
Shore City, NZ or TaKaRa Bio Inc., Kusatsu, Japan 
Ethanol, absolute Pure Science Ltd., Porirua, NZ 
Ethidium bromide 
Thermo Fisher Scientific New Zealand Ltd, North 
Shore City, NZ 
Ethylenediaminetetraacetic acid, 
EDTA 
AppliChem, Darmstadt, Germany 
Extaq Polymerase TaKaRa Bio Inc., Kusatsu, Japan 
GeneaidTM High-Speed Plasmid 
Mini Kit 
dnature Ltd, Gisbourne, NZ 
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Geneticin, G418 Ngaio Diagnostics Ltd, Nelson, NZ 
Glucose Sigma Aldrich, Auckland, NZ 
Glycerol 
Thermo Fisher Scientific New Zealand Ltd, North 
Shore City, NZ 
HEPES 
Thermo Fisher Scientific New Zealand Ltd, North 
Shore City, NZ 
Hotstar Taq Polymerase Qiagen, Venlo, Netherlands 
Hygromycin B, HygB Invivogen, San Diego, California 
Isoamyl alcohol 
Thermo Fisher Scientific New Zealand Ltd, North 
Shore City, NZ 
Ketoconazole 
Santa Cruz Biotechnology, Inc, Santa Cruz, California, 
USA, or Jinlan Pharm-Drugs Technology Co. Ltd, 
Hangzhou, China 
Lithium acetate Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Methylene blue Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Monosodium glutamate salt (MSG) Sigma Aldrich New Zealand Ltd, Auckland, NZ 
New England BioLabs restriction 
enzymes 
New England BioLabs Inc., Ipswich, MA, USA 
Nitrogen base 
Formedium, Norfolk, UK or Fort Richard, Auckland, 
NZ 
Nourseothricin, clonNAT Werner BioAgents, Jena, Germany 
Peptone 
Formedium, Norfolk, UK or Fort Richard, Auckland, 
NZ 
Phenol Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Polyethylene glycol (PEG) 3350 Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Potassium acetate Sigma Aldrich New Zealand Ltd, Auckland, NZ 
RNAse A Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Salmon sperm DNA Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Sodium acetate Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Sodium chloride, NaCl Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Sodium dihydrogen phosphate, 
NaH2PO4 
VWR Global Science, Auckland, NZ 
Sodium dodecyl sulfate, SDS Life Technologies, Auckland, NZ 
Sodium hydroxide, NaOH VWR Global Science, Auckland, NZ 
Sorbitol Sigma Aldrich New Zealand Ltd, Auckland, NZ 
Tris(hydroxymethyl)aminomethane 
(Tris) base 
Formedium, Norfolk, UK 
Triton X-100 VWR Global Science, Auckland, NZ 
Tryptone Acumedia, Lansing, Michigan, USA 
Yeast extract 
Formedium, Norfolk, UK or Fort Richard, Auckland, 
NZ 
Zymolyase 20T AMS Biotechnology (Europe) Ltd, Abingdon, UK 
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2.1.2. Consumables used 
All consumables discussed in this work and their respective sourcing information are listed 
in Table 2.2. 
Table 2.2: Consumables used in this study. 
96-well tissue culture plate Interlab, Wellington, NZ 
Centrifuge tube, 15 mL Interlab, Wellington, NZ 
Centrifuge tube, 50 mL Interlab, Wellington, NZ 
Cryotubes, 1.5 mL Interlab, Wellington, NZ 
Microcentrifuge tubes 1.5 mL Interlab, Wellington, NZ 
PCR tubes 0.2 mL Interlab, Wellington, NZ 
Polyester sealing film  Interlab, Wellington, NZ 
Polyethersulfone (PES) membrane 
filter 0.22 µm  
Interlab, Wellington, NZ 
Singer plates Singer Instrument Co. Ltd, Somerset, UK 
 
2.1.3. Equipment used 
All equipment and its respective sourcing information is listed in Table 2.3. 
Table 2.3: Equipment used in this study. 
Alpha Imager mini transilluminator Alphatech Systems, Auckland, NZ 
Canon EOS 600D camera Canon NZ Ltd, Wellington, NZ 
Electrophoresis gel tank Gentaur, Paris, France 
EnVision 2102 Multilabel Plate 
Reader  
Perkin Elmer, Waltham, MA, USA 
NanoDrop 2000 UV 
Thermo Fisher Scientific NZ Ltd, North Shore City, 
NZ 
Singer MSM 400 Automated 
Dissection Microscope 
Singer Instrument Co. Ltd, Somerset, UK 
Singer RoToR HDA  Singer Instrument Co. Ltd, Somerset, UK 
Talboys standard vortex mixer Bio-strategy Ltd, Auckland, NZ 
Transonic T460 Sonicating water 
bath  
VWR Global Science, Auckland, NZ 
UNICAM 8625 UV/VIS 
spectrometer 
Thermo Fisher Scientific NZ Ltd, North Shore City, 
NZ 
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2.2. Yeast strains 
2.2.1. Saccharomyces Genome Resequencing Project (SGRP) collection 
The SGRP strains originated from two sources. The original collection included all the 
strains (Table 2.4) and was a kindly gifted by Prof Richard Gardner (University of Auckland). 
The original collection did not carry any genetic modifications; a corollary of this is that all the 
member strains could not exist as stable haploids, due to the presence of the HO locus (Chapter 
1, Section 1.3.1). The HO locus normally encodes an endonuclease that allows mating type 
switching to occur in yeast cells by gene conversion at the MAT locus (Herskowitz, 1988). 
This, along with the lack of selectable genetic markers in this collection makes it impossible to 
mate the strains in a controlled manner. Therefore the second SGRP strain collection was 
purchased from the National Collection of Yeast Cultures (NCYC) (Table 2.4) (Cubillos et al., 
2009; The National Collection of Yeast Cultures).  
 
Table 2.4: SGRP strains used in this study. Strains in cells shaded in grey were not represented or were 
inviable in the commercially ordered NCYC collection. 
Genetic 
background 
(name) 
Origin NCYC commercially-ordered collection 
Location Source a/α a α 
273614N 
RVI, 
Newcastle, UK 
Clinical 
(faecal) 
NCYC 3558 NCYC 3585 NCYC 3611 
322134S 
RVI, 
Newcastle, UK 
Clinical 
(throat 
sputum) 
   
378604X 
RVI, 
Newcastle, UK 
Clinical 
(sputum) 
  NCYC 3610 
BC187 
Napa Valley, 
USA 
Barrel 
fermentation 
NCYC 3564 NCYC 3591 NCYC 3616 
DBVPG 1106 Australia Grapes NCYC 3569 NCYC 3596 NCYC 3621 
DBVPG 1373 Netherlands Soil NCYC 3568 NCYC 3595 NCYC 3620 
DBVPG 1788 Finland Soil NCYC 3571   
DBVPG 1853 Ethiopia White Teff NCYC 3563   
DBVPG 6040 Netherlands 
Fermenting 
fruit juice 
NCYC 3557   
DBVPG 6044 West Africa 
Bili wine 
from 
NCYC 3574 NCYC 3600 NCYC 3625 
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Osbeckia 
grandiflora 
DBVPG 6765 Unknown Unknown NCYC 3570 NCYC 3597 NCYC 3622 
K11 Japan Shochu sake    
L-1374 Chile 
Fermentation 
from must, 
Pais 
NCYC 3572 NCYC 3598 NCYC 3623 
L-1528 Chile 
Fermentation 
from must, 
Cabernet 
NCYC 3573 NCYC 3599 NCYC 3624 
NCYC 110 West Africa 
Ginger beer 
from Zingiber 
officinale 
NCYC 3575 NCYC 3601 NCYC 3626 
SK1 USA Soil NCYC 3562 NCYC 3590 NCYC 3615 
UWOPS03-461.4 Malaysia 
Nectar, 
Bertram palm 
NCYC 3576 NCYC 3602 NCYC 3627 
UWOPS05-217.3 Malaysia 
Nectar, 
Bertram palm 
NCYC 3577 NCYC 3603 NCYC 3628 
UWOPS05-227.2 Malaysia 
Trigona spp 
collected near 
Bertram palm 
NCYC 3578 NCYC 3604 NCYC 3629 
UWOPS83-787.3 Bahamas 
Fruit, Opuntia 
stricata 
NCYC 3561 NCYC 3589 NCYC 3614 
UWOPS87-2421 Hawaii 
Cladode, 
Opuntia 
megacantha 
NCYC 3556 NCYC 3582 NCYC 3609 
W303 Unknown NA  NCYC 3583  
Y12 Africa Palm wine NCYC 3579 NCYC 3605 NCYC 3630 
Y55 France Grape NCYC 3560 NCYC 3588 NCYC 3613 
Y9 Japan Ragi    
YIIc17_E5 
Sauternes, 
France 
Wine NCYC 3559 NCYC 3586 NCYC 3612 
YJM975 Bergamo, Italy 
Clinical 
isolate, 
vaginal 
NCYC 3567 NCYC 3594 NCYC 3619 
YJM978 Bergamo, Italy 
Clinical 
isolate, 
vaginal 
NCYC 3565 NCYC 3592 NCYC 3617 
YJM981 Bergamo, Italy 
Clinical 
isolate, 
vaginal 
NCYC 3566 NCYC 3593 NCYC 3618 
YPS128 
Pennsylvania, 
USA 
Soil beneath 
Quercus alba 
NCYC 3581 NCYC 3607 NCYC 3632 
YPS606 
Pennsylvania, 
USA 
Quercus 
rubra bark 
NCYC 3580 NCYC 3606 NCYC 3631 
YS4 Netherlands Baking    
YS9 Singapore Baking  NCYC 3584  
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The strains in the NCYC collection were converted to stable haploids by the deletion of the 
HO locus. Selection of these strains was made possible through the presence of two selectable 
markers namely; the hygromycin B antibiotic resistance cassette in place of the HO ORF 
(hoΔ::HphMX4; the HphMX cassette provides resistance to the aminoglycoside antibiotic 
through expression of the Klebstella pneumontae hygromycin B phosphotransferase (Goldstein 
& McCusker, 1999)) and the geneticin antibiotic resistance cassette in place of the URA3 ORF, 
which confers resistance to the aminoglycoside geneticin (ura3Δ::KanMX4; KanMX encodes 
aminoglycoside phosphotransferase gene from Escherichia coli) (Wach et al., 1994). 
Information about MX4 cassettes is provided in Section 2.13. Furthermore, the SGRP strains 
in the NCYC collection also carried unique restriction site barcodes at the URA3 locus to allow 
for independent verification of strain identity. Genotype information of the SGRP collection is 
summarised in Table 2.5. 
 
Table 2.5: Genotype information of SGRP strains. 
SGRP collection name Genotype 
Original SGRP collection MATa/α No genetic modification 
NCYC SGRP collection MATa/α ura3Δ::KanMX4-barcode/ura3Δ::KanMX4-    
barcode 
MATa    hoΔ::HphMX4 ura3Δ::KanMX4-barcode 
MATα    hoΔ::HphMX4 ura3Δ::KanMX4-barcode 
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2.2.2. Laboratory strains 
The non-SGRP collection laboratory strains used in this study are described in Table 2.6. 
All laboratory strains are derived from the genetic background S288C. The NatMX4 cassette 
listed below gives resistance to the aminoglycoside nourseothricin, isolated from Streptomyces 
nourset (Goldstein et al., 1999).   
 
Table 2.6: Laboratory strains used in this study. 
Strain name Genotype 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
BY4742 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 
BY4743 MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 LYS2/lys2Δ0 met15Δ0/MET15 
ura3Δ0/ura3Δ0 
BY4741 Δho MATa hoΔ::NatMX4 his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
BY4742 Δho MATα hoΔ::NatMX4 his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 
BY4743 
Δho/Δho 
MATa/MATα hoΔ::KanMX4/ hoΔ::NatMX4 his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 
LYS2/lys2Δ0 met15Δ0/MET15 ura3Δ0/ ura3Δ0 
 
2.3. Growth media 
All strains were cultured in the laboratory using the specific media needed for the specific 
experimental purpose. The media was sterilised by autoclaving at 121˚C for 15min before 
being cooled in a 65˚C water bath prior to the addition of glucose (to a final concentration of 
2% weight to volume (w/v)) and any relevant antibiotics or other compounds. If solid media 
was required, agar was added. The contents of the specific media is outlined in detail in Table 
2.7, where the percentage value represents w/v. 
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Table 2.7: Media components. 
Enriched sporulation medium  
Potassium acetate 1% 
Yeast extract 0.1% 
Glucose 0.05% 
Sporulation amino acid mix (histidine, leucine, lysine, uracil) 0.01% 
Agar (if applicable) 2% 
  
Luria-Bertani (LB) medium 
Yeast extract 0.5% 
Tryptone 1% 
Sodium chloride 0.5% 
Agar (if applicable) 2% 
  
Synthetic complete (SC) medium  
Nitrogen base (without amino acids or ammonium sulphate) 0.17% 
Monosodium glutamate salt 0.1% 
SC amino acid mix * 0.2% 
Glucose (added after autoclaving) 2% 
Agar (if applicable; autoclaved separately) 2% 
 
* SC amino acid mix contains:  
3 g adenine, 2 g uracil, 2 g inositol, 0.2 g para-aminobenzoic acid, 2 g alanine, 2 g arginine, 
2 g asparagine, 2 g aspartic acid, 2 g cysteine, 2 g glutamic acid, 2 g glutamine, 2 g glycine, 
2 g histidine, 2 g isoleucine, 10 g leucine, 2 g lysine, 2 g methionine, 2 g phenylalanine, 
2 g proline, 2 g serine, 2 g threonine, 2 g tyrosine, 2 g tryptophan, and 2 g valine (55.2 g 
total).  
 
Yeast peptone dextrose (YPD) medium  
Yeast extract 1% 
Peptone 2% 
Adenine 0.012% 
Glucose (added after autoclaving) 2% 
Agar (if applicable) 2% 
 
2.3.1. Antibiotic supplements 
All antibiotics were made up in dH2O, filter-sterilised through a 0.22 µm polyethersulfone 
(PES) membrane filter and stored as 800 µL aliquots at -20˚C. These are described in Table 
2.8.  
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Table 2.8: Antibiotics used in this study. 
Antibiotic Stock concentration Working concentration 
Ampicillin (Amp) 100 mg/mL 100 µg/mL 
Geneticin (G418) 200 mg/mL 200 µg/mL 
Hygromycin B (HygB) 100 mg/mL 400 µg/mL 
Nourseothricin (clonNAT) 100 mg/mL 100 µg/mL 
 
2.4. Agarose gel electrophoresis 
Agarose gels were prepared at a 1% w/v concentration using low electroendosmosis (LE) 
agarose and TBE buffer (89 mM Tris (hydroxymethyl) aminomethane (Tris), 89 mM Boric 
acid, 2 mM Ethylenediaminetetraacetic acid (EDTA); pH 8). Agarose was melted by 
microwaving until the mixture appeared homogenous and there was no visible signs of the 
unmelted agarose. Ethidium bromide was added to the gel to a concentration of 0.5 µg/mL to 
allow nucleic acid visualisation before it poured into a cast. The nucleic acid sample (4 µL) 
was mixed with 1 µL of 5X loading dye (glycerol 30% v/v, bromophenol blue 0.25% w/v) and 
loaded into the gel wells. For size comparison, 5 µL of 1 kb+ DNA Ladder mixture (10% v/v 
1 kb+ DNA Ladder, 20% v/v loading dye, 70% v/v dH2O) was also loaded into the well. The 
electrophoresis was run in a horizontal gel tank containing TBE buffer with ethidium bromide 
at 100 V for 35 mins. The gel was visualised and imaged using an Alpha Imager mini 
transilluminator at 302 nm excitation wavelength. 
 
2.5. Genomic DNA (gDNA) isolation 
2.5.1. Standard gDNA extraction 
Yeast culture (2 mL) was grown in YPD at 30˚ C for 24 h in a sterile 15 mL centrifuge tube. 
The cells were pelleted by centrifugation at 2000 g for 5 min and the supernatant was discarded. 
In order to wash the cells, the cell pellet was re-suspended in 0.5 mL of dH2O and was 
transferred to a sterile 1.5 mL micro centrifuge tube. The tube containing the suspension was 
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centrifuged at 13 200 g for 30 secs and the supernatant was removed. The cell pellet was re-
suspended in 0.2 mL of lysis buffer (2% v/v Triton X-100, 1% sodium dodecyl sulphate (SDS), 
100 mM sodium chloride (NaCl), 10 mM Tris pH 8 and 1 mM EDTA pH 8). 
 
To lyse the cells and extract the nucleic acid, an equal volume of phenol-chloroform-isoamyl 
alcohol (25:24:1 mixture) and approximately 300 µg of 0.45-0.52 mm acid-washed glass beads 
were added to the cell-lysis buffer suspension and the mixture was vortexed on a low (30% of 
maximal) setting for 10 mins on a multi-Eppendorf vortex rack on a Talboys standard vortex 
mixer. In order to separate the organic and aqueous phases, 0.2 mL of TE (10 mM Tris, 1 mM 
EDTA, pH 8) was added and the tube was vortexed briefly before being centrifuged at 13 200g 
for 10 mins. The upper aqueous phase was transferred to a new micro centrifuge tube.  
 
The nucleic acid was precipitated by adding 2.5 volumes of cold 100% v/v ethanol (EtOH) 
and 1/10 volume of 3 M sodium acetate pH 5.3 to the aqueous phase and the contents were 
mixed by gentle inversion. To encourage the precipitation further, the tube was incubated at -
20°C for additional 25 mins. The nucleic acid was pelleted by centrifugation at 13 200 g at 4˚C 
for 10 mins. The ethanol was removed by carefully pipetting, and the pellet was air dried and 
then re-suspended in 395 µL TE pH 8. To improve the dissolution of the nucleic acid in TE 
buffer, the suspension was incubated 65˚C for 15 mins. To remove any traces of RNA, RNAse 
A (final concentration of 125 µg/mL) was added to the nucleic acid solution and mixed by 
inversion. The tube was incubated at 37˚C for 30 min to allow for RNA digestion. 
 
To prevent the interference of RNAse A with subsequent steps, an additional phenol-
chloroform extraction was carried out to further purify the gDNA. An equal volume of 
phenol:chloroform:isoamyl alcohol was added to the tube and the mixture was vortexed before 
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being centrifuged at 13 200 g for 10 mins. The upper aqueous phase was transferred to a new 
tube for a subsequent chloroform extraction to remove any traces of phenol. One volume of 
chloroform was added to the tube and mixed by vortexing. The phases were separated by 
centrifugation at 13 200 g for 10 mins. The upper aqueous phase was again transferred to a new 
tube and the DNA was precipitated using EtOH as described above. The precipitated gDNA 
was washed using 70% (v/v) EtOH before being pelleted by centrifugation at 13 200 g at 4˚C 
for 5mins. The supernatant was removed and the pellet was air-dried. The gDNA was dissolved 
by adding 50 µL of TE pH 8 and incubating at 65°C for 15 mins. The tubes were briefly 
centrifuged and stored at 4˚C. The extracted gDNA was visualised by gel electrophoresis to 
verify the success of the extraction, to check for any degradation, and to estimate the quantity 
of material. The sample was also examined using the NanoDrop UV spectrophotometer in 
order to ascertain the quality of the extraction and to check for the presence of any potential 
contamination from phenol or protein. 
 
2.5.2. Large scale gDNA extraction for whole-genome sequencing 
For the purposes of genomic sequencing, a large volume of starting material was required 
than what could be extracted by standard methodology (for example Macrogen Ltd. had a 
requirement of 100 ng of gDNA for a Truseq Nano 350bp insert library). Therefore, the 
standard protocol was scaled up in order to increase yield. For large scale gDNA extraction, all 
methodology was followed as stated in (2.5.1) with the following modifications; the starting 
culture volume was increased from 2 mL to 15 mL, and was grown in a 250 mL conical flask 
in a 30˚C shaking incubator. The volume of lysis buffer used during the initial cell lysis stage 
was increased to 0.5mL. In addition, the RNAse A treatment was carried out in a final volume 
of 1500 µL TE containing 125 µg/mL RNAse A. To accommodate the larger volume of 
extraction, following the RNAse A treatment the total 1.5mL reaction volume was separated 
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into two sterile 1.5 mL cryotubes. The phenol-chloroform and the chloroform extractions were 
carried out as described previously (2.5.1). The ethanol precipitation procedure was modified 
by using 1 mL of 100% EtOH instead of 2.5 volumes. The final extracted gDNA was 
resuspended in 75 µL of TE. After suspension of gDNA, the two samples gDNA were 
combined in a single tube to give a final volume of 150 µL. 
 
Post-extraction quality determination and gDNA quantitation was undertaken as described 
in Section 2.5.1. In addition, NanoDrop UV Spectrophotometer data was used to verify that 
gDNA conformed to the quality requirements of the selected sequencing centre (i.e. absorbance 
ratio 260 nm/280 nm ≥1.7; no contamination with phenol or protein).  
 
2.6. Primers used 
All primers were suspended in dH2O to a final concentration of 100 µM and stored at -20˚C. 
Primer names and sequences are provided in Table 2.9. Primers were designed based on 
sequence information obtained from SGD (SGD Project). 
 
Table 2.9: Primers used in this study. 
Primer 
number 
Primer name Sequence 
3 5' NatMX internal R TACGAGACGACCACGAAGC 
30 3' NatMX internal F TGGCTGGAGGTCACCAACGTC 
351 5' PDR1-NatMX deletion F 
CATCTCAGCCAAGAATATACAGAAAAGA
ATCCAAGAAACTGGAAGACATGGAGGCC
CAGAATACCCT 
352 3' PDR1-NatMX deletion R 
AGGAAGGAAGTTTTTGAGAACTTTTATC
TATACAAACGTATACGTCAGTATAGCGA
CCAGCATTCAC 
353 5' PDR3-UraMX deletion F 
ACTGCATCAGCAGTTTTATTAATTTTTTC
TTATTGCGTGACCGCAACATGGAGGCCC
AGAATACCCT 
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354 3' PDR3-UraMX deletion R 
CCATTTACTATGGTTATGCTCTGCTTCCC
TATTTCTTTTGCGTTTCAGTATAGCGACC
AGCATTCAC 
365 5' PDR1 confirmation F GCAGGACCATAGCGGCCA 
366 3' PDR1 confirmation R CGCCTTTACTGGTGGGCC 
368 3' UraMX internal F GACACCTGGAGTTGGATT 
369 3' PDR3 confirmation R TTATGAACACGCACAGGC 
370 5' UraMX internal R AATTCAACGCGTCTGTGAGG 
371 5' PDR3 confirmation F TACCGCCTAGGTAACCAT 
410 5' HO external F TACAGGTCTTAACGTAGGTTT 
411 3' HO external R AGGTGCTATCTTGACCGGCCA 
 
2.7. Polymerase chain reaction (PCR) conditions 
2.7.1. General PCR 
All PCR reactions were prepared in a 0.2 mL thin wall PCR tube in 25 µL final volume 
containing 1X PCR buffer, 200µM of each deoxynucleotide (dNTP), 2 µM each of forward 
and reverse primers, a minimum of 4 ng/µL of template DNA in a 2.5 µL volume (substituted 
by an equivalent volume of dH2O in negative control reactions) and either HotStar Taq 
polymerase (0.625 units) or ExTaq Polymerase (0.625 units). The final reaction volume was 
reached by the addition of dH2O. The PCR cycle consisted of an initial denaturation step in 
which the samples were heated to 95˚C for 5 min followed by 36 cycles of 94 ˚ C (denaturation) 
for 45 sec, 58 ˚C (annealing) for 45 sec, 72 ˚C (extension) for 2 min and a further 72 ˚C (final 
extension) for 10 mins before being held at 10 ˚C. All cycles were preceded by heating the 
PCR machine lid to 105˚C. The success of the PCR reaction was verified by agarose gel 
electrophoresis as described in Section 2.5. 
 
2.7.2. Long-range PCR 
Long range PCR cycle was undertaken to include a longer extension time in order to allow 
for amplification of longer fragments (2-5 kb). All the reaction mixtures and conditions were 
identical except for the extension ad the final extension steps. The extension step time was 
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increased from 2 min to 5 min whereas the final extension step was increased from 10 min to 
15 min. 
 
 
2.7.3. Confirmation PCR 
Confirmation PCR was used to check that the desired transformation occurred at the correct 
location. Two sets of primers were used; one primer of each set was homologous to the 
appropriate inserted cassette while the other had homology to the flanking region of the locus 
that should have been transformed. The PCR mixture and conditions used were the same as 
those used for the general PCR (Section 2.7.1). The success of the transformation at the correct 
location was indicated by the production of two PCR products—one “front” product, formed 
between the 5’ flanking region forward primer and the resistance cassette-specific reverse 
primer and one “back” product, created from the resistance cassette-specific forward primer 
and the 3’ flanking region reverse primer. However, due to the high specificity required to 
produce either product, the presence of only the front or the back product alone was considered 
sufficient to deem a transformation successfully confirmed. The principle of the confirmation 
PCR is illustrated in Figure 2.1. 
 
 
Figure 2.1: Production of front and back products during confirmation PCR. FR denotes “flanking region”. 
YFR denotes “your favourite gene”. 
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2.8. Yeast transformation 
Transformation was carried out on the basis of the Gietz and Schiestl 2007 high-efficiency 
transformation protocol (Gietz & Schiest, 2007). A single colony of the strain to be transformed 
was inoculated into 2 mL liquid YPD medium overnight in a rotating drum at 30°C. The OD600 
of the culture was measured using a UNICAM 8625 UV/VIS spectrometer, and a total of 
2.5×108 cells were added to 50 mL of liquid YPD in a conical flask and grown on a shaking 
incubator set at 200 rpm at 30°C, until the culture reached an OD600 of 1 (~1×10
7 cells/mL). 
The cell culture was transferred to a 50 mL centrifuge tube and centrifuged at 3166 g for 5 min 
to pellet the cells. The supernatant was removed and the pellet was re-suspended in 25 mL 
dH2O and centrifuged again. The supernatant was removed, the cells were re-suspended in 1 
mL dH2O and the solution transferred to a 1.5 mL microcentrifuge tube and centrifuged at 13 
200 g for 30 sec before discarding the supernatant. The cells were re-suspended in 1 mL dH2O 
and from this suspension two 100 μL aliquots set up. The transformation mix was made 
consisting of 33.3% w/v polyethylene glycol molecular weight 3350 (PEG 3350), 100 µM 
lithium acetate (LiAc), 27.8 mg/mL denatured salmon sperm DNA and 2.78 µg/mL 
transformant DNA and made up to a final volume of 360 µL using dH2O. The negative control 
transformation mix was made in the same manner, except the transformant DNA was 
substituted with dH2O. The 100 μL cell aliquots that were set up previously were centrifuged 
at 13 200 g for 30 sec, the supernatant removed and the cells resuspended in the transformation 
mix by gentle pipetting. The tubes were placed in a 42°C water bath for 40 min for heat shock, 
centrifuged at 13 200 g for 30 sec, and the cells then re-suspended in 1 mL YPD, and left at 
room temperature overnight, to allow for expression of the resistance cassette encoded on the 
transformant DNA. Finally, the transformation mixture was plated out on a selective media and 
incubated at 30°C for 2 days to get growth of transformed colonies. 
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2.9. Preparation of template for colony PCR 
Colony PCR was used as a rapid alternative to genomic DNA extraction to provide template 
material for confirmation PCR (Section 2.7.4). Half a colony of the putative transformant was 
scraped from the selection plate and resuspended in 50 μL of 1 mg/mL zymolyase 20T solution 
(dissolved in dH2O) and incubated for 30 min at 30°C in order to induce enzymatic digestion 
of the cell wall, and liberate the template DNA. This zymolyase digest was then used directly 
in the PCR reaction as a template, as described in Section 2.7.1. 
 
2.10. Yeast stock preservation 
Any strain that required long-term storage was grown overnight to saturation 
(approximately 2×108 cells/mL) in 1.5 mL of liquid YPD. The cells were pelleted by 
centrifugation at 3166 g for 1 min and resuspended in 750 µL of YPD and 750 µL of 50% v/v 
glycerol (to a final glycerol concentration of 25% v/v). The suspension was transferred to a 1.5 
mL sterile cryotube, vortexed and stored for further use at -80˚C. 
 
2.11. Plasmids used 
All plasmids were maintained in Escherichia coli (E. coli) stored as 25% v/v glycerol stocks. 
All plasmids contained an ampicillin resistance cassette as a selectable marker, which permits 
the host E. coli strain to grow on the beta-lactam antibiotic (Sutcliffe, 1978). Information 
regarding plasmids used is provided in Table 2.10. 
Table 2.10: Plasmids used in this study 
Plasmid name E. coli strain name Description Source 
p4339 TOP10F NatMX4 (Tong & Boone, 2005) 
pAG60 DH5α UraMX4 (Goldstein et al., 1999) 
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2.12. Plasmid mini-prep 
Prior to isolation, E. coli were streaked from frozen stock on solid agar LB plates containing 
100 µg/mL ampicillin and grown overnight at 37°C. A single colony was inoculated in 3 mL 
of liquid LB medium with ampicillin and grown overnight in a 37°C shaking incubator. The 
plasmid was purified using the GeneaidTM High-Speed Plasmid Mini Kit (cat. Number PD100) 
according to the manufacturer’s instructions. The presence of purified plasmid was confirmed 
by agarose gel electrophoresis. The plasmid was also quantified using the NanoDrop UV 
spectrophotometer.  
  
2.13. Restriction digest 
New England BioLabs (NEB) reagents were used for restriction digests. The reaction was 
set up to contain 33.3 ng/mL of DNA, 10 units of desired restriction enzyme, 1X of matching 
NEBuffer and 1X bovine serum albumin (included as part of restriction digest kit), made up to 
a total volume of 30 µL with dH2O. The reaction was incubated at 37°C for 4 h to allow for 
digestion to occur. The digest was stopped by incubation at 65°C for 20 min. The success of 
the restriction digest was confirmed by agarose gel electrophoresis. 
 
2.14. Marker switching 
The marker switch procedure allows for simple interchange of different antibiotic resistance 
cassettes without requiring de novo PCR amplification and integration at a locus. All the 
antibiotic resistance cassettes used in this study belong to the MX4 series—in which the 
resistance gene is flanked by the same TEF promoter and terminator sequences, derived from 
the filamentous fungus Ashbya gossypii. The presence of these identical sequences allows the 
resistance genes to be swapped over by homologous recombination (Goldstein et al., 1999; 
Tong et al., 2005; Wach et al., 1994). An illustration of the method is shown in Figure 2.2. 
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Figure 2.2: Overview of antibiotic resistance cassette marker switch method. This example illustrates a 
switch from a kanamycin-resistance cassette to a nourseothricin-resistance cassette Adapted from (Tong et 
al., 2005), reprinted with permission. 
 
 
Marker switching was used in this study to switch from kanamycin resistance to 
nourseothricin resistance. The nourseothricin-resistance cassette (NatMX4) was obtained from 
the p4339 plasmid (a kind gift from Charles Boone, University of Toronto) and isolated by 
plasmid mini-prep, as described in Section 2.12. The plasmid was then subjected to a restriction 
digest with EcoRI (Section 2.13) to isolate the NatMX4 cassette from the plasmid backbone 
and produce sticky ends that increase transformation efficiency. This product was transformed 
into the desired strain using standard transformation procedure (Section 2.8). 
 
2.15. Dose-response testing 
The growth of all diploid SGRP strains were compared to a lab BY4743 control. The growth 
of haploid MATa and MATα SGRP strains were compared to the equivalent BY4741 or 
BY4742 control respectively. 
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2.15.1. Primary serial spot dilution assay 
Yeast from single colonies were inoculated in a 96-well tissue culture plate containing SC 
media using the Singer RoToR HDA. The plate was sealed with polyester sealing film and 
placed inside a Ziploc bag to minimise evaporation. Cultures were grown to saturation 
(approximately 2×108 cells/mL) at 30°C in a shaking incubator set to 200 rpm for 48 h. The 
strains were serially diluted 1:10 in dH2O four times using fresh 96-well tissue culture plates. 
The Singer RoToR was used to “spot” the serially-diluted cultures using 96 long-pin repads 
onto SC agar Singer plates containing increasing concentrations of the treatment compound of 
interest (Singer plates are rectangular 8 cm × 12 cm polystyrene dishes that are compatible with 
the Singer RoToR HDA (Singer Instruments)). Each strain was represented on the plate twice 
and the experiment was repeated independently two times. A representative plate illustrating 
the strain arrangement is shown in Figure 2.3. The plates were grown at 30˚C for 72 h and 
photographed using a Canon EOS 600D camera. 
 
 
Figure 2.3: A representative Singer plate in the primary serial spot dilution assay, showing the arrangement 
of strains. Each strain is outlined in red. The horizontal spots for each strain are ten-fold dilutions of the 
cells. Plate shown contains 50µM benomyl. 
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The growth score for each serial spot dilution in the assay was recorded using the system 
described in Table 2.11. 
 represents maximal to half-maximal growth;  represents minimal to half-maximal growth. 
107  
cells/mL 
106  
cells/mL 
105 
 cells/mL 
104  
cells/mL 
Score 
    8 
    7 
    6 
    5 
    4 
    3 
    2 
    1 
    0 
 
Residual growth was calculated by dividing the average score of the strain upon treatment 
by the average score of the strain in solvent only. This was done to eliminate the effect of 
differential growth rates between the strains. The mean average residual growth and standard 
deviation was calculated for each strain from its two replicates in the assay. The minimal 
inhibitory concentration (MIC; defined as the treatment concentration above which there is no 
further significant reduction in growth) was determined for each strain. In instances where the 
residual growth of the strain did not fall below 0.5, or where an end “plateau” was not reached 
(plateau is reached when two or more points do not show a significant difference), the MIC 
was classed as “not determined” (ND). “Resistant” strains were defined as those whose MIC 
was higher than that of the control; “susceptible” strains were those whose MIC was lower than 
that of the control. 
 
Table 2.11: Scoring system for growth in initial serial spot dilution assay screen. 
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2.15.2. Secondary serial spot dilution assay (confirmation of primary serial 
spot dilution assay results) 
Yeast were inoculated in 100 µL SC medium in a 96-well tissue culture plate, sealed with 
polyester sealing film and placed inside a Ziploc bag and grown overnight in a 30°C shaking 
incubator at 200 rpm. OD590 was measured on an EnVision 2102 Multilabel plate reader. 
Cultures were diluted to an OD590 of 0.1 in dH2O in a fresh 96-well tissue culture plate, and 
serially diluted 1:10 in dH2O six times. Three µL of culture was transferred using a 
multichannel pipette to SC agar plates containing increasing concentrations of the desired 
treatment compound. The plates were incubated at 30°C for 72 h and photographed. The 
experiment was independently repeated twice. 
 
Analysis 
The growth score for each strain in the secondary serial spot dilution assay was recorded 
using the system described in Table 2.12. 
 
Table 2.12: Scoring system for determining growth in secondary serial spot dilution assays. 
 represents maximal to half-maximal growth;  represents minimal to half-maximal growth. 
107  
cells/mL 
106  
cells/mL 
105 
 cells/mL 
104  
cells/mL 
103 
 cells/mL 
102 
 cells/mL 
Score 
      7 
      6 
      5 
      4 
      3 
      2 
      1 
      0 
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Analysis of growth was carried as described for serial spot dilution assays in the primary 
screen, with MIC being determined for each strain. “Resistant” and “sensitive” strains were 
determined as described in Section 2.15.1. 
 
2.15.3. Pinning assay in 384 colony format 
Yeast were inoculated in 100 μL of liquid SC medium in a 96-well tissue culture plate and 
grown overnight as described in Section 2.15.2. A buffer border of alternating BY and S288C 
controls was arranged to control for edge effects in colony size (  colonies at the edge grow 
more due to increased nutrient availability (Tong & Boone, 2007)).   Appropriate BY controls 
were also incorporated within the plate and these were used to determine the sensitivity or 
resistance of the SGRP strains tested. An exemplar plate is shown in Figure 2.4. The strains 
were arrayed to 384 colony format on SC agar using the Singer RoToR, and then grown at 
30°C for two days. This source plate was then pinned onto increasing concentrations of the 
compound of interest, using 15% source pinning pressure and 5% target pinning pressure. The 
pinning pressure was reduced from the default pressure of 32% in order to reduce the number 
of cells in the initial inoculum, as it was previously observed that too many cells led to 
decreased responsiveness to drug. The cells were then grown at 30°C for 72 h and 
photographed. The experiment was repeated independently three times. 
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Figure 2.4: A representative Singer plate in the 384 colony format pinning assay, showing the arrangement 
of strains. Each strain is outlined in red (quadrant of four repeated colonies). Plate shown contains 50µM 
benomyl. 
 
 
Analysis 
Colony size was measured using Gitter image recognition software (Wagih & Parts, 2014). 
The residual growth of each replicate on the plate (a quadrant of four colonies) was calculated 
by dividing the average colony size in treated plates by the average colony size in the solvent 
control plates, thus normalising for differences in growth rate, as described previously. This 
normalisation also helped to abolish differences in growth due to different positions on the 
plate (as caused by edge effects or by being positioned next to smaller colonies). The mean 
average of each pinning replicate was calculated for each wild type strain and the control strain. 
The MIC was determined for each strain as described in Section 2.15.1. 
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2.15.4. Determination of sensitivity or resistance 
 Sensitivity or resistance was quantified using the system described in Table 2.13. 
Table 2.13: Quantification system for SGRP strain sensitivity or resistance (relative to BY control strain). 
- or + Slight sensitivity or resistance (MIC less than two-fold that of the control). 
- - or + + Moderate sensitivity or resistance (MIC at least two-fold that of the control). 
- - -  or + + + High sensitivity or resistance (MIC three or more fold that of the control, or 
not determined). 
 
2.16. Tetrad dissection 
In order to obtain meiotic segregants from a cross between two strains of interest, standard 
mating and sporulation procedures were carried out (Amberg et al., 2005). Briefly—the two 
strains of interest were selected/engineered to contain different antibiotic resistance cassettes 
at the same locus that could be used for selection. The strains were mated on YPD agar in a 
chevron shape (see Figure 2.5), and grown at 30°C overnight. The checking of the appropriate 
growth of each parental strain, and selection of diploids was done by replica-plating the 
chevron onto YPD agar containing either selective antibiotic on its own or a combination of 
both antibiotics respectively. These plates were grown at 30°C overnight. 
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Figure 2.5: Graphical representation of the mating, sporulation and tetrad dissection steps to obtain meiotic 
segregants between two strains of interest—one carrying a clonNAT resistance cassette and the other an 
HygB resistance cassette. 
 
The selected diploids were induced to undergo sporulation by inoculation at a density of 
approximately 2×107 cells/mL) in 2 mL of enriched sporulation medium which simulates 
conditions of carbon and nitrogen starvation, which induces meiosis and spore formation in 
yeast (Amberg et al., 2005). Sporulation cultures were incubated on a rotating drum at room 
temperature for a minimum of five days. Sporulation efficiency was estimated by counting 
four-tetrad spores under a microscope.  
To isolate individual segregants, tetrad dissection was performed. A 200 μL of sporulation 
culture was pelleted, re-suspended in 50 μL of 0.25 mg/mL zymolyase 20T in 1 M sorbitol, 
and incubated at 30°C for 30 min. This zymolyase treatment induces the digestion of the hardy 
ascus sac that holds spores together, thus allowing their separation. The zymolyase digest was 
halted by adding 150 μL of dH2O and storing on ice. A 15 μL sample of zymolyase-digested 
sporulation culture was placed in a streak on a thin YPD agar plate. A Singer MSM 400 
YPD + HygB/clonNAT 
Strain 1 Strain 2 
YPD 
YPD + clonNAT 
YPD + HygB 
Sporulation  
culture 
Tetrad 
dissection 
YPD 
YPD + 
clonNAT 
YPD + HygB 
Tetrad 
genotyping 
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Automated Dissection Microscope was used to dissect tetrads as per manufacturer’s protocol 
(Singer Instruments) and isolated spores were grown at 30°C for two days. As tetrad dissection 
depends solely on visual recognition, they must be genotyped to confirm that they are true 
tetrads. This was done by identifying the 2:2 segregation of the two antibiotic markers used 
during the selection process. Therefore, the tetrads dissected on YPD were replica-plated onto 
YPD plates containing either one or the other antibiotic, grown overnight at 30°C, and growth 
on each plate was scored. Spores from true, fully-viable (i.e. four spore) tetrads were selected 
for further analysis. 
 
2.17. Construction of advanced intercross lines (AILs) 
Advanced intercross lines (AILs) were constructed between the strains selected for further 
QTL analysis. Briefly, this involved   repeated rounds of random mating and sporulation from 
resultant diploids   to break up linkage disequilibrium between closely associated genetic loci 
and to increase the number of recombination events in refinement of genetic maps. The first 
matings, diploid selection and sporulation steps were carried out as described in Section 2.16. 
In order to repeat the process the sporulation culture was subjected to treatment with zymolyase 
and dithiothreitol (DTT) to induce spheroblast formation, sonication and heat shock in order to 
selectively kill vegetative cells, leaving spores available for a new round of mating (Pais et al., 
2014; Siddiqi, 1971; Spencer et al., 1989). The protocol was adapted from one kindly provided 
by Prof Richard Gardner (University of Auckland). 
 
Following sporulation in liquid medium for five days, the number of spores in the culture 
was counted using a haemocytometer and a volume of culture was selected that contained a 
total of 2.5×108 tetrads. The cells were collected by centrifugation in a 1.5 mL microcentrifuge 
tube, the pellet was washed with 1 mL of dH2O and centrifuged at 13 200 g for 1 min before 
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the supernatant was discarded. The pellet was resuspended in 1mL of 100 mM Tris-Cl (pH 9.4) 
and 10 mM DTT and incubated in a 30˚C water bath for 10 mins. The tube was spun at 13 200 
g for 1 min, the supernatant was discarded, the cell pellet was resuspended in 1 mL of solution 
consisting of 0.5 mg zymolyase, 2.1 M sorbitol and 10 mM sodium dihydrogen phosphate 
(NaH2PO4) (pH 7.2) and the suspension was incubated in a 30˚C water bath for five hours to 
induce lysis of vegetative cells and ascus digestion. Upon completion of this period, a sample 
of the suspension was inspected microscopically with an equal volume of 0.1% w/v methylene 
blue to confirm that spores were still viable and vegetative cells were destroyed.  To ensure 
further killing of vegetative cells, the cells were pelleted, the supernatant was removed, the 
pellet was resuspended in 0.4% w/v SDS, 1 mM DTT and dH2O and the cells were subjected 
to sonication treatment. For this, cells were incubated in a Transonic T460 Sonicating water 
bath for 30 sec four times and incubated on ice for 1 min between each sonication. Following 
sonication, additional SDS was added to a final concentration of 1% and the cells were 
incubated at 37˚C for 1 h. As a final stress step to kill vegetative cells, the suspension was 
incubated in a 55˚C water bath for 10 mins. Following this, the suspension was vortexed and 
again inspected microscopically with methylene blue to ensure spores were viable and 
dispersed. The number of spores was counted using a haemocytometer to estimate how many 
spores were taken through to the next round of intercrossing. The cells were pelleted by 
centrifugation and the pellet washed with dH2O. The cells were pelleted again, the supernatant 
removed and the cells were resuspended in 1mL of YPD. The pellet was resuspended by 
vortexing and pipetting. This total volume of cells was delivered to a YPD agar plate and spread 
using a sterile L-shaped glass rod. Once the liquid was fully absorbed the plate was incubated 
at 30˚C for two days for the subsequent round of random mating between spores. Following 
mating, the YPD plate was replica-plated onto a YPD agar plate containing clonNAT and HygB 
for diploid selection and incubated at 30˚C for two days. Afterwards, a minimum of 2×107 
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diploids/mL were inoculated in 7.5 mL of sporulation medium and incubated on a rotating 
drum at room temperature for 5 days. The described process was repeated for a total of ten 
rounds of matings and sporulation. 
 
2.18. Construction and long-term storage of segregant progeny pools. 
Following the last (10th) round of vegetative cell killing, the total number of cells in the 
culture was counted using a haemocytometer before being subjected to the final round of 
mating and diploid selection (as described in Section 2.17). The cells were collected from the 
diploid selection plate by pipetting 1 mL of liquid SC medium on the surface of the agar, 
suspending the cells in liquid by gently scraping the surface with a sterile L-shaped glass rod 
and then collecting the cell suspension by pipette and transferring it to a sterile 15 mL 
centrifuge tube. This process was repeated two to three times until no cells remained on the 
agar. The total volume in the tube was then made up to 10 mL with liquid SC. The selected 
diploids were counted again, and the total number of cells in each collected cell suspension 
was calculated. Glycerol stocks were made for long-term storage by mixing 750 µL of the cell 
suspension with an equivalent volume of 50% v/v glycerol in a sterile 1.5 mL cryotube and 
storing at -80˚C. 
 
2.19. Drug treatment of pooled segregant progeny 
2.19.1. Optimisation of drug treatment in pooled format on agar (lawn 
concentration-response assay) 
Previous drug treatment formats discussed in this chapter have relied on isolation of single 
cells prior to inoculation on drug-containing agar plates and are not practicable for treating a 
large number of cells (on the order of 105) with drugs simultaneously. Therefore, a new 
treatment format was optimised to circumvent this problem. A “lawn” approach was selected, 
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in which a mixed cell population is cultured that is then spread over the surface of an agar plate 
containing the drug. The cells then grow as a lawn over the surface and can be quantified by 
scraping and counting, akin to the method described in Section 2.18. 
 
A concentration-response assay was performed in the above format with each AIL as well 
as its original parental strains (in diploid form). Strains were inoculated in 20 mL of SC and 
grown overnight at 30˚C in a shaking incubator set at 200 rpm. Following the outgrowth, cells 
were counted by haemocytometer and diluted to a concentration of 1×105 cells/mL using dH2O. 
SC agar plates were made containing increasing concentrations of the compound of interest. 
Following thorough vortexing, 1 mL of the cell suspension was spread over the surface using 
a sterile L-shaped glass rod. After the cell suspension had fully absorbed into the agar, the 
plates were incubated at 30˚C for 72 h. After photographing the plates, the cells were collected 
the same way as described in Section 2.18. Growth was quantified by cell counting. The 
concentration-response was carried out in triplicate for each compound of interest. 
 
2.19.2. Drug treatment format and gDNA extraction of pooled segregant 
progeny 
AIL segregant progeny pools were inoculated into 20 mL of SC and grown overnight at 
30˚C in a shaking incubator set at 200 rpm. Following cell counting, cultures were diluted to 
1×105 cells/mL using dH2O, and the diluted cells were spread onto SC agar plates containing 
the desired drug concentration using the method described in Section 2.19.1. Plates were 
incubated, and cells were collected as described in Section 2.18. Following cell collection, 
gDNA was extracted as described in Section 2.5.2. A single sample was created for each AIL 
under each drug treatment condition. 
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2.20. Single gene sequence alignment 
All sequence alignments for single genes and their translation products were performed 
using the Geneious 8.0.5 software package (www.geneious.com; (Kearse et al., 2012)). 
Multiple alignments were carried out using the MUSCLE iterative alignment algorithm using 
default settings. The percentage of pairwise identity in each set of alignments was calculated 
by Geneious, using the following formula: 
 
% 𝑝𝑎𝑖𝑟𝑤𝑖𝑠𝑒 𝑖𝑑𝑒𝑛𝑡𝑖𝑡𝑦 =  
# 𝑖𝑑𝑒𝑛𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑡𝑐ℎ𝑒𝑠 × 100
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑎𝑙𝑖𝑔𝑛𝑒𝑑 𝑟𝑒𝑔𝑖𝑜𝑛
 
 
In order to predict effects of polymorphisms that occur within ORFs, the coding region was 
translated with the appropriate Geneious tool, again using default settings, and the putative 
effect was derived, based on the predicted amino acid changes. 
 
2.21. Illumina whole genome sequencing 
All Illumina sequencing was performed at Macrogen Inc., Seoul, South Korea. Library 
preparation, sequencing, base calling and generation of FASTQ raw data files were completed 
at Macrogen. All subsequent bioinformatic analysis was carried out at VUW as part of this 
thesis. 
 
2.21.1. Parental strain genome sequencing 
A minimum of 100 ng of gDNA from the strain of interest was isolated as described in 
Section 2.5.2. A one gigabase package offered by Macrogen was selected for sequencing the 
parental strains of interest. This is estimated to produce ~88X coverage of an average S. 
cerevisiae genome, based on a genome size of ~12 Mb (SGD Project). Actual coverage per 
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sample is reported in Chapter 5. Truseq Nano 350 bp insert libraries of each sample were 
prepared at Macrogen. All samples were sequenced simultaneously in a single lane of a 
HiSeq2000 using 101 bp paired-end (PE) sequencing. Base calling was performed using the 
Illumina Pipeline (CASAVA) v1.8.2. The raw data was provided in FASTQ format with 
Sanger quality encoding (Phred Quality Value + 33). 
 
2.21.2. Segregant population sequencing 
Genomic DNA extraction and library preparation were performed as described in Sections 
2.5.2 and 2.21.1. All samples were sequenced simultaneously in a single lane of a HiSeq2500 
using 125 bp paired-end (PE) sequencing. Based on a sequencing output of 60 Gigabases per 
lane and 12 samples, each sample was estimated to have ~400X coverage, assuming equal 
coverage. Actual coverage per sample is reported in Chapter 5. Raw image processing was 
carried out using HiSeq Control Software v2.2.38. Base calling was completed by Real Time 
Analysis v1.18.61.0. The conversion of the base call file to FASTQ format was done by 
bcl2fastq v1.8.4. The raw data were provided in FASTQ format with Sanger quality encoding 
(Phred Quality Value + 33). 
 
2.22. Alignment of genomic Illumina read data to a reference genome 
An overview of the general workflow used to achieve the final pileup format used for 
downstream applications is given in Figure 2.6. The workflow is based on recommendations 
provided by Genome Analysis Tool Kit (GATK) (Broad Institute) and SAMtools (SAMtools). 
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Figure 2.6: Overview of Illumina genomic sequence data workflow. File formats of input and output files 
for each step are indicated. 
 
 
2.22.1. Quality assessment and trimming of Illumina raw read data 
To assess the quality of the raw data and to detect any possible anomalies, FastQC v0.11.3 
(Andrews, Andrews 2015) was used. FastQC assesses input data based on a number of 
modules, including average quality score, GC content and its distribution per read and the 
presence of any over-represented sequences and k-mers. The FastQC report was used to 
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determine if data required any trimming or manipulation prior to downstream analysis. Figure 
2.7 provides an example of “good” data that did not require much manipulation and “bad” data 
that required trimming. 
 
 
A. 
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Figure 2.7: Example of FastQC output modules, showing examples of “good” and “bad” data. 
A. Output of “per base sequence quality” module. The average Phred quality scores of all the reads 
are displayed as box plots. Red line represents median quality score; blue line represents mean 
score. Top graph: high quality data. Bottom graph: poor quality data, as evidenced by declining 
quality scores towards the 3’ end of the read. 
B. Output of “overrepresented sequences module” Top: example of clean data. Bottom: example of 
data showing contamination with Illumina primer sequence. 
 
If Illumina adapter sequences were detected, Trimmomatic v0.33 (Bolger et al., 2014) was 
used to eliminate them. The ILLUMINACLIP module of this software takes the universal 
Illumina primer and adapter sequences as input and trims the FASTQC files to remove all or 
part of these input sequences (or their complementary sequences). The input Illumina 
sequences used were as provided in the TruSeq2-PE.fa in Trimmomatic.  
All sequence data were also trimmed according to the Phred sequence quality score to 
eliminate low-quality data that may confound read mapping or variant calling. The 
SLIDINGWINDOW module of Trimmomatic was applied for this purpose with trimming 
options of 4 bp window size, Q30 required Phred quality (per window) and a minimum length 
of 20 bp for output reads. 
Additional trimming was done using the CROP and HEADCROP modules of Trimmomatic 
as the individual data sets required (for example, to trim out areas of imbalance in GC content 
at the beginning or ends of reads). This is discussed in more detail in Chapter 5. 
  
B 
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2.22.2. Alignment of reads to a reference genome 
Reference genome acquisition 
The S. cerevisiae S288C reference genome was downloaded from SGD on 9 Aug 2015 
(Engel et al., 2014; SGD Project). The selected release was the genome version R64-1-1 
(corresponding to the University of California Santa Cruz (UCSC) Genome Browser name 
sacCer2), originally released 3 Feb 2011. 
 
Read alignment/mapping to reference genome 
The BWA-MEM  v0.7.12 algorithm (Li, 2013) was used to align the raw read data to the 
aforementioned reference genome. BWA-MEM is the most recent alignment algorithm of the 
general BWA Burrows Wheeler Alignment (BWA) software (Li & Durbin, 2009). Prior to 
alignment, the reference genome was indexed in BWA using default parameters. BWA-MEM 
was then run in paired-end format using the options -M (marks split reads as secondary, for 
compatibility with downstream software) and -R (inserts read group names into the output 
SAM file). 
Following alignment, the output SAM file was further processes using SAMtools v1.2 (Li, 
Handsaker, et al., 2009). The “view –bS” command was used to convert the file to the binary 
BAM format. The “fixmate” command was used to fill in missing information about 
coordinates, insert size and mate-related flags for paired end reads. Finally the “sort” command 
was used to sort reads in the BAM file by chromosomal coordinate. 
 
2.22.3. Removal of PCR and optical duplicates 
During Illumina sequencing of the samples in this study, PCR was used both during library 
preparation to amplify the amount of starting material, and during cluster generation prior to 
the sequencing reaction, to create a sufficient amount of template to generate a sufficient optical 
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signal during sequencing-by-synthesis. However, such amplifications are prone to introduce 
artefacts within the aligned data where certain sequences are falsely overrepresented. 
Furthermore, incorrect cluster positioning on the Illumina flow cell can also lead to artificial 
sequence duplication. Such artefacts are referred to as PCR duplicates or optical duplicates and 
can interfere with downstream analysis (see Figure 2.8 for a description of how such duplicates 
arise). Therefore, the removal of these sequence duplicates is recommended (Altmann et al., 
2012; Schlotterer et al., 2014). The MarkDuplicates module of Picard Tools v1.138 (Broad 
Institute) was used to mark and remove PCR and optical duplicates. 
 
Figure 2.8: Generation of PCR (A) and optical (B) duplicates. 
A. PCR duplicates occur due to preferential amplification of a certain sequence over others. They can 
be identified post-alignment by virtue of their sequence identity (barring sequencing errors) as 
well as identical mapping coordinates (with PE data, identical insert size also gives weight to the 
sequence being a PCR duplicate). As an example, PCR-duplicated reads are shown in red. 
B. Optical duplicates form when a sequencing cluster is split between tiles on a flow cell (as exhibited 
by Cluster 1). The sequence from a single cluster is henceforth reported as two independent 
sequences. Optical duplicates are recognised on the basis of sequence identity (barring sequencing 
errors) and their adjacent coordinates on the flow cell. 
 
 
2.22.4. Local realignment of indels 
As short read mapping algorithms such as BWA align each read independently of others, 
they often fail to correctly map indels, which may only be detected by considering the 
alignment patterns of multiple reads at once (see Figure 2.9 for an illustration) (Altmann et al., 
2012; DePristo et al., 2011).  
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Figure 2.9: Improved alignment accuracy following local realignment around indels. 
A. Failure to map indels may lead to spurious variants being detected (sequence “ATC” in the reads 
would be erroneously considered to be SNPs relative to the reference). 
B. Local realignment around indels improves overall alignment accuracy and lowers the occurrence 
of false “variants”. 
 
Local realignment of indels was performed using GATK v3.4-46 (DePristo et al., 2011). 
Prior to indel realignment, the reference genome was indexed using SAMtools and a dictionary 
was created using Picard Tools, as per GATK requirements. For indel realignment, firstly the 
target regions for local realignment were detected using the RealignerTargetCreator module. 
This module requires a list of indels that are known to occur in S. cerevisiae. This list was 
compiled manually from sequence data downloaded from SGD on 9 Aug 2015 (Saccharomyces 
Genome Database). The list of strains whose indel data were included is found in Appendix 
7.1. Following creation of target regions, the indels were realigned using the IndelRealigner 
module. 
 
2.22.5. Base quality score recalibration 
The automated base-calling software used by Illumina is known to lack accuracy when 
reporting Phred base quality scores (Brockman et al., 2008; Li, Li, et al., 2009; Nielsen et al., 
2011). One source or error arises from cycle effect, in which sequencing accuracy decreases 
towards the 3’ end of the read due to accumulation of errors in the sequencing-by-synthesis 
reaction (such as occurrence of signal dephasing within sequencing clusters) (Dohm et al., 
2008; Metzker, 2010). Another error source is the dinucleotide context (i.e. the base in question 
Materials and Methods 
74 
 
and the previous base) which can influence whether the quality score is over- or under-
estimated (DePristo et al., 2011). Thus, raw base quality scores as reported by Illumina need to 
be recalibrated to make them closer to the true empirical base quality. The effect of base quality 
score recalibration is illustrated in Figure 2.10. 
 
Figure 2.10: Effect of base quality score recalibration on improving score accuracy. Adapted from 
(DePristo et al., 2011). 
 
 
The GATK BaseRecalibrator module was used to establish empirical base quality scores. In 
addition to adjusting the quality score based on position in read and dinucleotide context, 
BaseRecalibrator treats each mismatch between the aligned data and the reference as a 
mismatch and lowers the quality score accordingly. Clearly, true variants must not be counted 
as mismatches and this is addressed by inputting a list of known variant sites in S. cerevisiae. 
Such known variants were compiled from three sources. The list of known indels described in 
Section 2.22.3 formed one of the inputs. Additionally, a list of SNPs was compiled from the 
same source (SGD). Finally, a list of S. cerevisiae SNPs was obtained from Ensembl on 9 Aug 
2015 (Cunningham et al., 2015). SGD and Ensembl lists comprise different strains and were 
therefore combined together to maximise the number of variants available.  The list of strains 
whose SNP and indel data were included during base quality score recalibration is found in 
Appendix 7.1. The output of BaseRecalibrator comprised an information table for base quality 
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score recalibration. This information table was used as input for the GATK PrintReads module 
run with the BQSR option in order to create a new BAM file that contained the appropriately 
adjusted base quality scores. 
 
2.22.6. Removal of reads that fail to map, do not map uniquely or map with 
inadequate quality 
The SAMtools “view” command was used to filter the BAM file to eliminate unmapped, 
non-unique or poorly mapped reads. The “-q 30” option removed any reads with a mapping 
quality score of less than 30. This also eliminated any reads that have two or more alignments 
to the reference, as any such read would have a maximum mapping quality score of 3. The “-f 
0x0.0002” option was used to only retain reads that were in proper pairs. Finally, the “-F 
0x0004” and “-F 0x0008” options eliminated any reads in which the read itself or its mate 
failed to map to the reference at all. Finally SAMtools was used to index the final processed 
BAM file. 
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2.23. Genomic variant calling 
An overview of the variant calling pipeline is provided below in Figure 2.11. 
 
Figure 2.1: Overview of the genomic variant calling data workflow. 
 
The “mpileup” command of SAMtools was used with the “-u” (uncompressed output) and 
“-f” (reference genome in FASTA format) options to convert the BAM file created in Section 
2.22.6 to BCF format containing all the genomic positions. This global BCF file was then 
reduced to only the variant positions between the alignment and the reference genome using 
BCFtools v1.2-74-g6ccecd1+. The “call” command using options “-c” (specifies the original 
BCFtools calling method) “-g” (outputs a genomic VCF) and “-v” (limits the output to only 
the variant sites). The resultant VCF file was filtered to only retain variants that had a minimum 
depth coverage of 15X and a minimum variant quality score of 30 by virtue of the BCFtools 
“view” command in combination with the “-i 'MIN(DP)>=15 && MIN(QUAL)>=30' ” option. 
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2.24. Next generation sequencing-bulk segregant analysis (NGS-BSA)—
allele frequency calling 
An overview of the allele frequency calling pipeline is provided in Figure 2.12. Further 
description of specialised file formats used exclusively for allele frequency calling (such as 
sync files and count files) are described in the text. 
 
 
Figure 2.2: Overview of the allele frequency calling data workflow. 
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2.24.1. Creation of pileup file 
The “mpileup” command of SAMtools was used with the “-f” option to convert the BAM 
file created in Section 2.22.6 to pileup format. While the pileup file contains the basic 
information about allele frequencies at each genomic position, two modifications were required 
before it could be used in downstream analysis: 
 
a.) The pileup had to be converted into a “count file” in order to be compatible with 
downstream analysis software. The count file is a text file consisting of three columns. 
The first column denotes the position of each variant site. The second and third columns 
represent the counts of either the first or the second parent’s allele at that position. Each 
chromosome must have a separate count file. An example of the count file format is 
provided in Figure 2.13. 
 
b.) The count file must be edited to contain only allele counts at positions of known variant 
sites between the two parents. These variant positions were determined as described in 
Section 2.23. Only SNPs were included in this analysis. 
 
 
Figure 2.3: Example of count file format. 
File only contain positions that were confirmed as SNPs between Parents 1 and 2, which were established 
through a prior whole genome sequencing analysis. 
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2.24.2. Creation of count file 
Popoolation2 v1201 (Kofler et al., 2011) was used to convert the information contained in 
the pileup file to a format containing numerical counts of  nucleotides at each position in the 
genome. The mpileup2sync Perl script of Popoolation2 was used to create an output format 
known as a sync file. A sync file contains genomic positional information, the identity of the 
reference allele and counts, as well as the identity of nucleotides at that position. An example 
of a sync file layout is illustrated in Figure 2.14. 
 
Figure 2.24: Example of sync file format. File contains counts of every nucleotide at every genomic position.  
 
The sync file was manually edited to get it into the format of the count file. The resulting 
count file was further edited to only contain positions that were established to contain true 
variants (as determined in Section 2.23) and partitioned by chromosome.  
 
2.24.3. Editing of count file for MULTIPOOL compatibility 
MULTIPOOL (Edwards & Gifford, 2012) was used for the final analysis of allele 
frequency. MULTIPOOL is a software tailored for analysis of pooled NGS data in order to 
model allele frequencies and determine areas of association between allele frequency and 
phenotype along the genome. It uses the information for every SNP marker (as input by the 
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count file) to calculate maximum likelihood estimates (MLE) of allele frequencies within 
equal-sized bins along the genome (default bin size being 100 bp). Calculation of MLE 
provides a more clear view of allele frequencies than would be gained from looking at raw 
allele frequencies, due to the inherent noise of NGS data. A comparison of MLE-calculated 
allele frequencies versus raw allele frequencies is provided in Figure 2.15 to illustrate this 
point. In addition, it reports logarithm of odds (LOD) scores that are a measure of association 
between genotype and phenotype. In the “contrast” mode of MULTIPOOL (as was used in this 
study) the LOD score denotes regions of significant allele frequency differences between a case 
(or in this case, drug-treated) and a control population. 
 
Figure 2.35: Exemplar output of allele frequencies as provided by MULTIPOOL. 
Green markers denote raw allele frequencies at each SNP position, as calculated from count files. Blue line 
denotes MLE calculations of allele frequencies calculated by MULTIPOOL. 
 
Prior to MULTIPOOL analysis, several amendments had to be made to the count file to 
ensure optimal results. First, SNPs were filtered by distance using VCFtools (Danecek et al., 
2011) to ensure they come from independent reads. For this, the “--thin” command was used 
Materials and Methods 
81 
 
to eliminate SNPs that were less than 125 bp apart (based on the read length used during 
segregant population sequencing, Section 2.21.2). Previous publications have reported that 
MULTIPOOL produces false positive LOD peaks when SNPs are fixed for one of the parental 
alleles (Albert et al., 2014; Clowers et al., 2015). Therefore, as per recommendation in the 
Albert and Clowers publications, positions in which the allele of either parent was <0.1 or >0.9 
were eliminated. Furthermore, SNP positions that were covered by fewer than 15 reads were 
also removed to prevent low-coverage sites skewing the final results. Finally, the resultant 
count files for the control segregant population and the drug-treated population were edited to 
contain matching SNP sites. 
 
2.24.4. Use of MULTIPOOL to determine genomic regions associated with 
drug response 
MULTIPOOL was run in “contrast” mode in order to determine genomic regions that 
showed significant differences in allele frequency between the control segregant population 
and the drug-treated segregant population. The number of base pairs per centiMorgan (as 
defined by the “-c” parameter) was reduced from the default 3300 bp to 1500 bp to account for 
the increased recombination introduced during the establishment of AILs. This value was 
estimated based on measurement of “base pairs per centiMorgans” as used by Parts et al. during 
their construction of F12 AILs (Parts et al., 2011). The pool size (defined by the “-n” parameter) 
was set to 10,000. The ten-fold reduction from the actual estimated pool size in the segregant 
population was introduced to account for the fact that not all segregants may be represented in 
the final population. This makes the LOD score from MULTIPOOL a conservative estimate of 
the true association between genotype and phenotype. This is in line with the approach taken 
by other studies that employed this software (Albert et al., 2014; Clowers et al., 2015; Edwards 
et al., 2012). 
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2.25. Determination of quantitative trait loci (QTL) associated with drug 
response 
The LOD score output for each sample (as determined in Section 2.24.4) was used for all 
QTL analysis. The details of the samples (yeast cross and drug dosage used) are reported in 
more detail in Chapter 5. 
 
2.25.1. Setting of significance threshold for QTL analysis 
For each sample, the LOD scores over the entire genome were compiled into a single list to 
determine the genome-wide significance threshold for that sample. LOD scores were converted 
to p-values using the calculation provided by Nyholt 2000 (Nyholt, 2000). A Benjamini and 
Hochberg False Discovery Rate (FDR) was determined at a significance level of 0.0001 (which 
would normally correspond to a LOD score of approximately 3). The number of trials was set 
as the number of bins tested by MULTIPOOL. The adjusted p-value from this calculation was 
converted to a LOD score and this was used as a significance threshold for that sample. 
 
2.25.2. Identification of QTL 
LOD scores were plotted against genomic position as a scatter plot. Following the 
establishment of the significance threshold, any region with a LOD score that fell above the 
threshold was considered a putative QTL. The centre of the QTL was deemed to be the 
inflexion point of the LOD graph (i.e. the peak). Furthermore, the interval of the QTL (that is, 
what portion of the genome is captured within the QTL) was determined to be the region that 
lies within 3.0 LOD scores of the QTL peak (Cubillos et al., 2013). An illustration of how a 
QTL was determined is provided in Figure 2.16. When comparing between samples, a QTL 
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was deemed to be the same if the two QTL intervals under comparison fell within 10 kb of 
each other (Cubillos et al., 2013). 
 
Figure 2.46: Determination of QTL based on LOD chart. The QTL peak was defined as any inflection point 
that fell above the significance threshold. The QTL interval was the genomic interval that was captured 
within three LOD scores of the QTL peak. 
 
 
QTL 
peak 
QTL 
interval 
L
O
D
 s
c
o
re
 
Genomic position 
Significance threshold 
 85 
 
Chapter 3: Drug response testing for SGRP collection; 
selecting candidate strain for further study 
 
3.1. Introduction 
3.1.1. The SGRP collection as a source of individual strains 
This Chapter furthered the aim of investigating the genetic basis of individual variation in 
drug response using natural strains of S. cerevisiae in the set of 33 strains from the 
Saccharomyces Genome Resequencing Project (henceforth referred to as the SGRP strains). 
The Chapter describes testing growth response to two antifungal agents with characterised 
cellular targets: benomyl and ketoconazole. The strains in the SGRP collection were originally 
selected to represent the greatest range of genetic backgrounds possible in order to capture the 
diversity present in Saccharomyces cerevisiae as a species (Liti et al., 2009).  The majority of 
the SGRP strains have now been re-sequenced by SGRP to a high coverage using Illumina 
sequencing (Bergström et al., 2014; Skelly et al., 2013; Song et al., 2015; Strope et al., 2015). 
Phylogenetic analysis of these strains indicated that the S. cerevisiae population falls into five 
“clean” lineages (Malaysian, West African, Sake, North American and Wine/European) which 
have uniform SNP diversity along the length of the genome, with most SNPs private to each 
lineage (refer to Fig. 1.8). The rest of the strains are mosaic recombinants between the clean 
lineages as well as other lineages not sampled in the study (Liti et al., 2009). Most of these 
studies have indicated that the SGRP set has a low levels of divergence between each other 
(ranging from 0.5% to 0.8%) and contains a total of 80-88 non-reference (non-S288C) ORFs 
as determined by BLAST-based grouping of novel sequences. (Bergström et al., 2014; Song et 
al., 2015; Strope et al., 2015).   
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A number of phenotypic screens have been performed with members of the SGRP collection 
(Cubillos et al., 2011; Cubillos et al., 2013; Franco-Duarte et al., 2014; Liti et al., 2009; Shapira 
et al., 2014; Skelly et al., 2013; Spor et al., 2014; Tomar et al., 2013; Treusch et al., 2015; 
Warringer et al., 2011; Wimalasena et al., 2014; Zorgo et al., 2012) with some including drug 
response. However, the underlying genetics involved in drug response have not been 
investigated extensively within this collection and most of the inhibitors studied do not have 
application outside the laboratory. In terms of the drugs used in the current study, only 
ketoconazole had been examined using 11 of the SGRP strains as well as 89 other strains 
(Strope et al., 2015). A PDR5 introgressed from S. paradoxus was found to be associated with 
resistance to 10 mM ketoconazole (although none of the 11 SGRP strains carried this 
introgression), while resistance to 20 mM ketoconazole was found to be associated with a 
marker near LST4. However, the small number of individuals (100) used for this association 
study makes it   underpowered for maximising discovery of possible loci to   for ketoconazole 
resistance within the SGRP collection. 
 
3.1.2. The pleiotropic drug response (PDR) system 
Yeast cells have developed an efficient efflux system to eliminate environmental chemicals 
that are taken up known as the pleiotropic drug resistance (PDR) system. The PDR system 
comprises a collection of ATP-binding cassette (ABC) proteins that are plasma membrane or 
vacuole-associated xenobiotic pumps belonging to the major facilitator superfamily (MFS) 
proteins (Gulshan & Moye-Rowley, 2007; Jungwirth & Kuchler, 2006; Kolaczkowska & 
Goffeau, 1999). Upregulation of this system confers a multidrug resistance phenotype to a wide 
range of structurally unrelated xenobiotic substrates. The entire network is chiefly regulated by 
the transcription factors Pdr1p and Pdr3p. These binuclear Zn(II)2Cys6 zinc finger regulators 
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are homologs of each other and produce their action by binding as homo- or heterodimers to 
the PDR element (PDRE) sequence in target genes. The two master regulators have different 
activity levels and different (but partially overlapping) preference for different target genes. 
While Pdr1p and Pdr3p form the main input, the PDR network has additional modulation from 
other stress-regulated transcription factors, such as Yap1p (associated with oxidative stress). 
An overview of the entire system is illustrated in Figure 3.1 and relevant aspects to this thesis 
are discussed in greater detail later in this chapter.  
 
 
Figure 3.1: Overview of the PDR system in S. cerevisiae. Arrows represent upregulation while red blocked 
lines denote inhibition. Adapted from (Jungwirth et al., 2006; Kolaczkowska et al., 1999). 
 
3.1.3 How to measure a drug response 
 
A yeast drug response can be measured using a number of growth assay formats. Serial spot 
dilution assays are a standard agar-based method of comparing a strain to different drugs. It 
can be made semi-quantitative by arbitrary growth scoring. An alternate agar-based growth 
assay (and one that is more amenable to high-throughput screening) is the use of arraying robots 
such as the Singer Rotor HDA, which can replicate colonies in 96, 384, 768 or 1536 colony 
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format. The output is quantitated by measuring colony size with image-recognition software 
(Alamgir et al., 2010; Bloom et al., 2013; Dilworth & Nelson, 2015). 
 
3.1.3. Chapter aim 
The aim of the experiments in this section was to identify candidate strains from the SGRP 
collection that show the most extreme response phenotype (either resistance or sensitivity) to 
benomyl and ketoconazole. These candidate strains were then used to study genetic factors that 
affect drug response. It was desirable for the drug response phenotype to be consistent. 
Therefore, several drug response formats were used for testing and drug responses were 
carefully documented in diploids and haploids of both mating types to ensure robustness of 
phenotype. It would be of greater interest to investigate strains whose drug response phenotype 
is not caused by obvious factors, such alterations in the primary target of the drug in question 
or due to general up- or down-regulation of the PDR system. To this end, the target sequence 
was examined to look for correlations between any polymorphisms and general drug response. 
To eliminate strains whose phenotype could be caused by general hyper/hypoactivation of the 
PDR system, the strains of interest were examined for drug cross resistance or cross sensitivity. 
Additionally the candidate strains selected had to be able to produce fertile offspring when 
mated to the control BY strain as further experiments described in later chapters relied on 
intercross mating. 
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3.2.  Methods and Materials 
 
3.2.1. Dose-response testing of SGRP collection against benomyl and 
ketoconazole 
Benomyl was dissolved in DMSO at a stock concentration of 17.2 mM. Ketoconazole was 
dissolved in DMSO at a stock concentration of 9.4 mM. All drug stocks were stored at -20°C. 
Appropriate volumes of DMSO were used as the control for all dose-response experiments.  
 
Synthetic complete (SC) media was used for all dose-response experiments (media recipes 
are found in Chapter 2). This media was selected when working with drugs over yeast peptide 
dextrose (YPD) media based on the fact that it consists of defined components; conversely, 
YPD media consists of yeast extract, which contains autolysed yeast and their free cellular 
components. Therefore, findings derived from experiments using YPD media could potentially 
be due to drug-media interactions, rather than a reflection of the true effect of the drug within 
the cell. Benomyl was found to be more active at a higher media pH. Therefore, all experiments 
with benomyl were carried out in SC buffered with 25 mM of HEPES.  
 
An initial drug response screen was carried out on the unmodified diploid SGRP collection. 
The initial screening method chosen was a serial dilution spot assay because of its amenability 
to high-throughput screening by robotics and its established reliability. The resistance or 
susceptibility of each strain was determined relative to a BY4743 (MATa/α diploid) control. 
All dose-responses were carried out to a 72-hour end point, as this period was found to provide 
the optimal growth difference in response to drug between the control and SGRP strains. 
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The drug concentrations selected for the initial serial dilution spot assay screen were: 0 µM 
to 500 µM benomyl and 0 µM to 200 µM ketoconazole. The source plate used for pinning onto 
drug plates contained two replicates of each SGRP strain and a total of eight replicates of the 
control BY4743 strain (over a total of four source plates). The experiment was repeated twice. 
Using this procedure the phenotype of the SGRP strains, defined as either resistant or sensitive 
in the initial round of dose-response determinations. Confirmation was done through an 
additional round of serial dilution spot assays using more stringent conditions. At this point, 
the haploid derivatives of the wild type SGRP strains were purchased from the UK National 
Collection of Yeast Cultures (NCYC) and used for all subsequent experiments (these are 
described in Section 2.2). All confirmations were thus done using this haploid collection. 
BY4741 and BY4742 were used as controls for MATa and MATα, respectively. 
 
The drug concentrations selected for the secondary confirmation round of serial dilution 
spot assays were 0 μM to 500 μM benomyl and 0 μM to 160 μM ketoconazole. Two replicates 
were carried out for each SGRP strain. 
 
Because subsequent experiments were carried out in 384-colony format to allow for high-
throughput scanning, the dose-response screen using the entire SGRP haploid strain collection 
was also performed in this format to ensure that the drug response phenotype held up in this 
different format since lab acumen has shown that different formats for screening can give 
different results.   Subsequent experiments used an isogenic, but nevertheless different, control 
from the previous dose-response experiments   being the hoΔ::NatMX4 strain derived from the 
Open Biosystems deletion collection. Thus the hoΔ strain was included in this next round of 
dose-response testing to ensure that it behaved the same way as the BY controls used 
previously. The reasons for the use of this strain are discussed in Chapter 4. 
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The drug concentrations used for the 384-colony format pinning assay were 0 μM to 500 
μM benomyl and 0 μM to 330 μM ketoconazole. The experiment was repeated independently 
three times. 
 
3.2.2. Sequence comparison analysis of the primary drug targets of benomyl 
and ketoconazole 
To determine whether the resistance or sensitivity of selected SGRP strains to benomyl and 
ketoconazole could be attributed to alteration in the coding region of the primary target of each 
drug, a phenotype-genotype association appraisal was carried out. Genomic sequence and 
annotation data for all the SGRP strains was downloaded from the Saccharomyces Genome 
Resequencing Project (SGD Project). The sequence of the ORF of each primary drug target, as 
well as the region directly 1 kb upstream was extracted from the genome and multiple sequence 
alignment was performed as per Section 2.19.  
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3.2.3. Creation and drug response testing of Δpdr1Δpdr3 SGRP strains 
For drug testing of a select few cross-resistant and cross-sensitive strains, Δpdr1Δpdr3 
double deletion mutants were created. The PDR1 ORF was replaced with a nourseothricin 
resistance cassette (NatMX4) and the PDR3 ORF was replaced with a uracil prototrophy 
cassette (UraMX4) to produce pdr1Δ::NatMX4 pdr3Δ::UraMX4 null double mutants in the 
genetic backgrounds of NCYC110, W303 and Y55. The NatMX4 cassette was obtained from 
plasmid p4339 and the UraMX4 cassette came from plasmid pAG60. The source plasmids of 
the cassettes are described in Section 2.11 and were treated and isolated as described in Section 
2.12. For each ORF replacement, a PCR product was created that contained the desired cassette 
flanked by 55 bp regions of homology to the desired genomic target. The PCR was performed 
using conditions described in Section 2.7.1 using primers 351 and 352 (Section 2.6) with the 
p4339 plasmid to create the pdr1Δ::NatMX4 product for transformation. Meanwhile, primers 
353 and 354 were used in conjunction with pAG60 to create the pdr3Δ::UraMX4 product. 
Products were transformed into the desired yeast strain sequentially as described in Section 
2.8. Following each transformation, the correct integration of the ORF replacement construct 
was confirmed through confirmation PCR as described on Section 2.7.4. To confirm the 
pdr1Δ::NatMX4 ORF replacement, primers 365 and 3 were used to produce the front 
confirmation product and primer pair 30 and 366 were used to generate the back product. The 
primer pairs 371 and 370 (front product) and 368 and 369 (back product) were used for the 
analogous confirmation of the pdr3Δ::UraMX4 ORF replacement. 
 
Drug response testing was carried out by serial spot dilution assay, as described in Section 
2.15.2, but was performed independently three times, not twice. The strains tested were the 
three SGRP strains described above, the BY4741 control and the isogenic pdr1Δ pdr3Δ 
derivatives of each. The drug concentrations for testing cross-resistant strains (NCYC110 and 
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Y55) and their pdr1Δ pdr3Δ derivatives were 0 μM to 150 μM benomyl and 0 μM to 75 μM 
ketoconazole. The drug concentrations for testing the cross-sensitive strain (W303) were 0 μM 
to 50 μM. 
 
Testing of oxidative stress tolerance was carried out by pinning the diploid SGRP collection 
onto agar containing increasing concentrations of hydrogen peroxide (H2O2) as described in 
Section 2.15.3. The concentrations of H2O2 used ranged from 0 mM to 316 mM. 
 
3.2.4. Determination of SGRP strain fertility in crosses with BY 
Tetrad dissection was performed as described in Section 2.15 using SGRP strains of interest 
and the control BY strain. Complete absence of viable spores upon dissection or a reduction in 
spores to less than 50% was interpreted as infertility with BY. 
 
3.3.  Results 
 
3.3.1. Dose-response testing of SGRP collection against benomyl and 
ketoconazole 
Only summarised results and raw dose-response data for selected strains of interest are 
presented within this chapter. However, all dose-response graphs can be found in Appendix 
7.2. 
Note: The SGRP collection was also screened against the sterol synthesis inhibitor 
atorvastatin. However, the screening did not produce any candidate strains to take through to 
further analysis. It is considered that this was due to a problem with atorvastatin’s solubility in 
SC media; however, there was inadequate time to rectify it within the scope of this thesis. The 
summary of the atorvastatin screening results is provided in Appendix 7.3. 
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Benomyl 
The initial serial spot dilution assay using the diploid SGRP strain collection showed that 
two strains were sensitive to benomyl while 27 strains were resistant to it. The serial spot 
dilution confirmation showed five strains to be sensitive to benomyl; while, 18 strains were 
resistant.   A number of strains did not maintain their phenotype from the original serial spot 
dilution assay—BC187 MATa, YIIc17_E5 MATa and YS9 MATa switched from being 
benomyl-resistant to benomyl-sensitive. The strains 378604X MATα, BC187 MATα, 
DBVPG1373 and DBVPG6765 though benomyl-resistant in the original assay did not display 
any difference from the BY control. A number of strains also displayed mating type-specific 
differences in terms of benomyl response, including the BY control strain itself. A clear mating 
type-dependent response difference occurred with YIIc17_E5 in which the MATa was highly 
sensitive to benomyl; whereas, the MATα was resistant. There was good correspondence 
between the original serial spot dilution with diploids and the confirmatory serial spot dilution 
with haploids out of 26 of the strains tested in both assays maintained their benomyl response 
phenotype in both mating types.   
 
Using the 384-colony pinning format for drug testing the entire haploid SGRP showed 10 
strains were found to be sensitive to benomyl while 13 strains were resistant. Mating type-
specific response differences were also observed in this assay. Eight of the strains 
(DBVPG6765, L-1528, SK1, UWOPS03-461.4, Y12, YJM981, YPS128 and YPS606) only 
displayed a responsive phenotype (either sensitivity or resistance) in one mating type while the 
other mating type did not differ significantly from the BY control. As in the confirmation serial 
spot dilution assay, YIIc17_E5 MATa displayed extreme benomyl sensitivity, while the MATα 
was benomyl resistant. In contrast to the confirmation serial spot dilution assay, the BY MATa 
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and MATα controls displayed the same MIC in the 384-colony pinning format. Overall, there 
was a poor correlation between the results of the serial spot dilution assay and the 384-colony 
format pinning assay with only nine strains out of 26 that maintained the same benomyl 
response phenotype. An additional five strains displayed a consistent phenotype between the 
two assay formats, but only in a single mating type. Additionally, YJM975 only displayed a 
sensitivity response   in the 384-colony format pinning assay. The assay-dependent differences 
in MIC in drug effect probably reflected differences in initial cell numbers placed onto the 
drug-containing agar. Unfortunately, there was insufficient time to perform an optimisation of 
the starting cell number required to eliminate such differences. 
 
Ultimately, seven strains—DBVPG6044, NCYC110, UWOPS05-217.3, UWOPS05-227.2, 
UWOPS83-787.3, UWOPS87-2421 and Y55—showed a consistent resistant phenotype to 
benomyl in all the three dose-response assays. Two strains, L-1374 and W303, maintained a 
consistently sensitive phenotype to benomyl. These results are presented in Table 3.1, and a 
full list of growth curves is provided in Appendix 7.2.  
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Table 3.1: Overall summary of dose-response testing of the set of SGRP strains against benomyl in different 
testing formats. 
The scoring system of response intensity is as follows:  
-/+ slight susceptibility/resistance (MIC less than two-fold that of the control);  
- -/+ + moderate susceptibility/resistance (MIC at least two-fold that of the control);  
- - -/+ + + high susceptibility/resistance (MIC three or more fold that of the control, or not determined). 
“nil” means the strain response was the same as the BY control 
Strains in red boxes were selected as possible strains of interest for further study, as they maintained a 
consistent drug response phenotype in all three assay formats. Grey boxes denote that no further testing of 
the strain was carried out, either due to lack of drug response phenotype, or due to unavailability of a 
haploid derivative of that strain. 
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273614N + + + + nil 273614N + + + nil 
BC187 + - - BC187 + nil - 
DBVPG1106 + + + nil DBVPG1106 + + nil 
DBVPG1373 + nil nil DBVPG1373 + nil nil 
DBVPG6044 + + + + + + + DBVPG6044 + + + + + + + 
DBVPG6765 + nil nil DBVPG6765 + nil - 
L-1374 - - - L-1374 - - - - 
L-1528 + + + + + + L-1528 + + + +  +* 
NCYC110 + + + + + + + + + NCYC110 + + + + + + + + + 
SK1 + + + + nil SK1 + + +  nil 
UWOPS03-461.4 + + + + UWOPS03-461.4 + + + + nil 
UWOPS05-217.3 + + + + + + UWOPS05-217.3 + + + + + + 
UWOPS05-227.2 + + +  + UWOPS05-227.2 + + + + + 
UWOPS83-787.3 + + + + + UWOPS83-787.3 + + + + + + 
UWOPS87-2421 + + + + + + + + UWOPS87-2421 + + + + + + + + 
Y12 + + nil Y12 + + - 
Y55 + + + + + Y55 + + + + + 
YIIc17_E5 + + - - - - - YIIc17_E5 + + +  + 
YJM975 nil  - YJM975 nil  - 
YJM978 + + nil YJM978 + + nil 
YJM981 + + nil YJM981 + + + - 
YPS128 + + + + + + + YPS128 + + + + + + nil 
YPS606 + + + + + + + YPS606 + + + + + + nil 
W303 - - - - - - - 378604X + nil - 
YS9 + - -  
Represented as diploids only 
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322134S + + +  
DBVPG1788 nil 
DBVPG1853 + + 
DBVPG6040 nil 
K11 + + 
Y9 + 
YS4 nil 
 
Ketoconazole 
The initial serial spot dilution assay with diploids revealed 20 strains sensitive to 
ketoconazole and 11 resistant to this drug. The serial spot dilution confirmation assay with 
haploids narrowed this panel of strains to 14 strains that were ketoconazole sensitive and eight 
that were ketoconazole resistant. Out of the 14 strains that tested as sensitive in both serial 
dilution assays, 11 retained the phenotype in both mating types and one strain retained the 
sensitivity phenotype in one mating type. 273614N MATα and DBVPG1373 MATa switched 
their phenotype in the confirmation assays to being ketoconazole resistant.  Out of the eight 
strains that tested resistant in both assays, only five were confirmed as resistant in both mating 
types.    
 
The 384-colony format pinning assay of the entire haploid SGRP collection identified 18 
strains that were sensitive to ketoconazole and 10 that were resistant. Comparison of the initial 
serial spot dilution testing of the diploid SGRP collection with the 384-colony format pinning 
of the SGRP haploid collection indicated a fairly good agreement in the ketoconazole 
responses, unlike what was found for benomyl. Out of the 26 strains tested in both formats, 15 
showed the same ketoconazole response phenotype in both assays with some differences in the 
magnitude of the response: BC187 (both mating types), YJM981 MATα and YS9 MATa were 
only ketoconazole-responsive in the 384-colony pinning format. YIIc17_E5, YJM975 were 
both classified as highly ketoconazole-resistant in the initial serial spot dilution assay; however, 
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in the 384-colony pinning format assay, only the MATa of both these strains was resistant, 
while the MATα was sensitive. This is likely to indicate some sort of mating type-specific 
effect. A mating type-specific response was also observed in the 384-colony pinning format 
for the BY control strain, in which the MATα displayed a higher MIC than MATa (200 µM 
compared to 160 µM). This multiple level analysis of strain phenotype with ketoconazole, as 
with benomyl described above, eliminated many strains from further consideration due to 
unreliable drug response phenotype.  
 
Ultimately, two strains—DBVPG6044 and NCYC110—showed a consistently resistant 
phenotype to ketoconazole in all three dose-response assays (i.e. in the spot serial dilution 
initial screen, the spot dilution confirmation screen and the 384-colony plate assay). Eight 
strains, 378604X, UWOPS03-461.4, UWOPS05-217.3, UWOPS05-227.2, UWOPS83-787.3, 
UWOPS87-2421, Y12 and W303, were classified as sensitive to ketoconazole, based on the 
outcome of all three assays. 
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Table 3.2: Overall summary of dose-response testing of the set of SRP strains against ketoconazole in 
different testing formats. The scoring system of response intensity is as described in Table 3.1 
MATa MATα 
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273614N - + - 273614N - - - - - 
BC187 nil  - BC187 nil  - 
DBVPG1106 - nil - DBVPG1106 - - - 
DBVPG1373 - - + + DBVPG1373 - - nil + 
DBVPG6044 + + + + + + + + + DBVPG6044 + + + + + + + + + 
DBVPG6765 + + + + nil DBVPG6765 + + + + - 
L-1374 + + + nil + L-1374 + + + nil + 
L-1528 + + + + + + nil L-1528 + + + + + + nil 
NCYC110 + + + + + + + NCYC110 + + + + + + + + + 
SK1 - - - - + SK1 - - - - - nil 
UWOPS03-461.4 - - - - - - - UWOPS03-461.4 - - - - - - - - 
UWOPS05-217.3 - - - - - - - UWOPS05-217.3 - - - - - - - - 
UWOPS05-227.2 - - - - - - - - UWOPS05-227.2 - - - - - - - - 
UWOPS83-787.3 - - - - - UWOPS83-787.3 - - - - - - - 
UWOPS87-2421 - - - - UWOPS87-2421 - - - 
Y12 - - - - - Y12 - - - - - - - 
Y55 + + + Y55 + + + nil 
YIIc17_E5 + + + nil + + + YIIc17_E5 + + + + - 
YJM975 + + + + + + + YJM975 + + + nil - 
YJM978 + + + nil + YJM978 + + + nil nil 
YJM981 nil  nil YJM981 nil  - 
YPS128 - - - nil YPS128 - - - 
YPS606 - - - - nil YPS606 - - - - 
W303 - - - - - - 378604X - - - - - 
YS9 nil  -  
Represented as diploids only 
322134S + + +  
DBVPG1788 + + + 
DBVPG1853 - - 
DBVPG6040 - - 
K11 - - 
Y9 - - 
YS4 - 
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The strains that showed a consistent drug response phenotype, outlined in red as described 
above, made up the list of candidate strains that could be used for further study of the genetic 
determinants of drug response as described in subsequent chapters. 
 
3.3.2. Sequence comparison analysis of primary drug target of benomyl and 
ketoconazole 
To determine whether resistance or sensitivity response to benomyl and ketoconazole could 
be attributed to alterations in the primary target of each drug, a comparison was made between 
variants in the ORF and its upstream region (1 kb directly upstream) of the gene encoding each 
drug target and the response exhibited to that drug by the SGRP collection. 
 
The benomyl target TUB2 harboured 12 variants in the various SGRP strains in the upstream 
region and 18 in the coding region. Only one of the 18 coding region SNPs was predicted to 
cause any amino acid change, with the remaining 16 being synonymous substitutions. Position 
282 harboured a single base deletion in Y9 and Y12, predicted to cause a frameshift for almost 
90% of the ORF. This is surprising, as TUB2 is an essential gene and such a large modification 
would be expected to have catastrophic consequences. It is not clear whether there is a 
compensating suppressor mutation that partially restores the function of TUB2. Furthermore, a 
BLAST search of the SGRP sequence information does not reveal a redundant copy of TUB2. 
It is therefore not clear how the cell may compensate for such a large alteration and mistakes 
in the source sequencing data cannot be ruled out. Also, some strains display a glutamine to 
arginine substitution at position 446 of the ORF. However, this is present at the very end of the 
ORF, only 11 residues from the end. Overall, the whole region was highly similar between all 
strains, showing 99.8% pairwise identity. The alignment results (stripped to only present 
variant regions) are displayed in Table 3.3. 
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Table 3.3: Nucleotide variants within TUB2 ORF and 1kb upstream. Aligned using MUSCLE iterative 
multiple alignment, as output by Geneious. “.” symbol denotes that nucleotide is identical to consensus 
sequence. Strains arranged by alignment similarity. 
 
Strain name P
o
s
itio
n
 
(re
la
tiv
e
 
to
 
s
ta
rt c
o
d
o
n
) 
C
o
n
s
e
n
s
u
s
 
L
-1
5
2
8
 
U
W
O
P
S
0
3
-4
6
1
-4
 
U
W
O
P
S
0
5
-2
1
7
-3
 
U
W
O
P
S
0
5
-2
2
7
-2
 
Y
P
S
1
2
8
 
Y
P
S
6
0
6
 
U
W
O
P
S
8
3
-7
8
7
-3
 
R
E
F
E
R
E
N
C
E
, B
Y
 
W
3
0
3
 
D
B
V
P
G
6
0
4
4
 
N
C
Y
C
1
1
0
 
S
K
1
 
Y
5
5
 
Y
S
9
 
D
B
V
P
G
1
8
5
3
 
D
B
V
P
G
6
0
4
0
 
Y
9
 
Y
1
2
 
3
7
8
6
0
4
X
 
U
W
O
P
S
8
7
-2
4
2
1
 
K
1
1
 
2
7
3
6
1
4
N
 
D
B
V
P
G
1
1
0
6
 
D
B
V
P
G
1
3
7
3
 
Y
S
4
 
B
C
1
8
7
 
D
B
V
P
G
1
7
8
8
 
3
2
2
1
3
4
S
 
D
B
V
P
G
6
7
6
5
 
L
-1
3
7
4
 
Y
IIc
1
7
 E
5
 
Y
J
M
9
8
1
 
Y
J
M
9
7
5
 
Y
J
M
9
7
8
 
-959 C . T T T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-856 A . G G G . . . G G . . . . . . . . . G G G . . . . . . . . . . . . . 
-742 M A C C C A A A C C C C C C A C C C C C C C A A A C A A A A A A A A A 
-637 G . A A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-472 G . . . . . . . A A . . . . . . . . . . A . . . . . . . . . . . . . . 
-460 G A . . . . . . . . . . . . . . . . . . . . A A A . . . . . . . . . . 
-260 G . . . . A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-219 A - . . . . . . . . . . . . - . . . . . . . . . - . - - - - - - - . . 
-209 G . . . . . . . . . . . . . . . . . . . . . . . . . . C . . . . . . . 
-149 A . . . . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . 
-42 G A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-38 T . . . . C C . C C C C C C . . . . . C . . . . . . . . . . . . . . . 
+27 A G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+33 G A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+57 A G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+81 G A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+123 T C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+162 A G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+198 C . . . . . . . . . G G G G . . . . . . . . . . . . . . . . . . . . . 
+255 T C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+282 A G . . . . . . . . . . . . . . . - - . . . . . . . . . . . . . . . . 
+297 C T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+321 A T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+345 C T T T T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+519 A . . . . . . . G G . . . . . . . . . . . . . . . . . . . . . . . . . 
+804 C . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . 
+912 T . C C C . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+930 C . T T T . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+1125 A . . . . . . . . . . . . . . . . . . . . . . . . . G . . . . . . . . 
+1337 A G . . . . . . . . . . . . . . . . . . . . G G G G G G G G G G G G G 
 
Strain colour key:  
 Completely resistant (resistant phenotype in every assay trialled) 
 Mostly resistant (resistant phenotype in every assay, but "nil" or "R*" phenotype in one assay) 
 Completely sensitive (sensitive phenotype in every assay trialled) 
 Mostly sensitive (sensitive phenotype in every assay, but "nil" phenotype in one assay) 
 
Strains with ambiguous drug response phenotypes are left uncoloured. 
Nucleotide colouration corresponds to polymorphism effect. Colour key: 
 Synonymous substitution 
 Nonsynonymous substitution; similar amino acid 
 Nonsynonymous substitution; divergent amino acid 
 Frameshift 
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The target of ketoconazole ERG11 harboured 44 variants in the SGRP strains —only 14 of 
those within the coding region of the gene. Only two of the 14 coding variants were 
nonsynonymous and there were no indels in the coding region. The first nonsynonymous 
substitution was at position 1299 in the ERG11 ORF (just over 80% through the ORF) and 
altered a phenylalanine to a valine in the resultant protein. The second substitution occurred at 
position 1325 and produced a change from threonine to alanine in the resultant protein. There 
was 99.7% pairwise identity between all the sequences. 
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Table 3.4: Nucleotide variants within ERG11 ORF and 1kb upstream. Italicised positions lie within the 
neighbouring ORF YHR007C-A. Symbols, colour keys and strain arrangement as described in Table 3.3. 
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-999 T C C C C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-996 C . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . 
-980 T . . . . . . . . . . . . . . C C C . . . C C . C C C C C C . . . . . 
-959 - T T T T T T T T T T T T T T . . . T T T . . . . . . . . . . . . . . 
-958 - T T T T T T T T T T T T T T . . . T T T . . . . . . . . . . . . . . 
-957 C T T T T T T T T T T T T T T . . . T T T . . . . . . . . . . . . . . 
-794 T . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-776 A . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . 
-735 G . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . 
-730 A . . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . 
-670 A . . . . . . . . . . . . . . . . . G G . . . . . . . . . . G G G G . 
-638 A . . . . . . G G G G . . . . G . . . . . . . . . . . . . . . . . . . 
-515 C . . . . . . . . . . . G G G . . . . . . . . . . . . . . . . . . . . 
-511 - A A A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-510 - A A A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-509 - A A A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-508 - C C C C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-507 - G G G G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-371 A G G G G G G G G G G G G G G G G G . . . . . . . . . . . . . . . . . 
-332 A . . . . . . . . . . . . . . . . . . . . . G G G G G G G G . . . . . 
-305 A G G G G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-209 C . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . 
-195 C G G G G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-191 T A A A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-145 A G G G G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-105 T C C C C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
-83 T . . . . . . . . . . . A A A . . . . . . . . . . . . . . . . . . . . 
-63 A T T T T T T T T T T . . . . T T T . . . . . . . . . . . . . . . . . 
-56 T . . . . . . . . . . . . . . . . . A A . . . . . . . . . . A A A A . 
-53 T . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . 
+66 C T T T T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+207 T A A A A A A A A A A . . . . A . . . . . . . . . . . . . . . . . . . 
+369 G A A A A A A A A A A A A A A A A A . . . . . . . . . . . . . . . . . 
+654 A . . . . G G . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+738 A . . . . . . G G G G . . . . . . . . . . . . . . . . . . . . . . . . 
+1197 C . . . . . . . . A A . . . . . . . . . . . . . . . . . . . . . . . . 
+1203 A . . . . . . . . . . . T T T . . . . . . . . . . . . . . . . . . . . 
+1239 T C C C C C C C C C C . C C C . . . C C C . . . . . . . . . . . . . . 
+1299 C . . . . . . . . . . . . . . . A A . . . A A A A A A A A A . . . . . 
+1320 C T T T T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+1325 G . . . . . . . A A A . . . . . . . . . . . . . . . . . . . . . . . . 
+1437 G A A A A A A . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
+1458 T C C C C C C C C C C . C C C . . . C C C . . . . . . . . . . . . . . 
+1500 C T T T T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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3.3.3. Involvement of the PDR system in drug response of SGRP collection 
Atorvastatin (whose results are reported in Appendix 7.3), benomyl and ketoconazole are 
all substrates of the PDR efflux system. Therefore, it was presumed that if strains did not show 
resistance across all three dose-response testing formats (or sensitivity across all three testing 
formats) to all the three drugs, it was unlikely that their drug response arose as a result of a 
universal upregulation (or downregulation) of that system. This was the case for all the SGRP 
strains except for four: DBVPG6044, NCYC110, Y55 (which showed some level of resistance 
to both drugs) and W303 (which was hypersensitive to both). To investigate the role of PDR 
in these strains, a double deletion of PDR1 and PDR3 was attempted in each, with the intention 
of re-testing them against all three drugs. While the construction of the double deletion mutant 
was successful in NCYC110, Y55 and W303, it unfortunately was not achieved in 
DBVPG6044. The results for the testing of resistant across the strains are displayed in Figure 
3. 2.  
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Figure 3.2: Testing the involvement of the general PDR system in the drug resistance of Y55 and NCYC110. 
Strain arrangement is the same in all images, so is only indicated for the first image. All three replicates 
tested were similar to the results displayed above. 
 
The Y55 Δpdr1Δpdr3 double mutant appeared to have increased sensitivity to benomyl 
compared to its PDR-proficient counterpart. It was thus concluded that the PDR system appears 
to play a role in the benomyl resistance of Y55. However, this did not appear to be the case 
with NCYC110. In terms of ketoconazole response, neither the Y55 Δpdr1Δpdr3 double 
mutant nor the NCYC110 Δpdr1Δpdr3 double mutant appeared to have a growth defect 
compared to their wild type controls and indeed appeared to show a slight resistance. It is not 
known why such a resistance may arise. Overall   the PDR system did not appear to be involved 
in the resistance NCYC110 and Y55 display towards ketoconazole. 
 
0 µM 37.5 µM 75 µM 112.5 µM 150 µM 
Benomyl 
0 µM 12.5 µM 25 µM 50 µM 75 µM 
Ketoconazole 
a b c d e f 
a BY 
b BY Δpdr1,3 
c Y55 
d Y55 Δpdr1,3 
e NCYC110 
f NCYC110 Δpdr1,3 
Strain names: 
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A representative serial spot assay dilution is shown in Figure 3.3 for testing the involvement 
of the PDR system in the cross-sensitive drug phenotype of W303. 
 
Figure 3.3: Testing the involvement of the general PDR system in the drug sensitivity of W303. 
Strain arrangement is the same in all images, so is only indicated for the first image. All three replicates 
tested were similar to the results displayed above. Results for ketoconazole showed the same pattern of 
response and thus are not displayed. 
 
 
The W303 Δpdr1Δpdr3 double mutant displays a clear growth defect compared to its 
unaltered counterpart. If the cross-sensitivity of W303 was caused by a general down-
regulation of the PDR system, it would be expected that its wild type would bear a closer 
resembalance to the PDR-deficient mutant, but this does not appear to be the case. Therefore, 
the general down-regulation of the PDR system was not deemed to have a role in the drug 
sensitivity of W303. 
 
Additionally, the three   strains showing resistance and the single sensitive strain were tested 
for their ability to withstand oxidative stress by testing their response against H2O2. Three of 
the strains (DBVPG6044, NCYC110 and W303) displayed H2O2 sensitivity compared to the 
control BY strain, while Y55 appeared to match BY in its anti-oxidative potential (Figure 3.4). 
Therefore, while the drug sensitivity of W303 may be due to its decreased ability to handle 
0 µM 12.5 µM 37.5 µM 25 µM 50 µM 
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oxidative stress, the analogous conclusion cannot be drawn for DBVPG6044, NCYC110 and 
Y55 (that is, their cross-resistance to all three drugs does not correlate with increased potential 
to handle oxidative stress). 
 
 
  
Figure 3.4: 384-colony format pinning of DBVPG6044, NCYC110, W303 and Y55 on increasing 
concentrations of H2O2. Data are represented as mean ± SD. 
 
3.3.4. SGRP strains discontinued from further testing 
During the course of the investigation, a number of strains were found to be problematic in 
a variety of ways (data not shown). The following strains were found to be partially or fully 
inviable when crossed with the control BY strain, which precluded their use in further analysis: 
UWOPS03.-461.4 
UWOPS05-217.3 
UWOPS05-227.2 
UWOPS83-787.3 
YIIc17_E5 
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Apart from these, two other strains were discontinued. NCYC110 had overall low viability 
and displayed unusual growth characteristics, in that it formed colonies of highly variable size. 
It was therefore discarded, as later experiments relied on creating crosses between two parental 
strains with approximately equal growth rates; having one parent with a clear disadvantage 
would likely create a bias against that parent in terms of its genetic contribution to the offspring 
(see Chapter 5 for further details). Meanwhile, although all the commercially ordered strains 
were supposed to have the hoΔ::HphMX4 construct, W303 failed to grow on hygromycin B 
selection media. This likely indicated some deficiency with that construct in this particular 
strain. Unfortunately, as the hoΔ::HphMX4 was used in later experiments for diploid selection 
between parents, this meant that W303 could not be used as a parental strain. 
 
3.3.5 SGRP strains selected for further investigation. 
After eliminating the problematic strains discussed in Section 3.3.4, there were three 
candidate strains left (DBVPG6044, UWOPS87-2421 and Y55) that could be used to study 
benomyl resistance. From these, UWOPS87-2421 was selected as it showed the greatest extent 
of resistance. L-1374 was selected for investigating benomyl sensitivity by virtue of being the 
only option. In a similar fashion, DBVPG6044 was selected for investigating ketoconazole 
resistance. 378604X, UWOPS87-2421 and Y12 remained available for looking at ketoconazole 
resistance. 378604X was only represented in the collection as MATα and thus it could not be 
discounted that it would be consistently ketoconazole sensitive in both mating types. Out of 
the two remaining strains, Y12 was selected due to it greater sensitivity. 
 
Representations of the strains selected for further study are presented in Figures 3.5 and 3.6. 
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A 
 
 
 MIC (BY4741) = 300 µM 
MIC (UWOPS87-2421 MATa) = ND 
MIC (BY4742) = 300 µM 
MIC (UWOPS87-2421 MATα) = ND 
B 
  
 MIC (BY4741) = 300 µM 
MIC (L-1374 MATa) = 200 µM 
MIC (BY4742) = 300 µM 
MIC (L-1374 MATα) = 150 µM 
Figure 3.5: 384-colony format pinning of the strains selected or studying resistance (A) and sensitivity (B) 
to benomyl. Data are represented as mean ± SD. 
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A 
  
 MIC (BY4741) = 160 µM 
MIC (DBVPG6044 MATa) = ND 
MIC (BY4742) = 200 µM 
MIC (DBVPG6044 MATα) = ND 
B 
  
 MIC (BY4741) = 160 µM 
MIC (Y12 MATa) = 100 
MIC (BY4742) = 200 µM 
MIC (Y12 MATα) = 100 
Figure 3.6: 384-colony format pinning of the strains selected or studying resistance (A) and sensitivity (B) 
to ketoconazole. Data are represented as mean ± SD 
 
3.4. Discussion 
The goal of this part of the study was to narrow down the available SGRP collection of 33 
strains to a more practical number in order to carry those through for further study of the genetic 
underpinning of drug response phenotypes (one resistant and one sensitive strain for each 
drug). There was an attempt to avoid strains whose drug response was due to “trivial” factors. 
These were eliminated because it was deemed that they would not be informative for the 
purposes of answering what cellular-level or off-target pathways might control drug response. 
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Ultimately UWOPS87-2421 and L-1374 were selected for investigating benomyl response 
while DBVPG6044 and Y12 were selected for studying response to ketoconazole.  
 
The first experiment tested the entire SGRP collection against benomyl and ketoconazole in 
two agar-based dose-response formats (those being serial spot dilution assays and 384 format 
colony pinning). Agar-based methods for testing drug response were chosen over liquid-based 
approaches as they were considered more suitable for this particular study. Liquid-based 
culturing methods may be prone to spontaneous drug-resistant mutants overtaking the culture 
and giving rise to incorrect results (Wilkening et al., 2014); this may be of particular concern 
due to the prolonged drug treatment period (72 hours) chosen for this study. However, a more 
pertinent problem was that the natural flocculence exhibited by many strains in this collection 
made them refractory to correct optical density-based measurements. The variance in drug 
response phenotype between the two testing formats highlighted the importance of using 
different measures in order to get more robust data. Such robustness was confirmed by the 
study of Strope et al, who subsampled the SGRP collection—seven of the nine strains 
(273614N, DBVPG1853, NCYC110, UWOPS87-2421, Y12, Y55 and YPS606) grown in 20 
mM ketoconazole displayed the same pattern of response phenotype as was found in the current 
study (Strope et al., 2015). It is not clear why mating-type specific responses arise, although 
mating type was shown to influence MAPK-mediated traits (Treusch et al., 2015). 
 
Genotype-phenotype analysis of the entire SGRP collection between the sequence of the 
primary drug target and response to that drug did not identify any variants exclusive to any of 
the drug response phenotypes. Ideally this would suggest that the variance in drug response of 
the SGRP collection to both drugs trialled is likely to be an off-target effect. However, since 
some strains harbour substitution mutations, such a statement cannot be made conclusively. 
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Other investigations into drug response on a cellular level have found multiple QTL, many of 
them outside the primary drug target under investigation and not related to the primary 
mechanism of the drug or the PDR system, and these details for benomyl and ketoconazole are 
discussed in greater detail in Chapter 5. 
 
It was determined that a general up- or downregulation of the PDR system is not likely to 
be the main contributor to drug response for most of the strains due to lack of cross-resistance 
or cross-sensitivity to all three drugs that were trialled in this thesis. The limitation remains that 
benomyl and ketoconazole (the agents selected for further analysis) have preferential affinities 
for different efflux pumps—ketoconazole is exported by Pdr5p while benomyl is handled by 
Snq2p (Fowler et al., 2011; Rogers et al., 2001). this work did not examine possible variations 
in single pumps that may have affected response to only one of the drugs. Nevertheless, the 
role of the PDR system was directly tested in strains that displayed cross-resistance and cross-
sensitivity to both drugs by creating Δpdr1Δpdr3 mutants. Interestingly, while PDR appears to 
play a role in the resistance of Y55 to benomyl, this effect is not observed for ketoconazole, 
despite both drugs being PDR substrates. It is unfortunate that the DBVPG6044 Δpdr1Δpdr3 
mutant was not derived in the scope of this thesis, due to a lack of successful pdr1Δ::NatMX4 
pdr3Δ::HphMX4 transformants. However, such a mutant may be expected to display a similar 
PDR phenotype as NCYC110 and Y55, which are related to it (see Figure 1.8).  
 
The role of oxidative stress response was briefly examined as well, based on the cross-talk 
between the PDR and the oxidative stress system through Yap1p (as is discussed in the 
introduction of this chapter). However, there did not appear to be any correlation between 
response to oxidative stress (as tested through resistance to H2O2) and cross-resistance (or 
cross-sensitivity) to the drugs trialled in this study. All four strains trialled (those being 
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DBVPG6044, NCYC110, W303 and Y55) showed varying degrees of sensitivity to H2O2. It is 
not clear why this sensitivity to oxidative stress was present. However, this finding is supported 
by a previous study that examined response of the same four strains to paraquat (which 
generates superoxide anions) (Warringer et al., 2011). Specifically, it was found that the four 
strains have a reduced growth efficiency and rate in the presence of 250 µg/mL and 400 µg/mL 
paraquat. 
 
Finally, the lack of fertility shown by certain strains in the SGRP collection has been 
reported by others. Cubillos et al. found that UWOPS03-461.4 was infertile when crossed to 
any of the other four strains representing the major lineages in the SGRP collection, although 
it shows full intra-lineage fertility (eliminating the possibility of a tetrad formation defect) 
(Cubillos et al., 2011). This is in agreement with this and other strains of the Malaysian lineage 
being infertile when crossed with the reference strain (Naumov et al., 2006). Tetrad analysis 
by Strope et al. also recapitulated other dramatically reduced fertilities between SGRP strains 
and S288C—UWOPS83-787.3 (50.5% viable spores), UWOPS05-227.2 (5.5% viable spores) 
and YIIc17_E5 (56.8% viable spores) (Strope et al., 2015). It is not yet clear what the 
underlying reason for this reduced fertility is, as these strains do not appear to drastically differ 
in terms of sequence divergence and a chromosomal rearrangement has so far not been found. 
However, presumably they harbour some yet-undiscovered genetic incompatibility that 
interferes with meiotic recombination. It is also not clear what caused the reduced viability of 
NCYC110. It has been discovered to be aneuploid for chromosome VII (Strope et al., 2015), 
which may interfere with viability. It is also known that the West African S. cerevisiae strains 
are phenotypically divergent from many of the other strains and carry a series of growth 
deficiencies and temperature sensitivity characteristics (Warringer et al., 2011); however, 
DBVPG6044 (the other closely-related West African strain in the collection) appeared to show 
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relatively normal growth compared to NCYC110, so lineage alone may not explain the 
observed growth defects. 
 
In conclusion, the series of screens performed in this chapter were successful in selecting 
strains for further investigation of benomyl and ketoconazole response—UWOPS87-2421 for 
benomyl resistance, L-1374 for benomyl sensitivity, DBVPG6044 for ketoconazole resistance 
and Y12 for ketoconazole sensitivity. The rigorous screening process helped to ensure that the 
selected strains maintain the same drug response phenotype under multiple testing conditions 
and that this response can be confidently used to find  novel loci that contribute to drug 
responses that may not have been described in the literature. 
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Chapter 4: Creation of Advanced Intercross Lines (AILs) 
and Heritability Studies in SGRP Strains of Interest 
 
4.1. Introduction 
The aim of this chapter was to further elucidate the genetic basis of the drug response 
phenotypes exhibited by the four SGRP strains selected in the previous chapter for further study 
(these were UWOPS87-2421 that was resistant to benomyl; L-1374 that was sensitive to 
benomyl; DBVPG6044 that was resistant ketoconazole; and Y12 that was sensitive to 
ketoconazole. All the drug response classifications were made relative to the BY control strain). 
The first question we asked was what proportion of the phenotype could be predicted by genetic 
factors. This can be estimated by measures of heritability, as described in Chapter 1 (Section 
1.2.1). Various calculation methods for heritability have been published (Tenesa & Haley, 
2013; Visscher et al., 2008).   Estimation of broad sense heritability (H2) is fairly straight 
forward if there are phenotype data available for parental strains (as is the case for the four 
strains of interest crossed to the control BY strain) and their segregant progeny (Marullo et al., 
2006). The segregant progeny would encapsulate the total phenotypic variance since their 
phenotype includes both variance due to genotype and variance due to environment. 
Meanwhile, the phenotypic variance displayed by each parental strain would only reflect 
variance due to environment (since clonal replicates of the same parental strain are assumed to 
be genetically identical). Natural traits can display a wide range of heritabilities—for instance, 
life history traits  (viability, fecundity, survival, development rate) in Drosophila tend to have 
low values (<0.2) (Roff & Mousseau, 1987), while traits like human height or cadmium 
chloride tolerance in S. cerevisiae are much higher (0.8 and 0.96, respectively) (Bloom et al., 
Heritability studies of SGRP strains 
 
116 
 
2013; Visscher et al., 2008).  A high heritability estimate means that the trait in question could 
be viably studied by genetic means (Mackay, 2001). 
 
 If the drug response phenotypes in the four strains of interest were confirmed to be 
genetically determined, the next question to be asked is how many genetic loci underpin the 
trait. This can be estimated by crossing two parental strains, obtaining segregant offspring and 
calculating the fraction of that offspring that displays a parental drug response phenotype. A 
logical assumption is that the number of loci responsible for the phenotype, such as resistance 
to a drug, would be inversely related to the fraction of offspring that display the parental 
resistant phenotype. This principle is illustrated in Figure 4.1. 
 
 
Figure 4.1: Inverse relationship between the number of loci responsible for a parental phenotype (for 
example drug resistance) and fraction of offspring that display that phenotype. The number of loci 
responsible can be related to the fraction of parental-like segregants through the equation 1/2n. 
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This type of estimate has been a hallmark in many QTL mapping studies, which use it to 
establish whether a trait has mono- or multigenic inheritance (Deutschbauer et al., 2005; Gerke 
et al., 2006; Steinmetz et al., 2002; Wilkening et al., 2014). Information gained about the 
number of loci underlying a trait can be used to determine the most appropriate mapping 
strategy to reveal those genetic determinants. 
 
Upon construction of crosses between the SGRP strain of interest and the BY control strain, 
further information can be obtained from the proportion of transgressive segregation that is 
exhibited by the offspring of each cross. Transgressive segregation is defined as the production 
of segregant offspring that display a more extreme phenotype than that exhibited by their 
parents—for example, when looking at drug resistance, transgressive segregants would be 
more drug resistant than the resistant parent. Although the natural presumption is that the 
superior (drug resistant) parent in a cross should contain all/most of the superior alleles (and 
vice versa for the inferior (drug sensitive) parent), this is not always the case. Multiple yeast-
based investigations have demonstrated the presence of strains that harbour QTL opposite to 
their overall phenotype, leading to the occurrence of transgressive segregation due to the 
meiotic reshuffling of parental alleles into new combinations (Ben-Ari et al., 2006; Brem et al., 
2002; Cubillos et al., 2011; Diezmann et al., 2011; Nogami et al., 2007; Perlstein et al., 2007; 
Rieseberg et al., 2003; Steinmetz et al., 2002).  
 
In addition to strains containing alleles that have an antagonistic effect, another recurrent 
theme uncovered by yeast QTL studies is that QTL that affect a phenotype tend to be linked. 
Fine-scale dissection of a QTL has sometimes revealed it to consist of several linked loci, each 
having an individual contribution (sometimes with opposite effect to overall parental 
phenotype) (Ben-Ari et al., 2006; Steinmetz et al., 2002; Swinnen, Schaerlaekens, et al., 2012). 
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In light of this, an approach to reduce this type of linkage and isolate the QTL may lead to a 
more accurate insight into their heritability. One way of doing this is through the creation of 
advanced intercross lines (AILs) (Darvasi et al., 1995; Gonzales & Palmer, 2014; Parts et al., 
2011). AILs are derived from repeated intercrossing of two parental strains—typically up to 
ten rounds of such (performing more than ten rounds only leads to negligible narrowing of the 
QTL interval and is thus not considered beneficial (Darvasi et al., 1995)). This leads to a 
breakdown of the linkage disequilibrium (LD) present in the parental strains and concomitant 
dissociation of linked QTLs. Furthermore, AILs offer an advantage for QTL mapping by 
refining the resolution and localisation power and expanding the genetic map owing to 
increased numbers of meioses. This will be discussed in greater detail in Chapter 5. 
 
The relative dominance or recessiveness of a drug response in each cross may also provide 
useful insights into the architecture of the phenotype. Judging the underlying genetic factors 
behind dominance/resistance in multigenic traits is not straightforward, as they arise from 
multiple Mendelian loci acting together and can be further complicated by epistasis (Falconer 
& Mackay, 1996b; Mackay, 2014). Nevertheless, estimates of dominance or recessiveness may 
provide interesting clues regarding underlying trait structure and the relationship between 
parental alleles (Zorgo et al., 2012). 
 
Finally, it could be interesting to explore whether cells respond differently under increasing 
amount of stress enacted by the drug treatment. Previous studies have indicated that additional 
loci can come into play upon raised cellular stress (Swinnen, Schaerlaekens, et al., 2012) or 
that different QTL networks may be prominent under different drug treatment dosages (Wang 
& Kruglyak, 2014). Therefore, it could be of interest to explore how such factors change upon 
increasing dose treatment with benomyl or ketoconazole. 
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4.1.1. Chapter aim 
The aim of this chapter was to elucidate the heritability of the drug response phenotype of 
the four SGRP strains selected in Chapter 3. These were UWOPS87-2421 that was resistant to 
benomyl compared to the BY control strain; L-1374 that was sensitive to benomyl compared 
to BY; DBVPG6044 that was resistant ketoconazole compared to BY; Y12 that was sensitive 
to ketoconazole compared to BY. The aspects of heritability that were examined were: 
 Estimates of broad sense heritability of the drug response phenotype of each of the four 
strains. 
 Estimates of the number of genetic loci that were responsible for the drug response 
phenotype in each of the four strains.  
 A measure of transgressive segregation displayed when each of the four strains was 
crossed to the BY control. 
 A measure of whether the drug response phenotype was a dominant or a recessive trait. 
 
4.2. Methods and Materials 
4.2.1. Creation of advanced intercross lines (AILs) 
A total of four AILs were created—one for each strain as described in Section 3.3.5. Each 
AIL was formed through intercrossing the MATa parent of the selected SGRP strain to the 
MATα control BY strain parent followed by repeated sporulation and random mating of 
offspring. To do this, both parental strains involved in the cross must carry selectable markers 
at the same locus. The HO locus was selected for this purpose—each SGRP strain carried the 
hoΔ::HphMX4 construct, while a BY parent with an analogous hoΔ::KanMX4 mutation was 
obtained from the Open Biosystems deletion collection. However, it has been previously 
discovered that hygromycin (HygB) and geneticin (G418) selection antibiotics cannot be used 
in conjunction with each other in the same plate because the presence of G418 inactivates HygB 
(Kiew, 2010). Therefore, a marker-switch procedure was applied to replace the G418 resistance 
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marker (KanMX4) cassette with another antibiotic marker (NatMX4) using nourseothricin 
(clonNAT) resistance for selection. The marker-switch was performed as described in Section 
2.14. The correct insertion of the NatMX4 marker was verified by confirmation PCR as 
described in Section 2.7.4 using the primers #410 and #3 to create the front PCR product and 
primers #30 and #411 to create the back PCR product (primers described in Section 2.6). 
Following the construction of the BY parent, AILs were created as described in Section 2.17.  
 
4.2.2. Creation of source plate for 384-colony format pinning drug response assay 
Upon the last (10th) round of sporulation during the construction of the AILs, tetrads were 
dissected from the liquid sporulation culture and spores isolated, as described in Section 2.16. 
Selection on HygB and clonNAT was used in order to identify four-spore tetrads that displayed 
2:2 segregation of resistance to either antibiotic. A total of 308 spores were inoculated in a 
randomised order in a 384-well microplate containing 75 µL of liquid SC per well. The 76-
well border of the plate were inoculated with control strains. These control strains comprised 
both the haploid and the diploid versions of each parent used to produce the AIL segregant 
progeny, an F1 diploid hybrid between the SGRP parent and the BY parent and an F10 diploid 
hybrid between the SGRP parent and the BY parent. The last strain was acquired from the last 
(10th) diploid selection round during AIL construction (Section 2.17). The layout of an 
exemplar 384-well microplate showing arrangement and identity of all the strains is presented 
in Figure 4.2. 
 
A total of three replicate segregant progeny source plates were created for each AIL. In 
order to create a new replicate plate, the same spores were inoculated in identical conditions, 
but in a newly randomised order. The plate was then sealed with polyester sealing film, placed 
inside a Ziploc bag to minimise evaporation and was incubated at 30˚C for 48 hours.  
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Following this outgrowth, 75 µL of 50% v/v glycerol was added to each well and the plate 
shaken at 2000 rpm for 15 sec to thoroughly mix the components. The plate was sealed with 
an aluminium sealing foil and stored at -80˚C. 
 
Figure 4.2: Layout of 384-well microplate used for testing drug responses of recombinant AIL progeny in 
addition to the parental strains used to produce those AILs. 
The plate consists of a total of 308 AIL segregants positioned in the middle of the plate, surrounded by six 
control strains arranged in 12 repeating blocks. The colour key for the identity of the control strains is 
listed below: 
 
Haploid SGRP parental 
strain  
Diploid SGRP/BY hybrid, 
F10 
 Haploid BY parental strain  Diploid SGRP strain 
 
Diploid SGRP/BY hybrid, 
F1  
Diploid BY strain 
    
Image of 384-well microplate modified from (Bio-Rad Laboratories Inc.). Used with permission. 
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4.2.3. 384-colony format pinning assay for testing drug response of segregant 
progeny parental strains and hybrid strains 
The 384-well source plate was fully thawed, then shaken at 2000 rpm for 1 min to mix the 
contents. The RoToR HDA was used to transfer the strains to an SC agar plate (see Figure 2.4 
for an example) using 384 format long pin repads. After the inoculum was allowed to fully 
absorb into the agar, the plates were incubated at 30˚C for 48 hours. After 24 hours, the plate 
was examined for any colonies that failed to pin, and these were filled in manually. 
 
To test drug response, the segregants were pinned from the SC agar plate onto SC agar 
containing increasing concentrations of the selected drug. The drug concentrations were 
selected in order to test response at an “intermediate” drug dosage (a point that corresponds to 
the maximal growth difference between the parental strains) and a “high” drug dosage (where 
the resistant strain is still growing, while the sensitive strain is completely inhibited). The 
rationale for selecting the intermediate and high drug dosages is illustrated in Figure 4.3.  
 
Figure 4.3: Illustration of position on the dose-response curve of the parental strains which constituted 
“intermediate” and “high” drug dosage. Pictured are the parental strains used for investigating benomyl 
sensitivity. N = 3. Data are presented as mean ± SD. 
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The desired drug concentrations were selected based on the outcome of the 384-colony 
format pinning assay, as described in Chapter 3. The drug concentrations used for each AIL 
are described in Table 4.1. 
Table 4.1: Drug concentrations used for “intermediate” and “high” drug dosage treatments to test the 
response of segregant progeny and parental strains. 
AIL identity 
Drug response 
phenotype of SGRP 
parent 
Drug dosage used 
UWOPS87-2421 × BY Benomyl resistant 
Intermediate 150 µM benomyl 
High 250 µM benomyl 
L-1374 × BY Benomyl sensitive 
Intermediate 75 µM benomyl 
High 137.5 µM benomyl 
DBVPG6044 × BY Ketoconazole resistant 
Intermediate 150 µM ketoconazole 
High 200 µM ketoconazole 
Y12 × BY Ketoconazole sensitive 
Intermediate 60 µM ketoconazole 
High 100 µM ketoconazole 
 
The inoculation of the drug plate via pinning, incubation and colony size measurements 
were performed as described in Section 2.15.3. Residual growth was obtained for each 
segregant and its control strain by calculating the ratio of its growth under treatment to its 
growth in the solvent control plates. 
 
4.2.4. Analysis of AIL segregant progeny drug response and estimating the number 
of responsible loci 
The mean average residual growth was calculated for each segregant and for the haploid 
parents that produced the AILs. As each replicate plate had 12 representatives of each parent, 
only one of the 12 was selected randomly from each replicate. The growth range of the 
segregant progeny was plotted as a scatter plot. The fraction of segregants that displayed a 
parental drug response phenotype (of either the superior or the inferior parent) was calculated. 
A segregant was defined as having a parental phenotype if its mean growth fell within one 
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standard deviation of the mean growth of either the superior or the inferior parent, and also if 
it was more extreme than either parent. The method for defining a segregant as having a 
“parental phenotype” is illustrated in Figure 4.4. 
 
Figure 4.4: Hypothetical growth plot of segregant progeny (individual segregants represented by green 
dots) at a given drug concentration. The superior (i.e. drug resistant) and inferior (i.e. drug sensitive) 
parents are also marked. The blue and red boxes demarcate which segregants would be considered to have 
the drug response phenotype of the inferior and superior parents, respectively. 
 
 
The fraction of segregants that displayed the parental drug response phenotype was related 
to the number of genetic loci that underlie that phenotype through the following equation: 
 
 𝑆𝑒𝑔𝑟𝑒𝑔𝑎𝑛𝑡𝑠 𝑃𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒
𝑆𝑒𝑔𝑟𝑒𝑔𝑎𝑛𝑡𝑠 𝑇𝑜𝑡𝑎𝑙
⁄ =  1 2 𝑛⁄  
 
where “n” is the number of genetic loci.  
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4.2.5. Calculation of % transgressive segregation and broad sense heritability 
Both the calculation of the percent of segregants that displayed transgressive segregation 
and that of broad sense heritability were carried out as described by Marullo et al.  (Marullo et 
al., 2006). Segregants that displayed transgressive segregation were defined as those whose 
mean growth was two standard deviations higher than that of the superior parents or two 
standard deviations lower than that of the inferior parent (using the standard deviation of the 
parent strains). Broad sense heritability (H2) was calculated from the following formula: 
 
𝐻2 =  
𝜎𝑃
2 −  𝜎𝐸
2
𝜎𝑃
2  
𝜎𝑃
2 denotes total phenotypic variance. This is the sum of genetic variance and environmental 
variance and was estimated by calculating the phenotypic variance of the segregant progeny. 
𝜎𝐸
2  refers to the environmental variance and was estimated from the average phenotypic 
variance of each haploid parental strain (from 12 replicate colonies inoculated on the test plate, 
as indicated in Figure 4.1). To get overall environmental variance, the phenotypic variance of 
the two parents was averaged. An independent estimate of H2 was obtained for each of the 
three replicate plates. The overall estimate of H2 was obtained by calculating a mean average 
of the three replicates. 
 
4.2.6. Analysis of parental and hybrid strains—dominance of drug response 
The mean average residual growth was calculated for each of the diploid parental strains 
and the F1 and F10 hybrid strains in each replicate plate. This average growth of each strain per 
replicate plate was further averaged across all three replicates. Furthermore, the three replicates 
were used to calculate the standard deviation of the mean. An unpaired one-tail Student’s t-test 
was used to determine the significance of growth differences between the strains. 
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4.3. Results 
For unknown reasons, the ketoconazole-resistant phenotype of DBVPG6044 relative to BY 
could not be replicated from the studies in Chapter 3, despite this strain displaying consistent 
ketoconazole resistance in previous drug response testing. Possible reasons for this are included 
in the Discussion section of this chapter (Section 4.4). Results from the DBVPG6044 × BY 
cross are therefore omitted from this chapter. 
 
4.3.1. Number of genes and heritability of drug response 
The drug response of haploid segregant progeny was compared to that of their parental 
strains (also haploid) in order to investigate the heritability patterns of the drug response 
phenotype of the candidate strains that were selected in Chapter 3. The segregant progeny used 
here were F10 AIL progeny and therefore possessed reduced linkage disequilibrium and better 
separated antagonistically-acting determinants of drug response compared to F1 progeny.  As 
a result of the AIL strategy the estimates of the number of loci underlying the phenotype are 
more likely to represent the true number of resistance or sensitivity-determining loci.  
 
A summary of the results for the heritability of benomyl resistance in the strain UWOPS87-
2421 (relative to the BY control strain) is presented in Figure 4.5 and Table 4.2.  
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Figure 4.5: Distribution of UWOPS87-2421 × BY AIL segregants in terms of response to 150 µM and 250 
µM benomyl. The growth of the haploid parental strains used to produce the AILs are indicated by arrows. 
Segregants marked in yellow represent transgressive segregants. Data are presented as the mean. N = 3. 
Error bars have been omitted in the interest of clarity except in the case of the haploid parents. 
 
Table 4.2: Heritability characteristics of UWOPS87-2421 × BY AIL segregants. Orange text represents 
UWOPS87-2421 × BY AIL segregants treated with 150 µM benomyl; green text represents the same set of 
segregants treated with 250 µM benomyl. “% transgressive” refers to the fraction of transgressive 
segregants. “H2” refers to broad sense heritability. 
 
Fraction with 
parental phenotype 
# loci % transgressive H2 
BY phenotype 
(benomyl sensitive) 
103/299 105/296 1.5 1.5 19.7% 12.2% 
0.75 0.87 UWOPS87-2421 
phenotype (benomyl 
resistant) 
150/299 170/296 1.0 0.8 19.7% 23.3% 
 
Both with the intermediate (150 µM) and the high (250 µM) dosages of benomyl, segregants 
ranked in order of growth appeared to display a relatively continual distribution, suggesting 
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that multiple genetic determinants to the benomyl response segregate in the UWOPS87-2421 
× BY cross. For comparison, a representative segregant growth curve is provided in Appendix 
7.4 that shows the expected curve shape in the case of a single-locus trait (resistance to 
clonNAT). This single-trait curve exhibits a sharp distinction between high growth and low 
growth segregants, suggesting that the segregants tend to fall into two distinct categories of 
growth. The fact that such a bi-category separation is not seen in the UWOPS87-2421 × BY 
cross suggests the contribution of multiple loci. Despite this continual distribution, estimates 
based on the fraction of segregants displaying the phenotype of either parent revealed that only 
0.8-1.5 loci contribute to the phenotype. The possible reasons for this disparity are discussed 
in Section 4.4 of this chapter. Another feature of the UWOPS87-2421 × BY cross is the 
relatively high percentage of segregants that displayed a transgressive phenotype compared to 
either parent. With the intermediate dosage, just fewer than 40% of segregants displayed such 
transgressive segregation, showing an even distribution at the sensitive and resistant end of the 
curve. High-dose treatment produced slightly fewer transgressive segregants—35%—but these 
displayed a slight skew, with a greater proportion lying on the resistant end of the curve. 
Estimates of broad sense heritability revealed that in this cross, the benomyl response was 
largely determined by genetic factors—with the intermediate-dose treatment, H2 was estimated 
at 0.75, which rose to 0.87 at the high-dose treatment.  
 
On the opposite end of the phenotype continuum, L-1374 was selected as the benomyl 
sensitive strain compared to the BY control. When studying a sensitive strain, because “drug 
sensitivity” is not a selectable phenotype, what was examined instead were the factors that 
contribute to the relative resistance of the control (BY) strain. The outcomes of the heritability 
study from the L-1374 × BY cross are presented in Figure 4.6 and Table 4.3. 
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As with the previous cross, both the intermediate (75 µM) and the high (137.5 µM) dose 
treatments produced smooth relatively normal-shaped distributions of segregants. However, 
conversely to the UWOPS87-2421 × BY cross, the locus number estimation clearly revealed a 
multigenic trait, with between 2.3 to 7.3 contributing loci. Interestingly, the distribution of loci 
contributing to the benomyl response was not symmetrical. Under both treatment conditions, 
the L-1374 parent fell much closer to the sensitive end of the growth curve than the BY parent. 
Thus, apparently there were 4.9 or 7.3 loci that accounted for the phenotype of L-1374, 
depending on whether the benomyl treatment was intermediate or high dose. On the other hand, 
the fraction of BY-like segregants was much bigger; this caused the estimate of the number of 
loci responsible for the BY-like benomyl resistant phenotype to go down to only 2-3 loci. 
Another difference from the UWOPS87-2421 × BY cross was that the L-1374 × BY cross 
exhibited a negligible amount of transgressive segregation. Nevertheless, as with the previous 
cross, the benomyl response phenotype in L-1374 × BY displayed a high heritability of 0.91-
0.92.  
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Figure 4.6: Distribution of L-1374 × BY AIL segregants in terms of response to 75 µM and 137.5 µM 
benomyl. Data represented the same way as described for Figure 4.3. 
 
Table 4.3: Heritability characteristics of L-1374 × BY AIL segregants. Orange text represents L-1374 × BY 
AIL segregants treated with 75 µM benomyl; green text represents the same set of segregants treated with 
137.5 µM benomyl. Table categories are the same as described in Table 4.2. 
 
Fraction with 
parental phenotype 
# loci % transgressive H2 
L-1374 phenotype 
(benomyl sensitive) 
10/308 2/308 4.9 7.3 0% 0.3% 
0.91 0.92 
BY phenotype 
(benomyl resistant) 
45/308 62/308 2.8 2.3 0.3% 1.0% 
 
Although it did not prove possible to examine the heritability patterns within the 
DBVPG6044 × BY cross, the Y12 × BY cross nevertheless provided some valuable insight 
into the genetics of the ketoconazole response. The results of this cross are summarised in 
Figure 4.7 and Table 4.4. The growth distribution of segregants in this cross did not produce 
as smooth a curve as was seen with the other crosses. There appears to be a slight over-
representation of low-growth segregants with a smaller fraction of high growth segregants, 
producing a “kink” in the curve (circled in the figure). Possible reasons for this are presented 
in the chapter discussion in Section 4.4. This effect becomes more pronounced in the high dose 
(100 µM) treatment compared to the medium dose (60 µM). This situation may reflect a 
possible change in the genetic architecture of QTL responsible for growth at a high dose of 
ketoconazole—such as an increased contribution by a single (or a very limited number) of loci.  
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Figure 4.7: Distribution of Y12 × BY AIL segregants in terms of response to 60 µM and 100 µM 
ketoconazole. Data are presented as described in Figure 4.3. Encircled are the “kinks” in the growth curve 
that are further discussed in the text. 
 
Table 4.4: Heritability characteristics of Y12 × BY AIL segregants. Orange text represents Y12 × BY AIL 
segregants treated with 60 µM ketoconazole; green text represents the same set of segregants treated with 
100 µM ketoconazole. Table categories are as described in Table 4.2. 
 
Fraction with 
parental 
phenotype 
# loci % transgressive H2 
Y12 phenotype 
(ketoconazole 
sensitive) 
5/305 2/301 5.9 7.2 0.3% 0.3% 
0.90 0.88 
BY phenotype 
(ketoconazole 
resistant) 
84/305 62/301 1.9 2.3 9.8% 13.3% 
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The Y12 × BY cross exhibited the same curious pattern in terms of asymmetrical 
distribution of segregant growth as did the L-1374 × BY cross. From the fraction of segregants 
that displayed a Y12-like sensitivity to ketoconazole, about 5.9 and 7.2 loci are responsible for 
the phenotype upon intermediate and high dose treatment, respectively. However, based on the 
fraction of BY-like segregants, only around two loci are expected to be involved in the 
ketoconazole resistance of that parent relative to its Y12 partner. The pattern of transgressive 
segregation showed a similar anomaly. While the amount of transgressive segregants on the 
sensitive end of the curve was negligible (0.3%), on the resistant end of the curve, 9.8-13.3% 
of segregants displayed a transgressive phenotype relative to the BY parent. As with all the 
tested drug response phenotypes, the heritability was high—0.90 with intermediate-dose 
treatment and 0.88 upon high-dose treatment.  
 
4.3.2. Dominance/recessiveness of drug response in diploids 
The dominance (or recessiveness) of drug response in each cross was tested by comparing 
the growth of the F1 diploid hybrid of the two parents to the growth of the parental strains (in 
diploid form). Additionally, the F10 diploid hybrid derived during AIL construction was 
included to determine if the breakup of linkage disequilibrium (which, as stated earlier, may 
separate antagonistically-acting alleles) produced any alteration in terms of dominance 
patterns. 
 
The relative dominance of the benomyl response in the UWOPS87-2421 × BY cross is 
presented in Figure 4.8. 
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Figure 4.8: Dominance/recessiveness characteristics of BY, UWOPS87-2421 and their hybrids (F1 and F10) 
in terms of response to benomyl. Data are presented as the mean ± SD. N = 3. * denotes that growth 
difference is significant at p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Both the F1 and the F10 hybrids displayed an intermediate level of growth compared to the 
parental UWOPS87-2421 and BY strains. Under an intermediate treatment dosage of benomyl 
(150 µM), the hybrids only displayed a significant growth difference to the sensitive parent in 
the cross (BY). However, in this particular case the UWOPS87-2421 benomyl resistant parent 
displayed an unusually high level of growth variability compared to other growth 
measurements in this experiment; thus, the growth difference between the hybrids and the 
UWOPS87-2421 parents may be biologically meaningful, despite not reaching statistical 
significance. Under a high dose treatment of benomyl (250 µM), the growth difference between 
the hybrid strains and the two parental strains were either significant or highly significant. 
However, comparison of the mean growth of each strain revealed that with both intermediate 
and high dose benomyl treatment, the phenotype of the two hybrids lay closer to that of the 
sensitive BY parent. This suggests that in the UWOPS87-2421 × BY cross, benomyl sensitivity 
is partially dominant.  
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The results of a similar analysis for the sensitive end of the benomyl response spectrum—
those coming from the L-1374 × BY cross—are shown in Figure 4.9. 
 
Figure 4.9: Dominance/recessiveness characteristics of BY, L-1374 and their hybrids (F1 and F10) in terms 
of response to benomyl. Data are presented as the mean ± SD. N = 3. * denotes that growth difference is 
significant at p < 0.05; ** p < 0.01; *** p < 0.001. 
 
With intermediate-dose benomyl treatment (75 µM) both the F1 and F10 hybrids showed a 
similar intermediary phenotype. The growth of the F1 hybrid more closely resembled that of 
the resistant BY parent, while the growth of the F10 hybrid was more akin to that of the 
sensitive L-1374 parent. However, this growth difference between the F1 and F10 hybrids 
never reached a level of statistical significance. With this treatment regime, it remained difficult 
to conclude whether any dominance effects exist between the parental strains, but it could be 
said there was partial dominance towards the resistant BY strain, although it wasn’t significant. 
The picture was very different, however, with the high-dose benomyl treatment (137.5 µM). 
The F1 hybrid showed no significant difference compared to the sensitive L-1374 parent. The 
F10 hybrid was significantly different from the same parent; however, the overall variation in 
growth between the two strains was small and was dwarfed by the difference between the 
hybrid and the BY parent. Therefore, in these conditions, the relative benomyl sensitivity in 
the L-1374 × BY cross was almost completely dominant. 
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The examination of the dominance of the ketoconazole response in the Y12 × BY cross is 
shown in Figure 4.10. 
 
Figure 4.10: Dominance/recessiveness characteristics of BY, Y12 and their hybrids (F1 and F10) in terms 
of response to ketoconazole. Data are presented as the mean ± SD. N = 3. * denotes that growth difference 
is significant at p < 0.05; ** p < 0.01; *** p < 0.001. 
 
The F1 and F10 hybrids presented an intermediate phenotype with both the intermediate 
dose (60 µM) and the high dose (100 µM) treatment regimes. Nevertheless, in both treatments 
their phenotypes lay considerably closer to that of the ketoconazole sensitive parent (Y12), 
suggesting that ketoconazole sensitivity is partially dominant. This dominance became more 
pronounced in the high dose treatment. However, the growth levels of all strains tested were 
significantly different from each other. Moreover, in this cross the growth difference between 
the F1 and the F10 hybrids was much more pronounced than in the other crosses, with the F10 
hybrid being more ketoconazole resistant. This suggests that in this strain combination, alleles 
that act in an antagonistic manner to each other but whose effect may be cancelled out due to 
them being in linkage disequilibrium with each other may play a more prominent role than in 
other crosses and treatment regimens examined in this chapter. 
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4.4. Discussion 
This chapter explored the patterns of heritability that underpinned response to benomyl or 
ketoconazole in the four SGRP strains selected for further study in Chapter 3 (those being 
UWOPS87-2421, L-1374, DBVPG6044 and Y12). However, prior to the heritability 
investigation four AILs were created—one each for all four strains intercrossed with BY 
control strain. The advantage of AILs is that they reduce the linkage disequilibrium (LD) 
present in the original parental lines through recombination introduced through repeated rounds 
of random intercrossing. This can genetically separate nearby loci that have antagonistic effects 
on the phenotype in question and thus increase the accuracy of heritability studies—for 
example, by allowing more accurate estimates of the number of genetic loci underlying a trait. 
The increased recombination present in AILs also leads to an expansion of the genetic map and 
is greatly helpful for improving the localising power of genetic mapping studies when one 
wants to map such genetic loci—this is described more in Chapter 5. During the creation of 
AILs, ten rounds of random intercrosses were made to break up LD. This is based on estimates 
from the study that pioneered AILs, which concluded that after ten intercrosses, the advantages 
gained in terms of breaking up LD and improving the genetic mapping accuracy of the AILs 
were negligible (Darvasi et al., 1995). The size of the breeding population (i.e. the effective 
population used during the intercrossing) was also kept large (over 107 individuals) in order to 
avoid any limitations to mapping accuracy that may arise from small population sizes (Darvasi 
et al., 1995) and to reduce the chance of losing parental SNP markers through genetic drift 
(Cubillos et al., 2013). One possible limitation with the use of AILs is the fact that because the 
strains go through an extended period of growth during their construction, there is a potential 
that random mutations will be introduced into the AIL population. Previous studies have 
discovered that a small number of loci (less than ten) that provide an advantage in mating and 
sporulation undergo selection during the construction of AILs (Cubillos et al., 2013; Parts et 
Heritability studies of SGRP strains 
 
137 
 
al., 2011). Furthermore, Cubillos et al. discovered approximately 100 new SNPs that arose 
during their construction of four-parent AILs (those being single AILs which incorporate 
information from four founding parents). However, considering that the current study only used 
two-parent AILs and that the minimum number of total SNPs in any cross combination used in 
the current study is over 35 000 (described in Chapter 5), this would represent less than a 0.15% 
change in total genomic differences between the strains. This, in conjunction with the fact that 
the selections used during AIL construction are not clearly related to the final phenotype of 
interest (i.e. drug response) could suggest that any mutations and polymorphisms that arise 
during AIL construction are not likely to affect the   outcome of this study. 
 
It is unfortunate that the ketoconazole resistant phenotype of DBVPG6044 could not be 
replicated in this chapter. It remains unclear why this occurred, as the conditions used in the 
384-colony pinning assay used were the same as those that successfully produced the resistance 
phenotype in Chapter 3. By way of possible explanation, DBVPG6044 had the smallest growth 
difference relative to the control BY strain compared to the other three SGRP strains and the 
MATα version of BY (as used in the crosses in this chapter) had a considerably higher drug 
MIC than its MATa counterpart. This likely contributed to the abolishment of the apparent 
ketoconazole resistance of DBVPG6044 compared to BY. Nevertheless, as DBVPG6044 
showed ketoconazole resistance when tested in serial spot dilution assay format (Chapter 3) as 
well as in the lawn dose response format (Chapter 5), its apparent lack of ketoconazole 
resistance in this chapter was probably an artefact of the drug testing format used. 
 
Following the creation of AILs, a number of aspects of the heritability of drug response 
were examined. The first of those was an estimate of the number of loci that underpinned this 
phenotype in each of the three SGRP strains that were examined, which is described in Section 
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4.2.4. However, a major limitation of this estimate is that it presumes relatively equal 
contribution of all loci involved (Wilkening et al., 2014). Yet numerous QTL studies have 
demonstrated that a typical multigenic trait typically contains variable contribution by different 
loci (Mackay, 2001). The presence of a major-effect QTL may mask the contribution of 
smaller-effect QTL to the phenotype (Kim et al., 2009; Sinha et al., 2008) and by corollary, the 
presence of such a major-effect QTL may result in this assay underestimating the true number 
of loci involved. This would potentially explain why in the UWOPS87-2421 × BY cross only 
one locus was estimated to be involved in benomyl response although the segregant progeny 
produced by that cross displayed a bell-shaped distribution in terms of benomyl response, 
which is usually a mark of a multigenic trait (Falconer et al., 1996b). Taking this into account, 
it may be reasonably concluded that every drug response phenotype examined in this chapter 
was a multigenic trait, although the exact number of responsible loci cannot be established 
conclusively from this assay alone. 
 
The segregant progeny assay that allowed any such estimate of locus number allowed 
another estimate to be calculated—the proportion of progeny that showed transgressive 
segregation compared to the parents. The considerable level of transgressive segregation found 
within the UWOPS87-2421 × BY cross (35-40%) when testing benomyl resistance strongly 
suggested that both strains harboured alleles that were contrary to their overall phenotype. 
Interestingly, the L-1374 × BY cross, which explored the opposite end of the benomyl response 
phenotype, showed almost no transgressive segregation  suggesting that in this cross the 
parental strains contained the expected drug response alleles. Meanwhile, the Y12 × BY cross 
that was used to explore ketoconazole response showed a curious pattern of asymmetry. There 
was effectively no transgressive segregation relative to the sensitive Y12 parent in the cross, 
suggesting this parental strain already contained all the alleles that would cause its relative 
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sensitivity. However, there was a considerable level of transgressive segregation relative to the 
resistant BY parent. It is not immediately obvious why this occurs. However, one possible 
explanation is epistasis. It may be that certain QTL that lead to a phenotype (for instance, 
ketoconazole resistance in this cross) may only do so upon interaction with other QTL within 
a certain genetic background, whereas neither of those loci would affect the phenotype in 
isolation from each other. This phenomenon of background-specific QTL has been well 
described (Cubillos et al., 2011; Deutschbauer et al., 2005; Sinha et al., 2006). Further evidence 
of epistatic effects in the Y12 × BY cross can be gathered by observing the distribution of 
segregant progeny growth upon ketoconazole treatment, as displayed in Figure 4.7. Converting 
those data to a histogram form (Figure 4.11 below) reveals that instead of the bell-shaped curve 
that may be expected with multigenic traits, the segregants display more of an “L-shape” 
distribution. Such a distribution shape has been previously described by Marullo et al. for 
certain fermentative traits following crossing of parental strains derived from the wine strains 
VL1 and Bo213, those authors then confirming the influence of epistatic interactions within 
these traits (Marullo et al., 2006). 
 
Figure 4.11: Histogram view of Y12 × BY AIL segregants in terms of response to 60 µM and 100 µM 
ketoconazole. The red bar represents the growth bin that contains the ketoconazole-sensitive Y12 parent 
while the blue bar is the bin that contains the resistant BY parent. 
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The heritability of drug response was also investigated. A previous study that investigated 
response to drugs and general stresses found wide variation in terms of heritability estimates 
(broad sense: 0.4-0.96) (Bloom et al., 2013). A follow up study focusing on haloperidol 
response indicated consistently high H2 heritability (>0.75), akin to those found in the current 
study. Mammalian cell and human studies have also indicated a substantial variation in 
heritability ranging from 0.25 to 0.73 depending on drug class (McGeachie et al., 2013; Roden 
et al., 2011; Shuldiner et al., 2009). This suggests a wide variety of possible genetic architecture 
that can underlie drug response with this study representing the higher end of the spectrum. As 
broad sense heritability incorporates both additive and epistatic genetic interactions, it would 
be interesting to perform follow up studies to dissect narrow sense heritability (additive genetic 
factors only) in these strains and contrast that to the proportion of phenotype described by 
epistatic interactions (Bloom et al., 2013). 
 
Another aspect of the drug response phenotype that was explored in the present study was 
whether the overall phenotype tended to be dominant or recessive. In two of the three crosses, 
the phenotype was intermediate. This would be expected considering that the hybrid phenotype 
is the result of multiple loci, all with independent and different dominance characteristics. 
Nevertheless it could be argued that in five of the six conditions examined (with the exception 
being the intermediate-dose benomyl treatment of the L-1374 × BY cross), the relative drug 
sensitivity tended to be partially (or in one case) completely dominant. Without testing the drug 
response QTL individually for relative dominance/recessiveness, it is hard to make conclusions 
about what this means. The population history of these strains should be considered, as their 
drug response phenotype may not have arisen as a result of direct selection but rather as a result 
of hitchhiking on another selected trait in their evolutionary history (Liti et al., 2012) or through 
genetic drift (Dujon, 2010). Furthermore, given the tendency of loss-of-function alleles to be 
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recessive (Bourguet, 1999) and the known prevalence of loss-of-function alleles in yeast 
populations (Zorgo et al., 2012), it may be that loss-of-function alleles may play some role in 
drug response in the strains tested here. This would need to be confirmed by further study. 
 
The effects of intermediate versus high drug treatment dosages were considered. It was of 
interest whether the two treatment regimens relied on the same underlying QTL network, or 
whether different genetic factors may come into play as drug dosage is increased. Overall, the 
heritability patterns between the two treatment dosages tended to resemble each other—the 
segregant progeny showed similar patterns of growth distribution and the dominance testing 
showed similar trends (as would be expected). The high dose treatment tended to produce more 
extreme results in terms of greater number of loci estimated to be responsible for the trait, more 
pronounced differences in strain growth and dominance effects. Based on this, it seems likely 
that the overall QTL network architecture is conserved between the intermediate dose treatment 
and high dose treatment—although it is still possible that additional genetic factors come into 
play as drug treatment dose increases. 
 
Overall, the investigations described in this chapter provided considerable insight into the 
genetic underpinnings of the drug response phenotype. The finding that in each of the tested 
cases the varaiance of the phenotype is largely due to genetic variance  and that multiple genetic 
loci appear to be responsible logically sets up the concept that a QTL mapping approach would 
be fruitful in uncovering the identity of these genetic determinants. Furthermore, the AILs 
described in this chapter not only likely provided an improved insight into the heritability 
patterns of the  selected SGRP strains but also form a valuable resource for the optimal way of 
doing QTL mapping. 
 
Heritability studies of SGRP strains 
 
142 
 
 
 143 
 
Chapter 5: The Quantitative Trait Loci (QTL) of Benomyl and 
Ketoconazole Response 
 
5.1. Introduction 
As drug response to benomyl and ketoconazole in the selected SGRP strains of interest was 
confirmed to be a multigenic trait, and the variance of the phenotype was largely explained by 
genetic factors, the natural next step was to determine which loci contribute to this response. 
This was the aim in this chapter, with next-generation sequencing bulk segregant analysis 
(NGS-BSA) being applied for this purpose. 
 
5.1.1. Off-target factors contributing to benomyl and ketoconazole response 
Although benomyl and ketoconazole act via well-characterised primary targets, many off-
target modifiers of their effect have been characterised. As benomyl primarily targets 
microtubules, changes in genes whose functions are dependent on microtubules often result in 
altered benomyl responses. Genes involved in cell cycle progression and the spindle checkpoint 
are known to modify the benomyl response (Chen et al., 1999; Hoyt et al., 1991; Pan et al., 
2004). Moreover, factors are also involved that enable correct attachment of chromosomes to 
the spindle (such as kinetochore components and nucleosomal histones), mediate correct 
chromosomal segregation and ensure chromosome and DNA integrity (Hoyt et al., 1997; 
Kawashima et al., 2011; Stearns, 1990; Wysocka et al., 2004). Finally, elements that affect 
microtubule formation and integrity also contribute to benomyl responses (Stearns, 1990; 
Voloshin et al., 2010). 
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There are off-target factors that alter ketoconazole response such as altered cellular sterol 
composition (particularly build-up of the toxic intermediate 14α-methyl-3,6-diol) and 
alteration in the ergosterol synthesis pathway  (Lamb et al., 1999; Lupetti et al., 2002).  A 
number of other processes are also involved in off-target effects including mitochondrial 
function  known to affect azole susceptibility (Lupetti et al., 2002; Traven et al., 2001),  cell 
wall integrity (Barker et al., 2003; Chung et al., 2014; Singh et al., 2012), disruption of vacuolar 
function (perhaps related to the regulation of vacuolar H+-ATPase activity by ergosterol), and 
endosomal trafficking in terms redistributing the toxic ketosteroid intermediates produced upon 
azole treatment (Luna-Tapia et al., 2015; Zhang, Gamarra, et al., 2010; Zhang & Rao, 2010). 
It is an aim of this chapter to investigate the genes underlying the effects of benomyl and 
ketoconazole by comparing resistant and susceptible pairs of strains. 
 
5.1.2. Bulk segregant analysis (BSA) 
BSA was first proposed as an economical method for genotyping a mapping population to 
determine loci associated with a trait (Michelmore et al., 1991). Individuals within the mapping 
population are sorted into “bulks” based on whether they possess the trait of interest or not, and 
the total DNA from each population is extracted and genotyped en masse. Such a technique 
allows much larger mapping populations to be genotyped for the same (or lesser) cost than 
would be achievable when genotyping individual segregants. BSA relies on individuals in the 
initial mapping population having a high degree of heterozygocity. It is therefore assumed that 
any locus with no contribution to the trait will maintain such initial heterozygocity, but any 
locus that is linked to the trait will be over-represented in the trait-positive population compared 
to the control population. See Figure 5.1 for an illustration of the principle of BSA. 
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Figure 5.1: Description of the principle of BSA. 
 
BSA was initially developed for studying plant traits, but in recent times has also been 
successfully applied to investigate a wide variety of yeast traits (Segrè et al., 2006), including 
industrial traits such as xylose utilisation (Wenger et al., 2010), ethanol tolerance (Swinnen, 
Schaerlaekens, et al., 2012),  wine characteristics (Roncoroni et al., 2011) and response to 
chemical and general stresses (Cubillos et al., 2013; Ehrenreich et al., 2010; Parts et al., 2011). 
A particularly valuable adaptation has been the application of next generation sequencing 
(NGS) for the genotyping step of BSA (Ehrenreich et al., 2010). Here, instead of genotyping 
each marker site, the DNA extracted from each bulk is put through a whole genome sequencing 
reaction. As the DNA is derived from a population, the reads therefore represent a sampling of 
the sequence from different individuals. The read data are mapped against a reference genome 
and the relative allele frequency of parental alleles at each marker site is determined. Generally, 
large bulks and high sequencing coverage are required to achieve optimal detection power and 
accuracy (Ehrenreich et al., 2010; Magwene et al., 2011; Schlotterer et al., 2014). The benefit 
of this method is that all available marker sites are genotyped simultaneously, providing direct 
sequence information about the loci, without the need for follow up sequence analysis. Such 
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high-resolution genotyping, combined with the large mapping populations made feasible by 
BSA typically leads to NGS-BSA successfully uncovering a greatly increased number of QTL 
than would be possible using classical linkage disequilibrium mapping methodology (Cubillos 
et al., 2013; Parts et al., 2011). 
 
5.1.3. AILs for increased mapping resolution 
A persistent problem with QTL studies is that pervasive linkage disequilibrium often results 
in detection of large QTL intervals that require further fine-mapping in order to achieve more 
practicable intervals for identifying candidate genes. Advance intercross lines (AILs) help to 
overcome this limitation by breaking down linkage disequilibrium through repeated rounds of 
random intermating among segregants. Moreover, as well as breaking up linked QTL, AIL 
expand the genetic map of the segregants because of the increased recombination introduced 
with each cross (Darvasi et al., 1995). This greatly improves the resolution of QTL studies as 
it provides a finer QTL interval and improved ability to localise causative loci (Darvasi, 1998; 
Wang et al., 2003). The combination of AILs with NGS-BSA by Parts et al. (illustrated in 
Figure 5.2) has proved particularly powerful for detecting a large number of QTL with a good 
level of localisation (Parts et al., 2011). 
 
Figure 5.2: illustration of creation of AILs and the NGS-BSA (next generation sequencing-bulk segregant 
analysis) method used by Parts et al. to investigate the genetic basis of heat tolerance between 
phenotypically divergent yeast strains. WA stands for “West African” and NA represents “North 
American”—the two lineages used in the study. From (Parts et al., 2011). 
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5.1.4. Chapter aims 
The aims of this chapter were: 
 To establish genomic markers that can be used for QTL mapping. These comprise high-
quality SNPs between the parental strains used in each of the four AILs, as determined 
by whole genome sequencing. 
 To select an intermediate and high treatment dose in a new drug treatment format (lawn 
format on agar) 
 To treat AIL segregants with benomyl and ketoconazole in appropriately sized bulks. 
Bulks were selected to include a minimum of 105 segregants (prior to clonal 
amplification that occurs during subsequent growth), as such sizes are considered 
necessary for optimal QTL detection (Ehrenreich et al., 2010). 
 Perform NGS-BSA to establish QTL contributing to drug response phenotypes in each 
of the four strains of interest. The primary aim was to investigate off-target genetic loci 
which may contribute to variation in terms of individual drug response in an unbiased 
genomic manner. 
 
5.2. Methods and Materials 
5.2.1. Establishment of genomic markers in parental strains 
Genomic markers for subsequent QTL mapping were determined by whole genome 
sequencing. For this purpose, SNPs were identified between each pair of parental strains for 
each of the four AILs. To achieve this, sequencing data were mapped to the S288C reference 
genome (source described in Chapter 2), and variants were called relative to that genome. 
S288C is the genetic background of the BY strain that was used as a parent in each of the four 
AILs. Slight deviations exist between the BY and S288C genome; therefore, variant sites 
between the BY and the SGRP parent in each AIL were established by calling variants between 
the SGRP parent and the S288C reference and then subtracting any of these variants that were 
also called between the S288C reference and the BY parent.  
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Illumina genome raw sequence data were obtained either through whole genome sequencing 
(as described in Sections 2.5.2 and 2.21.1) or by downloading from published sources. The 
sourcing information of sequence data for each of the five strains is provided in Table 5.1. 
Table 5.1: Sourcing information for Illumina genome raw sequence data used in this thesis. Sequence read 
archive (SRA) number refers to the unique identifier for the raw data from NCBI (National Center for 
Biotechnology Information). 
Strain name Data source SRA number 
BY This thesis NA 
UWOPS87-2421 (Bergström et al., 2014) ERR049930 
L-1374 This thesis NA 
DBVPG6044 (Song et al., 2015) SRR1568151 
Y12 (Strope et al., 2015)  SRR800842 
 
Alignment to the S288C reference genome and variant calling were performed as described 
in Sections 2.22 and 2.23.  
 
5.2.2. Drug treatment of AIL segregant progeny in lawn format on agar 
Optimisation of the lawn drug treatment format was carried out as described in Section 
2.19.1. The intermediate and high drug treatment dosages were selected based on the criteria 
described in Section 4.2.3.  
 
 
 
Based on these outputs, the following treatment regimens were selected for intermediate and 
high dose treatment of each AIL: 
  Intermediate dose High dose 
Benomyl 
UWOPS872421×BY 45 µM 80 µM 
L-1374×BY 30 µM 50 µM 
Ketoconazole 
DBVPG6044×BY 25 µM 65 µM 
Y12×BY 11.5 µM 15 µM 
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Each of the four AILs was treated with the intermediate dose, high dose or vehicle only 
(DMSO), totalling 12 samples. For each AIL, each treatment contained an equal amount of 
DMSO. Drug treatment of AIL progeny and subsequent gDNA extraction was carried out as 
described in Section 2.19.2. 
 
5.2.3. NGS-BSA for determining QTL that contribute to benomyl and 
ketoconazole response 
The sequencing of the pooled AIL progeny gDNA, allele frequency analysis and QTL 
calling were carried out as described in Sections 2.21.2, 2.24 and 2.25. In order to identify 
ORFs within QTL intervals, the genome features format (GFF) file of the S288C reference 
genome was used. 
 
5.3. Results 
5.3.1. Sequencing outputs 
The amount of raw sequence data obtained for the parental strains and the corresponding 
coverage (based on a 12 Mb genome) are displayed in Table 5.2. 
 
Table 5.2: Sequencing output information of parental strains used for establishing AIL. G denotes 
gigabases. 
Strain name Number of bases Fold coverage (approximate) 
BY 1.2 G 100× 
UWOPS87-2421 10 G 833× 
L-1374 1.2 G 100× 
DBVPG6044 2.1 G 175× 
Y12 4.1 G 342× 
 
The raw sequence output for the AIL segregant population and the corresponding coverage 
within each sample are described in Table 5.3. 
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Table 5.3: Sequencing output information of pooled AIL segregant populations. G denotes gigabases. 
Sample name Number of bases Fold coverage (approximate) 
UWOPS87-2421×BY AIL 
High dose treatment 
3.6 G 300× 
UWOPS87-2421×BY AIL 
Intermediate dose treatment 
4.9 G 408× 
UWOPS87-2421×BY AIL 
Untreated 
5.2 G 433× 
L-1374×BY AIL 
High dose treatment 
5.0 G 417× 
L-1374×BY AIL 
Intermediate dose treatment 
4.9 G 408× 
L-1374×BY AIL 
Untreated 
4.8 G 400× 
DBVPG6044×BY AIL 
High dose treatment 
4.3 G 358× 
DBVPG6044×BY AIL 
Intermediate dose treatment 
3.9 G 325× 
DBVPG6044×BY AIL 
Untreated 
4.7 G 392× 
Y12×BY AIL 
High dose treatment 
5.5 G 458× 
Y12×BY AIL 
Intermediate dose treatment 
5.4 G 450× 
Y12×BY AIL 
Untreated 
5.5 G 458× 
 
5.3.2. Genomic markers 
Variant calling revealed candidate sites that could be used as suitable markers to demarcate 
genomic locations. Such analysis revealed a relatively high level of genetic divergence between 
BY and each of the four SGRP parents—the lowest level of divergence was 0.3%, displayed 
between BY and L-1374, while the most highly divergent pair was BY and DBVPG6044 at 
0.7%. The total number of variants found between BY and each of the four SGRP strains is 
described in Table 5.4. 
Table 5.4: List of total variants between BY and each of the four SGRP strains 
SGRP parent Total SNPs Total Indels Sequence divergence (to BY) 
UWOPS87-2421 68 863 2 388 0.6% 
L-1374 35 213 2 361 0.3% 
DBVPG6044 76 819 4 569 0.7% 
Y12 63 760 4 286 0.6% 
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Following filtration of the variant positions in order to ensure compatibility with 
MULTIPOOL (as described in Sections 2.24.2 and 2.24.3), the number of SNP markers was 
considerably reduced. The markers had approximately even distribution throughout the 
genome. The actual marker distribution is presented in Appendix 7.6. The final quantity of 
variant markers found between BY and each SGRP strain is presented in Table 5.5. 
Table 5.5: Final number and frequency of markers used for QTL mapping in each sample. 
Sample name Number of markers Marker frequency 
UWOPS87-2421×BY AIL 
Intermediate dose treatment 
30 044 1 per 400 bp 
UWOPS87-2421×BY AIL 
High dose treatment 
31 482 1 per 380 bp 
L-1374×BY AIL 
Intermediate dose treatment 
17 601 1 per 680 bp 
L-1374×BY AIL 
High dose treatment 
17 590 1 per 680 bp 
DBVPG6044×BY AIL 
Intermediate dose treatment 
33 689 1 per 360 bp 
DBVPG6044×BY AIL 
High dose treatment 
33 731 1 per 360 bp 
Y12×BY AIL 
Intermediate dose treatment 
29 928 1 per 400 bp 
Y12×BY AIL 
High dose treatment 
29 969 1 per 400 bp 
 
5.3.3. Drug treatment of AIL segregant progeny in lawn format on agar 
The output of the optimisation of the lawn drug treatment format (described in Section 5.2.2) 
is displayed in Figure 5.3. 
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Figure 5.3: Dose-response to benomyl and ketoconazole in lawn testing format. Dashed red lines denotes 
the selected dose for intermediate treatment and high dose treatment. N=3. Data are presented as means. 
Error bars omitted for clarity. 
 
5.3.4. QTL outputs governing response to benomyl and ketoconazole 
Following derivation of allele frequencies from the sequencing data of the AIL progeny 
populations selected on either intermediate dose, high dose or no drug, QTL were determined 
for each treated sample using MULTIPOOL. The output of these analyses are displayed in 
Figures 5.4-5.11. Note that in these diagrams, the different colour lines represent the 16 
chromosomes of S. cerevisiae. The numbers above the peaks denote QTL (the number before 
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the period denotes chromosome number; the number following the period refers to QTL found 
on that chromosome). The red line in each graph is the significance threshold, as calculated 
through a Benjamini and Hochberg FDR correction at a significance level of 0.0001. The 
numerical description of QTL intervals is provided in Appendix 7.5.  
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In order to detect QTL that contribute to benomyl resistance, the UWOPS87-2421×BY cross 
was tested. In cells that survived an intermediate dose treatment with benomyl (45 µM), a total 
of nine QTL were detected between BY and UWOPS87-2421 (Figure 5.4). 
 
Figure 5.4: Benomyl response QTL detected between UWOPS87-2421 and BY following intermediate dose 
treatment of AIL segregants with benomyl. 
 
When the benomyl treatment was increased to 80 µM, the number of detected QTL in the 
surviving cells increased to 18 (Figure 5.5). 
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Figure 5.5: Benomyl response QTL detected between UWOPS87-2421 and BY following high dose 
treatment of AIL segregants with benomyl. 
 
On the other end of the benomyl response phenotype spectrum, the L-1374×BY cross was 
tested in order to detect loci that segregated to give BY its relative resistance (which should 
conversely be responsible for the benomyl sensitivity of L-1374). Upon intermediate dose 
treatment (30 µM benomyl), three QTL were detected in the surviving cells (Figure 5.6). 
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Figure 5.6: Benomyl response QTL detected between L-1374 and BY following intermediate dose treatment 
of AIL segregants with benomyl. 
 
When the benomyl dosage was increased to 50 µM (high dose), another two QTL became 
significant, to give a total of five QTL (Figure 5.7). 
 
Figure 5.7: Benomyl response QTL detected between L-1374 and BY following high dose treatment of AIL 
segregants with benomyl. 
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In order to identify loci that mediate resistance to ketoconazole, the DBVPG6044×BY cross 
was examined. Intermediate dosage treatment with 25 µM ketoconazole revealed that the 
surviving cells harboured 12 QTL that contribute to this phenotype (Figure 5.8). 
 
Figure 5.8: Ketoconazole response QTL detected between DBVPG6044 and BY following intermediate dose 
treatment of AIL segregants with ketoconazole. 
 
In contrast to the benomyl findings, increasing the ketoconazole dose to 65 µM (high dose) 
produced fewer QTL—10 in total (Figure 5.9). Two of the QTL detected with the intermediate 
dose ketoconazole treatment (2.1 and 4.1) each split into two subpeaks. 
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Figure 5.9: Ketoconazole response QTL detected between DBVPG6044 and BY following high dose 
treatment of AIL segregants with ketoconazole. 
 
Examination of the Y12×BY cross to detect QTL responsible for ketoconazole sensitivity 
revealed a surprisingly high number of loci. Intermediate dose treatment uncovered a total of 
41 QTL underpinning the ketoconazole response in this cross (Figure 5.10). 
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Figure 5.10: Ketoconazole response QTL detected between Y12 and BY following intermediate dose 
treatment of AIL segregants with ketoconazole. 
 
Increasing the ketoconazole treatment to a high dosage (15 µM) increased the corresponding 
number of underlying QTL to 56 (Figure 5.11) 
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Figure 5.11: Ketoconazole response QTL detected between Y12 and BY following intermediate dose 
treatment of AIL segregants with ketoconazole. In some regions QTL are grouped together for the sake of 
clarity. 
 
 
5.3.5. Effects of varying drug treatment dosage on the underlying drug 
response QTL network 
Comparing the set of QTL that come up under different treatment regimens with the same 
drug and in the same cross served to reveal whether similar or different QTL networks were 
required to deal with the increasing levels of cellular stress produced by the drug. It should be 
noted that a common and confounding finding was that the same QTL peaks were sometimes 
evident under different forms of treatment, but these failed to reach the significance threshold 
in one treatment sample. This created difficulty in conclusively stating which QTL were shared 
between regimens. Therefore, the following analysis of QTL network conservation presents 
both the strict estimates of the number of shared QTL (i.e. where QTL reached significance in 
both samples being compared) and the more liberal estimates of the same (i.e. the QTL was 
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only significant in one of the two samples). A comparison between intermediate and high dose 
drug treatments is presented in Figure 5.12. 
 
Figure 5.12: Comparison of shared vs unique QTL between the intermediate and high treatment dose.  
Black numbers in the middle of the diagram represent the number of QTL shared between treatment types 
when the QTL were significant in both treatment regimens. The bracketed number represents the more 
liberal estimate of the total number of shared QTL—loci that only achieved significance under one 
treatment type. Meanwhile, completely unique loci are represented on the non-overlapping areas of the 
diagrams. 
 
In each cross, the majority of QTL were shared between the different drug treatment 
regimens. Nevertheless, in the case of benomyl resistance (tested by the UWOPS87-2421×BY 
cross) and ketoconazole sensitivity (tested in the Y12×BY cross), the high treatment dose led 
to more unique QTL arising (representing 26% and 24% of the total QTL in each cross, 
respectively). Conversely, in the case of ketoconazole resistance (tested in the 
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DBVPG6044×BY cross), there were more unique QTL under the intermediate treatment dose 
than under high concentration drug treatment.  
 
In addition to comparing the numbers of QTL between the “shared” (between intermediate 
and high dose treatment) and the “unique” groups, the average LOD scores of those groups 
were also compared. This could be informative as it can denote whether any of the groups in 
question harbour a greater proportion of minor QTL. This would be reflected in lower overall 
QTL scores and it could be argued that the QTL of that group are likely to have a weaker 
association or have less effect on the phenotype. This comparison is presented in Figure 5.13. 
 
Figure 5.13: Box and whisker representation of the average LOD scores of the QTL that were shared 
between drug treatment regimens versus the QTL that were unique to either one or the other regimen. 
“Benomyl R” represents the UWOPS87-2421×BY cross that tested benomyl resistance. “Ketoconazole R” 
describes the DBVPG6044×BY cross. “Ketoconazole S” denotes the Y12×BY cross. The L-1374×BY cross 
is not displayed as all its QTL were shared between treatments. Whiskers represent the 5th and 95th 
percentile. The top LOD score value is omitted from the “Ketoconazole S Unique” group (that of QTL 2.2 
high dose treatment; LOD 299) for the sake of clarity. Only QTL that fulfil the strict definition of “shared” 
(i.e. are detected as significant in both intermediate and high dose treatment) are presented in the graph. 
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Both the median average and the maximum scores tended to be higher in the “shared” group 
compared to the analogous “unique” group for the same cross. One exception to this was QTL 
2.2 from the high dose ketoconazole treatment in the Y12×BY cross, which had a LOD score 
of 299 (the highest score output by MULTIPOOL) and did not have a match in the intermediate 
dose treatment in the same cross. Nevertheless, because the QTL that were shared between 
treatment types had higher LOD scores and there was a greater number of QTL in that group, 
it was concluded that the majority of the QTL network remains conserved upon increasing 
doses of drug. 
 
5.3.6. Conservation of drug response QTL networks between individual 
strains 
A major question of this study was not only which QTL contribute to the variant drug 
response in individuals, but also whether those QTL networks are the same or different between 
individuals. In order to evaluate this, I compared the QTL networks that govern the two 
extremes of response to benomyl and ketoconazole. A comparison of the numbers of QTL that 
were either shared between the phenotypic extremes or were unique to one or the other extreme 
are presented in Figure 15.14. 
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Figure 5.14: Comparison of the number of shared vs unique QTL between the phenotypic extremes of drug 
response. The description of the numbering system is the same as described for Figure 15.12. 
 
There was a considerable amount of overlap between the resistant and sensitive end of the 
response both for benomyl and ketoconazole. For benomyl, at least 25% of QTL (or 40% if 
one uses the more liberal estimate of the number of shared QTL) were shared between the 
UWOPS87-2421×BY and the L-1374×BY crosses. For ketoconazole, at least 39% of QTL (or 
65% using the more liberal estimate) were shared between the DBVPG6044×BY cross and the 
Y12×BY cross. Nevertheless, substantial variation was evident in some crosses. The 
UWOPS87-2421×BY cross included all the QTL found in the L-1374×BY cross and also 
displayed an additional 12 QTL that were distinct to the L-1374×BY cross. Similarly, all but 
one of the QTL found to segregate in the DBVPG6044×BY cross were also present in the 
Y12×BY cross. However, the latter cross also contained 21 QTL for ketoconazole response 
that were unique to it. 
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In order to establish the importance of these cross-specific QTL, the average LOD scores 
between the “shared” QTL (i.e. QTL that were common to both drug responses for benomyl or 
ketoconazole) and the cross-specific QTL were compared. This is shown in Figure 5.15. 
 
Figure 5.15: Box and whisker representation of the average LOD scores of the QTL that were shared 
between the phenotypic extremes of drug response versus QTL that were unique to one of the phenotypic 
extremes. “Benomyl QTL: general” denotes QTL shared between the UWOPS87-2421×BY cross and the 
L-1374×BY cross. “Benomyl QTL: cross-specific” describes the extra UWOPS87-2421×BY set of unique 
QTL. “Ket. QTL: general” signifies QTL shared between the DBVPG6044×BY cross and the Y12×BY 
cross. “Ket. QTL: cross-specific” includes the single DBVPG6044×BY-specific QTL and the 21 Y12×BY-
specific QTL. Whiskers represent the 5th and 95th percentile. One LOD value (Y12×BY QTL 2.2 high dose 
treatment; LOD 299) is omitted for the sake of clarity. Only QTL that fulfil the strict definition of “shared” 
(i.e. were significant in both samples examined) are presented in the graph. 
 
Unlike with the drug-dose LOD score comparison, there was no clear-cut distinction 
between the “shared” QTL and the “cross-specific” QTL. In the benomyl response the shared 
QTL group had the higher median average and upper quartile limit showing that this group had 
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a greater portion of major-effect QTL that contribute to the benomyl response. Nevertheless, 
the cross-specific group possessed a higher maximal score. Meanwhile the ketoconazole 
response QTL displayed a different pattern. The “shared” QTL group had lower LOD statistics 
compared to the “cross-specific” group—in terms of median average, upper quartile limit and 
maximal score. This showed that most minor effect QTL were in   the “shared” group and the 
QTL of greater effect segregated with the different genetic backgrounds. 
 
Overall, there was a large number of cross-specific QTL that arose for both benomyl and 
ketoconazole response. There was no clear-cut pattern of LOD score differences between the 
general drug response QTL versus cross-specific QTL that applied to both drugs indicating 
differences in major and minor QTL contributions. It is concluded that individuals on opposite 
ends of the drug response phenotype (both for benomyl and for ketoconazole) have partially 
overlapping QTL networks that contribute to their respective phenotypes, but individual 
variation contributes to a considerable, if not the major portion of phenotypic variation. 
 
5.3.7. Potential causative genes within top-ranking QTL 
The final point of interest in this study was to explore potential causative genes within the 
five highest ranked QTL in each of the eight samples. It should be noted that this was not an 
unbiased search, as it is impossible to verify which genetic variants actually contributed to the 
phenotype without undertaking further experiments, such as allele swapping or hemizygocity 
analysis (Swinnen, Thevelein, et al., 2012). Therefore this analysis relies on previous 
knowledge to identify potential causes for the QTL. Nevertheless, an exploration of genomic 
annotations that fall within a QTL interval of interest can provide useful insight into the genetic 
underpinnings of a drug response phenotype and give leads for further exploration. 
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The QTL discussed in this section are summarised in Tables 5.6 and 5.7. QTL that are shared 
between samples are colour coded accordingly. 
Table 5.6: The top five benomyl QTL from each sample, ranked by LOD score. Cells sharing a colour 
denote that the QTL is the same between samples. 
Benomyl 
UWOPS87-2421×BY (Resistance) L-1374×BY (Sensitivity) 
Intermediate dose High dose Intermediate dose High dose 
QTL Max LOD QTL Max LOD QTL Max LOD QTL Max LOD 
15.2 31.28 15.2 67.97 5.1 47.36 5.1 60.08 
14.1 29.03 15.1 35.14 1.1 14.18 15.1 18.95 
15.1 19.12 12.1 25.63 15.1 7.86 1.1 15.66 
15.3 13.91 14.1 19.29   5.2 11.85 
1.1 8.59 15.3 18.29   14.1 9.47 
 
Table 5.7: The top five ketoconazole QTL from each sample, ranked by LOD score. Cells sharing a colour 
denote that the QTL is the same between samples. 
Ketoconazole 
DBVPG6044×BY (Resistance) Y12×BY (Sensitivity) 
Intermediate dose High dose Intermediate dose High dose 
QTL Max LOD QTL Max LOD QTL Max LOD QTL Max LOD 
2.2 29.86 2.2 25.21 5.1 76.49 2.2 299 
7.1 18.96 15.2 18.75 15.2 61.99 15.4 103.74 
13.1 17.9 4.1.b 8.16 2.3 50.04 5.1 93.1 
4.3 14.41 10.1 7.94 15.1 48.87 9.1 65.37 
4.1 12.53 12.1 7.64 2.2 41.72 16.3 58.23 
 
SGD annotations were used to assign likely candidate genes within each QTL interval. The 
candidate genes for the benomyl response are listed in Table 5.8, and an analogous list is 
provided for the ketoconazole response in Table 5.9. The genes whose mutation corresponded 
to a “benomyl resistance: decreased” or “benomyl resistance: increased” category on SGD 
were selected as candidate genes for benomyl response. Similarly, genes whose mutant 
phenotype corresponded to “triazole resistance: decreased/increased”, “fluconazole resistance: 
decreased/increased” or “miconazole resistance: decreased/increased” were selected as 
candidate genes underpinning ketoconazole response (SGD did not have a category for 
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“ketoconazole response”). Cells coloured dark blue were described by SGD as having 
involvement with the relevant drug. Cells in lighter blue are candidate genes not listed on SGD 
but that are proposed to be involved in drug response based on their function (as described in 
the introduction of this chapter). What is presented is not an exhaustive list of every gene within 
the selected QTL, but only potential causative genes based on their literature-based association 
to the mechanism of action of benomyl or ketoconazole. The overall functionality of the 
candidate genes and potential drawbacks of the selection approach of these genes is described 
in more detail in the discussion section of this chapter. 
Table 5.8: Candidate genes within the top-ranking QTL that may contribute to the benomyl response. 
Genes in dark blue are described on SGD as being linked to the benomyl response. Processes/functions that 
are represented more than once are denoted in the right hand column. Genes in light blue are proposed to 
be related to the benomyl response based on their function. 
QTL name 
ORF 
name 
Gene 
name 
Description Process/function 
UWOPS87-
2421×BY  
Intermediate 15.2 
YOR162C YRR1 Yeast Reveromycin-A Resistant Export pump 
YOR172W YRM1 
Yeast Reveromycin resistance 
Modulator 
Export pump 
UWOPS87-
2421×BY 
Intermediate 14.1 
YNL172W APC1 
Anaphase Promoting Complex 
subunit 
Cell division 
YNL175C NOP13 NucleOlar Protein rRNA 
YNL177C MRPL22 
Mitochondrial Ribosomal Protein, 
Large subunit 
rRNA 
YNL180C RHO5 Ras HOmolog  
YNL182C IPI3 Involved in Processing ITS2 Cell division 
YNL188W KAR1 KARyogamy 
Nuclear 
migration 
YNL197C WHI3 WHIskey Cell division 
UWOPS87-
2421×BY 
Intermediate 15.1 
YOL041C NOP12 NucleOlar Protein rRNA 
UWOPS87-
2421×BY 
Intermediate 15.3 
YOR233W KIN4 KINase Cell division 
YOR234C RPL33B 
Ribosomal Protein of the Large 
subunit 
rRNA 
YOR244W ESA1   
Chromosome 
segregation 
YOR249C APC5 Anaphase Promoting Complex Cell division 
YOR256C TRE2 Transferrrin REceptor like  
YOR257W CDC31 Cell Division Cycle Cell division 
YOR265W RBL2 Rescues Beta-tubulin Lethality Tubulin 
YAL020C ATS1 Alpha Tubulin Suppressor Tubulin 
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UWOPS87-
2421×BY 
Intermediate 1.1 
YAL026C DRS2 Deficiency of Ribosomal Subunits rRNA 
YAL040C CLN3 CycLiN Cell division 
YAL046C AIM1 
Altered Inheritance of 
Mitochondria 
 
YAL047C SPC72 Spindle Pole Component Cell division 
UWOPS87-
2421×BY High 
12.1 
YLR102C APC9 Anaphase Promoting Complex Cell division 
YLR103C CDC45 Cell Division Cycle Cell division 
L-1374×BY 
Intermediate 5.1 
YER007W PAC2 Perish in the Absence of Cin8p Tubulin 
L-1374×BY 
High 5.2 
YER095W RAD51 RADiation sensitive Cell division 
YER106W MAM1 
Monopolar microtubule 
Attachment during Meiosis I 
Cell division 
YER110C KAP123 KAryoPherin 
Chromosome 
segregation or 
rRNA 
Table 5.9: Candidate genes within the top-ranking QT that may contribute to the ketoconazole response. 
Genes in dark blue are described on SGD as being linked to the benomyl response. Processes/functions that 
are represented more than once are denoted in the right hand column. Genes in light blue are proposed to 
be related to the benomyl response based on their function. 
QTL name 
ORF 
name 
Gene 
name 
Description Process/function 
DBVPG6044×BY 
Intermediate 2.2 
YBR147W RTC2 Restriction of Telomere Capping 
Vacuole/ 
endosome 
YBR159W IFA38  Lipid 
DBVPG6044×BY 
Intermediate 7.1 
YGL173C XRN1 eXoRiboNuclease  
DBVPG6044×BY 
Intermediate 13.1 
YML071C COG8 
Conserved Oligomeric Golgi 
complex 
Vacuole/ 
endosome 
YML072C TCB3 
Three Calcium and lipid Binding 
domains (TriCalBins) 
 
YML075C HMG1 
3-Hydroxy-3-MethylGlutaryl-
coenzyme a reductase 
Lipid 
YML078
W 
CPR3 
Cyclosporin-sensitive Proline 
Rotamase 
 
DBVPG6044×BY 
Intermediate 4.3 
YDR484W VPS52 Vacuolar Protein Sorting 
Vacuole/ 
endosome 
YDR487C RIB3 RIBoflavin biosynthesis Mitochondria 
YDR490C PKH1 Pkb-activating Kinase Homolog  
YDR493W MZM1 Mitochondrial Zinc Maintenance Mitochondria 
YDR495C VPS3 Vacuolar Protein Sorting 
Vacuole/ 
endosome 
YDR496C PUF6 
PUmilio-homology domain 
Family 
 
DBVPG6044×BY 
Intermediate 4.1 
YDL004W ATP16 ATP synthase Mitochondria 
YDR007W TRP1 TRyPtophan  
YDR011W SNQ2 
Sensitivity to 4-NitroQuinoline-N-
oxide 
Export pump 
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YDR020C DAS2 Dst1-delta 6-Azauracil Sensitivity  
YDR031W MIX14 
Mitochondrial Intermembrane 
space CX(n)C motif protein 
Mitochondria 
DBVPG6044×BY 
High 15.2 
YOR231W MKK1 
Mitogen-activated protein Kinase-
Kinase 
Cell wall 
YOR232W MGE1 Mitochondrial GrpE Mitochondria 
DBVPG6044×BY 
High 10.1 
YJL066C MPM1 
Mitochondrial Peculiar Membrane 
protein 
Mitochondria 
YJL063C MRPL8 
Mitochondrial Ribosomal Protein, 
Large subunit 
Mitochondria 
YJL062W-
A 
COA3 Cytochrome Oxidase Assembly Mitochondria 
YJL062W LAS21 Local Anestheticum Sensitive Cell wall 
YJL054W TIM54 
Translocase of the Inner 
Mitochondrial membrane 
Mitochondria 
DBVPG6044×BY 
High 12.1 
YLR154W
-C 
TAR1 
Transcript Antisense to Ribosomal 
RNA 
 
YLR164W SHH4 SDH4 Homolog  
YLR170C APS1 
clathrin Associated Protein 
complex Small subunit 
Vacuole/ 
endosome 
Y12×BY 
Intermediate 5.1 
YEL013W VAC8 VACuole related 
Vacuole/ 
endosome 
YEL012W UBC8 UBiquitin-Conjugating  
YEL003W GIM4 
Gene Involved in Microtubule 
biogenesis 
 
Y12×BY 
Intermediate 15.2 
YOR043W WHI2 WHIskey  
YOR049C RSB1 
Resistance to Sphingoid long-
chain Base 
Lipid 
Y12×BY 
Intermediate 15.1 
YOL023W IFM1 Initiation Factor of Mitochondria Mitochondria 
YOL018C TLG2 
T-snare affecting a Late Golgi 
compartment 
Vacuole/ 
endosome 
Y12×BY 
Intermediate 2.2 
YBR037C SCO1 
Suppressor of Cytochrome 
Oxidase deficiency 
Mitochondria 
YBR039W ATP3 ATP synthase Mitochondria 
YBR041W FAT1 FATty acid transporter Lipid 
Y12×BY 
High 2.2 
YBL005W PDR3 Pleiotropic Drug Resistance 
transcription 
factor for 
export pumps  
YBR003W COQ1 COenzyme Q Mitochondria 
YBR006W UGA2 Utilization of GAba  
YBR008C FLR1 FLuconazole Resistance Export pump 
Y12×BY 
High 9.1 
YIL112W HOS4 Hda One Similar  
YIL111W COX5B Cytochrome c OXidase Mitochondria 
Y12×BY 
High 16.3 
YPL002C SNF8 Sucrose NonFermenting  
YPR002W PDH1 prpD Homolog Mitochondria 
YPR004C AIM45 
Altered Inheritance rate of 
Mitochondria 
Mitochondria 
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YPR009W SUT2 Sterol UpTake Lipid 
 
5.4 Discussion 
 
This chapter identified the QTL that gave rise to the drug response phenotypes of the four 
SGRP strains of interest—those being UWOPS87-2421 which exhibited benomyl resistance, 
L-1374 which was benomyl sensitive, DBVPG6044 which displayed resistance to 
ketoconazole and Y12 which was sensitive to ketoconazole. The application of NGS-BSA as 
a QTL mapping technique proved to be highly successful to this end. However, prior to QTL 
mapping it was necessary to create a molecular marker map of the parental strains used in each 
cross.  Hybridising microarrays are often used for this end but they suffer from shortcomings 
such as being limited to the set of probes represented on the array (both in terms of identity and 
number) and not being able to identify variants directly (Gresham et al., 2008; Winzeler et al., 
1998). NGS provides a superior alternative for marker discovery as it can overcome such 
limitations (Davey et al., 2011; Schneeberger, 2014; Swinnen, Thevelein, et al., 2012). Whole 
genome sequencing can theoretically uncover the maximum number of variants present 
between strains and  this can be particularly advantageous when QTL mapping is combined 
with the use of AILs, due to the reduced LD present (Gonzales et al., 2014). 
 
The use of AILs has been advantageous for enhancing the localisation power of QTL 
studies. Parts et al. have reported that F12 intercross segregants possessed a doubling of their 
genetic map size due to introduction of more recombination events, with a subsequent 2.5 fold 
reduction of observed QTL interval size (Parts et al., 2011). Cubillos et al. estimated that their 
four-parent AILs should have reduced the 3-LOD QTL interval size from 64 kb in F1 to 6 kb 
in F12 (Cubillos et al., 2013). However, the actual median QTL interval observed in their study 
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was 27.8 kb which was explained by possible linkage between QTL peaks resulting in a wider 
variance in the observed peak, or from non-uniform recombination. These factors are likely to 
apply to the current study as well where a 3-LOD QTL gave an estimated median interval of 
43 kb. The 3-LOD cut off may be an unnecessarily large an interval since others have suggested 
a 1.5-LOD estimate (Broman, 2001) which would narrow the numbers of genes subtending the 
QTL peak considerably.   It should also be noted that both the previous studies used a prolonged 
selection to achieve their phenotypes of interest. Such prolonged selection maximises the allele 
frequency differences between samples, which may contribute to better defined QTL peaks and 
thus a smaller QTL interval.  Also, sequencing individual segregants to directly assess the 
effect of additional crossings on the reduction of QTL interval within the particular crosses 
used here may have more refined QTL intervals, an option that was not available owing to time 
constraints for the studies in this thesis. Nevertheless, the 43 kb interval of the current study 
still presents a reduction of the predicted 64 kb F1 interval estimated by Cubillos et al. and 
indicates that the AIL procedure improved the QTL resolution. 
 
Comparison with the literature showed a reasonable overlap between this and other studies 
that performed QTL mapping for benomyl or ketoconazole response. Ehrenreich et al. 
investigated the effect of varying genetic backgrounds on QTL networks controlling benomyl 
response (Ehrenreich et al., 2012). They found a total of 26 QTL that contribute to benomyl 
response when comparing four genetic backgrounds. Of these, three (Chr. I position 74 787, 
Chr. XIV pos. 260 522 and Chr. XV pos. 640 639) were found within the UWOPS87-2421×BY 
cross in the current study. An additional five QTL (Chr. III pos. 529 546, Chr. IV 474 860, Chr. 
V pos. 322 550, Chr. XII pos. 312 033 and Chr. XV 215 694) lay near benomyl response QTL 
in this study (i.e. within 50 kb). These could potentially represent similar or overlapping QTL 
with the difference in position arising due to different analysis methodology between the 
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studies. In a different study Perlstein et al. reported a QTL for ketoconazole response in the 
vicinity of the gene SWH1 on Chr. I (Perlstein et al., 2007). This is likely to correspond to the 
Chr. I QTL (position 204 200-226 400) found for ketoconazole in the Y12×BY cross but this 
QTL is not reported directly in the current study as it is subtelomeric. Another study that 
examined genome-wide association to ketoconazole response in a panel of 100 yeast strains 
found a major contribution from an extraneously-acquired copy of PDR5 from S. paradoxus 
and a smaller contribution from a locus at the beginning of Chr. XI (position 115 888; (Strope 
et al., 2015). However, these loci were not found in the current study. Overall, the fact that at 
least a part of the QTL found in this study were supported by literature was a good validation 
of the methodology used. However, it is not unexpected that there was considerable variation 
found between studies because different genetic backgrounds have different genetic variants 
segregating between them and may uncover a different set of contributing loci to a phenotype 
in question. (Ehrenreich et al., 2012). Thus this study expands current knowledge, as it 
contributes additional information regarding the genetics of benomyl and ketoconazole 
response. The effect of genetic background on QTL detection is discussed in greater detail 
below. 
 
When the effect of increasing drug dosage on the underlying QTL network was studied it 
appeared that the majority of the network remained constant between treatment regimens, and 
the additional unique loci that arose tended to have lower LOD scores overall i.e. were 
relatively minor contributors. One extreme outlier to this pattern was Y12×BY QTL 2.2 was 
detected under high dose ketoconazole treatment with a LOD score of 299 but was not detected 
under intermediate dose treatment. In general, when loci unique to drug concentrations did 
appear, their numbers generally increased with increasing drug dosage. Swinnen et al. observed 
a similar pattern when examining the QTL required to tolerate varying levels of ethanol 
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(Swinnen, Schaerlaekens, et al., 2012). This could be explained by additional cellular 
mechanisms becoming important to help cope with the increased level of cellular stress. An 
independent study from our laboratory that examined the effect of increased protein misfolding 
stress in the endoplasmic reticulum (ER) upon the activation of the unfolded protein response 
(UPR) displayed findings to corroborate this hypothesis (Low, 2013). This study found that 
under increased ER stress, distinct and functionally different genetic interaction networks are 
required to ensure cell viability compared to those networks that are needed under basal 
(unstressed) conditions. It should be noted that in the case of the DBVPG6044×BY cross, a 
higher dose of ketoconazole led to fewer QTL being detected (a finding that was in contrast to 
the other three crosses examined). It can be observed that a number of peaks that reached 
significance upon intermediate-dose treatment with ketoconazole (specifically QTL 4.2, 7.1, 
7.2, 8.1, 12.1 and 16.1, Figure 5.8) failed to do so under high-dose treatment (although their 
peaks could still be observed under the threshold of significance). It is not clear why this 
phenomenon occurred, but may reflect different sets of cellular pathways playing a role in 
response to intermediate vs high drug dose. Further exploration into the unique QTL required 
following higher dose drug treatment is thus likely to be informative in further elucidating how 
the cell copes with therapeutic stress. 
 
It is concluded here that QTL networks of two individual strains that fall on the extreme 
ends of a single phenotype (e.g. benomyl response) partially overlap but that there are 
nevertheless strain-specific QTL that form important contributions to the phenotype. The latter  
may be context-dependent QTL  only  detectable in   particular cross and environment 
combinations arising from epistatic or gene-environment interactions (Mackay et al., 2009). 
An in-depth study that investigated   stress response in S. cerevisiae concluded that such QTL 
comprise most of the determinants of a phenotype, but tend to have lower LOD scores and 
QTL of benomyl and ketoconazole response 
175 
 
explain a smaller portion of phenotypic variance (Cubillos et al., 2011). Another study 
concluded that the phenotype being investigated is a better predictor of the QTL network than 
is the strain cross that is being used (Ehrenreich et al., 2012). By contrast, the current study 
may add additional information to this exploration of strain-specific phenotype contribution, 
in half of the strains tested, cross-specific QTL make up the majority of the QTL network. 
Furthermore, in the case of ketoconazole-response QTL, these cross-specific QTL also have 
higher overall LOD scores indicating that alleles specific to individual strains may have a 
considerable contribution to phenotype. A study of in-laboratory evolution lends support to this 
hypothesis, as it discovered alternate QTL networks can arise to deal with the same stressor 
(alkali stress) (Romano et al., 2010). When comparing the contribution of the alleles from 
multiple strains to a single phenotype other studies have shown that most cases of the 
contribution are made by alleles that are private to one strain (an occurrence called “allelic 
singletons”) (Cubillos et al., 2013; Ehrenreich et al., 2012). This notion is supported by findings 
in different human populations that appear to have evolved carrying rare and lineage-specific 
alleles that have a high level of functional phenotypic contribution (Abecasis et al., 2012; 
Keinan & Clark, 2012; Tennessen et al., 2012). 
 
The present study attempted to evaluate potential causative genes within a selection of the 
highest ranking QTL (in terms of LOD score). These putative causative genes were selected 
on the basis of known literature relationships to the mechanism of action of the drug in 
question. Such literature relationships were selected based on previous knowledge of the 
mechanisms involved in response to benomyl or ketoconazole, or by selecting genes whose 
mutation (usually null mutation) was reported to cause resistance or sensitivity to benomyl or 
azoles, as reported in SGD. It has to be appreciated that such an analysis is prone to 
confirmation bias in the sense that no novel mechanism can be derived for response to benomyl 
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or ketoconazole. Another potential limitation is that given the large number of total genes and 
ORFs considered (the top-ranked intervals considered in Section 5.3.6 contained a total of 
approximately 550 genes) and the fact that both benomyl and ketoconazole affect fundamental 
cellular processes (with multiple interacting processes described in literature), it may be 
expected that putative candidate genes may appear in the QTL intervals by chance. The 
presented lists of candidate genes are not intended as a definitive list of causative factors, but 
rather as a speculation of what those causative factors may be. It also cannot be established 
with certainty that the causative polymorphism underlying a QTL lies in a gene, but may be 
extragenic (such as in a promoter or terminator region). Other factors (such as how close a gene 
lies to the centre of the QTL interval) may provide information for likely causative genes 
(however, the reliability of such measures may be limited by the noise in the allele frequency 
data). Independent analysis (such as hemizygocity analysis) would be required to establish the 
causative factors underlying each QTL. 
In depth examination of the top QTL within each sample indicated that each QTL contained 
at least one or several genes that could be linked to modulating the activity of the drug. 
However, the following discussion regarding these genes is a speculative one of potential 
mechanisms involved, as without further validation it is impossible to definitively establish 
which genes are causative. The top QTL for the benomyl response contained YRM1 and YRR1 
(Cui et al., 1998; Lucau-Danila et al., 2003). These are paralogous transcription factors that 
control the expression of various PDR genes, including SNQ2—an export pump with 
specificity for benomyl (Rogers et al., 2001). This indicates that in the strains used for this 
study, altered drug export may be one basis for the cell to cope with benomyl stress. 
Additionally, the benomyl response QTL contained multiple genes involved in cell cycle 
progression and the spindle checkpoint—APC1, APC5, APC9, CDC31, CDC45, CLN3, KIN4 
and WHI3 (Chen & Madura, 2008; D'Aquino et al., 2005; Nash et al., 1988; Schladebeck & 
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Mosch, 2013; Tye, 1999; Zachariae & Nasmyth, 1999). These processes are well-linked to 
microtubule function within the literature. As described in Chapter 1 (Section 1.4.2), yeast 
microtubules play a central role in mediating chromosome and nuclear movement during 
meiosis and mitosis (Winsor et al., 1997). The interference of benomyl with microtubule 
function thus interrupts these processes and likely triggers cell death through apoptosis (Jordan 
et al., 2004). Genes involved in histone formation, chromosome and DNA stability, spindle 
pole body and microtubule attachment to chromosomes (ESA1, KAP123, MAM1, RAD51 and 
SPC72) were also represented (Clarke et al., 1999; Mosammaparast et al., 2002; Soues & 
Adams, 1998; Sung, 1994; Toth et al., 2000). As also described in Chapter 1, these components 
are generally related to the attachment and functioning of the mitotic spindle and the separation 
of chromosomes and chromatids. Incorrect functioning of these aspects leads to cell cycle block 
and eventual apoptosis, as described above. ATS1, PAC2 and RBL2, genes involved in tubulin 
formation and functionality, were also present in the QTL intervals (Archer et al., 1995; Hoyt 
et al., 1997; Kirkpatrick & Solomon, 1994). These are related to the primary target of benomyl. 
Finally DRS2, MRPL22, NOP12, NOP13 and RPL33B may add additional support to the link 
between rRNA/ribosome biogenesis and benomyl activity that was described in Section 5.1.1 
(Graack & Wittmann-Liebold, 1998; Planta & Mager, 1998; Ripmaster et al., 1993; Wu et al., 
2001). The functionality of this link is not clear (if it is confirmed), but could be a promising 
avenue for further study. 
 
The top ketoconazole response QTL included multiple candidate genes that were linked to 
ketoconazole activity including several export pumps, namely FLR1, and SNQ2 and one of the 
transcription factors that acts as a master regulator of these pumps (PDR3). The contribution 
of PDR3 and SNQ2 is debatable. PDR3 was only found on the very periphery of the Y12×BY 
high dose QTL 2.2 and may not be the causative gene in that locus and SNQ2 does not have 
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high specificity for ketoconazole observations in the current work and (Rogers et al., 2001). 
On the other hand, FLR1 may be involved in ketoconazole response, as it was positioned in the 
centre of its QTL and is well established to have a role in azole resistance (Alarco et al., 1997). 
Therefore, as with benomyl, if the causative genes are verified then variability in drug export 
may lead to individual strain variation. A number of genes with roles in synthesis and transport 
of ergosterol and other membrane lipid components (Basson et al., 1986; Beaudoin et al., 2002; 
Kihara & Igarashi, 2002; Ness et al., 2001; Zou et al., 2002) were also found associated with 
the QTL identified here. These were FAT1, HMG1, IFA38, RSB1 and SUT2. These could be 
related to the role azoles have in ergosterol synthesis, although a further discussion about other 
possible roles of some of these genes is provided in Chapter 6. Mitochondrial function genes 
(Ashby & Edwards, 1990; Atkinson et al., 2010; Boyer, 1997; Deloche & Georgopoulos, 1996; 
Gabriel et al., 2007; Garofalo et al., 2003; Geier et al., 1995; Graack et al., 1998; Inadome et 
al., 2001; Jin et al., 2003; Kerscher et al., 1997; Lopes et al., 2010; Ohlmeier et al., 2004; 
Schulze & Rodel, 1988) were also found—specifically AIM45, ATP3, ATP16, COA3, COQ1, 
COX5B, IFM1, MGE1, MIX14, MPM1, MRPL8, MZM1, PDH1, RIB3, SCO1 and TIM54. The 
presence of these genes in the QTL may suggest the previously described link between 
mitochondria function and azole toxicity, as described in Chapter 1. It is thought that 
mitochondrial function may be involved in the formation of toxic ketosteroids that form the 
main inhibitory effect of azoles (Kontoyiannis, 2000). The genes APS1, RTC2, TLG2, VAC8 
VPS3 and VPS52 suggests that vacuolar function or trafficking to the vacuole may play a role 
in ketoconazole response (Cowles et al., 1997; Holthuis et al., 1998; Jezegou et al., 2012; 
Raymond et al., 1990; Subramanian et al., 2006). This link is a fairly recent discovery; 
ergosterol is thought to modulate vacuolar function and influence the viability of the cell 
through vacuolar-mediated pH changes (Zhang & Rao, 2010). Finally, LAS21 and MKK1 
known to be involved in cell wall integrity (Benachour et al., 1999; Heinisch et al., 1999) could 
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also be contributors to the variable ketoconazole response in the strains investigated here. Links 
between cell wall integrity and azole function have been described earlier (see Introduction of 
this chapter). A relationship between the cell wall and the membrane may explain the synergy 
between echinocandins (cell wall targeting agents) and plasma membrane targeting agents 
which include azoles and polyenes (Chen et al., 2011). 
 
Overall, the finding that the discovered QTL subtended genes that were consistent with 
previous findings of off-target effects of benomyl and ketoconazole was another promising 
indication of the validity of this study.  However, further validation would be needed to confirm 
that genes within these processes that are discussed in this thesis are indeed the ones that 
underlie the QTL found in this study. Allelic exchange and hemizygocity analysis are 
demonstrated avenues for further validation as in previous yeast QTL studies (Steinmetz et al., 
2002; Swinnen, Thevelein, et al., 2012). As previously discussed in this chapter, independent 
of the actual genes that may comprise a QTL, QTL of strain-specific crosses make up the 
majority of the QTL networks defined here. Furthermore, in the case of ketoconazole-response 
QTL, these “cross-specific QTL” also have higher overall LOD scores showing that alleles 
specific to individual strains make a considerable contribution to phenotype. 
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Chapter 6: General Discussion 
 
This thesis aimed to investigate the genetic basis of individual variation in drug response in 
yeast. Individual variation was modelled by natural strains of Saccharomyces cerevisiae that 
originated from the Saccharomyces Genome Resequencing Project (the SGRP collection). The 
strains in the SGRP collection had slightly higher divergence (based on SNPs) than occurs 
between human individuals (0.5-0.8% divergence within the SGRP strains compared to 0.1% 
divergence between human individuals (Levy et al., 2007; Song et al., 2015; Strope et al., 2015; 
The 1000 Genomes Project Consortium, 2010; Wang et al., 2008)). Nevertheless, it was 
considered an appropriate approximation of individuality, as the SGRP strains are members of 
the same species, and the divergence between the yeast strains does not exceed the divergence 
between humans and their closest relatives, the chimpanzee (1.24% (Ebersberger et al., 2002)). 
The SGRP collection was first dose response tested against the two antifungal agents, benomyl 
and ketoconazole which both have well-characterised primary cellular targets. This revealed 
that different natural S. cerevisiae isolates display a continuous range of drug response 
phenotypes (that is, resistance or sensitivity to each agent tested, with resistance and sensitivity 
being defined as relative to the control BY genetic background). If the primary drug target was 
the main (or only) component to govern drug response a bimodal distribution of this phenotype 
would be expected, which was not observed. This indicated that drug response in this instance 
is a quantitative trait controlled by multiple quantitative trait loci (QTL). In-depth investigation 
using four strains of interest (one resistant and one sensitive strain to each of the two drugs) 
revealed that most of the variance in drug response was explained by genetic factors, with 
multiple QTL likely contributing. QTL mapping using next-generation sequencing bulk 
segregant analysis (NGS-BSA) revealed the identity of these QTL and confirmed the 
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hypothesis that the benomyl and ketoconazole responses represented quantitative traits in the 
strains of interest. Furthermore, individual genetic variation was compared in strains displaying 
opposite phenotypes to drugs revealing significant QTL in the comparisons. The approach and 
outcomes of this dissertation have potential implications not only to the development of 
improved antifungal agents but also in terms of general drug therapy, as discussed below. 
 
6.1. Relation of heritability estimates to the final QTL network 
Knowing the actual QTL network underlying drug response allowed for evaluation of the 
heritability measures performed in Chapter 4. The ramifications of this statement are further 
discussed below but to aid the discussion the main QTL comparisons performed in the current 
work are re-iterated here: Four SGRP strains were selected on the basis of drug resistance or 
sensitivity relative to the laboratory strain BY. These were L-1374 that was sensitive to 
benomyl compared to BY; UWOPS87-2421 that was resistant to benomyl compared to BY; 
Y12 that was sensitive to ketoconazole compared to BY; DBVPG6044 that was resistant 
ketoconazole compared to BY. The estimates of transgressive segregation were compared to 
actual allele frequencies generated during the analysis of the NGS-BSA experiment in Chapter 
5. Transgressive segregation is presumed to arise when a phenotypically inferior strain 
harbours alleles that contribute to the superior phenotype (or vice versa). The UWOPS87-
2421×BY cross had considerably higher levels of transgressive segregation compared to the L-
1374×BY or the Y12×BY crosses, suggesting that in the UWOPS87-2421×BY cross a 
substantial proportion of QTL alleles contributing to the benomyl response phenotype 
originated from the parent that showed the opposite overall phenotype (e.g. an allele granting 
benomyl resistance came from the benomyl-sensitive BY parent). This counter-intuitive 
conclusion was supported by the QTL mapping. Upon intermediate dose benomyl treatment, 
only three of the total nine QTL had the UWOPS87-2421 allele increasing in frequency relative 
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to the control pool. In addition, the loci at which the UWOPS87-2421 allele contributed to the 
benomyl resistance had a lower median LOD score than those loci where the BY allele 
contributed (4.7 for the former versus 12.7 for the latter). The same pattern was evident in that 
cross upon high dose benomyl treatment; only six of the total 18 QTL showed an UWOPS87-
2421 allele increase in abundance and those loci had a median LOD of 7.3 compared to the 
16.5 median LOD score of loci where the BY allele appeared to be contributing. The Y12×BY 
cross showed the next highest level of transgressive segregation (9.8-13.3%) in terms of 
ketoconazole response, but only on the resistant end.  As previously discussed, this pattern may 
be caused by an unequal distribution of epistatic interactions occurring within that cross. 
Evaluation of which parental allele contributes within each QTL indicated that under both 
intermediate and high dose treatment there was almost an equal distribution of parental alleles 
and LOD scores. However, the results of the L-1374×BY cross were confounding—the alleles 
of the QTL with the highest LOD that contributed to the relative benomyl resistance in that 
cross appeared to originate from the sensitive L-1374 parent. However, it has to be taken into 
consideration that the transgressive segregation estimates were done in haploids while the QTL 
mapping was performed in diploids. Diploid cells may contain additional dominance effects 
(which Chapter 4 established are also likely to be present in the crosses), making the relation 
between the portion of transgressive segregants and the actual QTL mapped less 
straightforward.  
 
It was also determined that the “estimation assay” for the number of loci responsible for the 
drug response phenotype was often inaccurate, probably due to being overly simplistic. This 
estimation was based on relating the fraction of segregants showing parental phenotype to the 
number of loci responsible (n) through the formula 1/2n. A comparison between this estimation 
and the actual number of loci found is presented below in Table 6.1. 
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Table 6.1: Comparison of estimated number of drug response loci to actual number found. The 
DBVPG×BY cross is not represented as no estimate of locus number was obtained for it. 
 Estimated # loci Actual # loci 
UWOPS87-2421×BY 
Intermediate dose treatment 
1-1.5 9 
UWOPS87-2421×BY 
High dose treatment 
0.8-1.5 18 
L-1374×BY 
Intermediate dose treatment 
2.8-4.9 3 
L-1374×BY 
High dose treatment 
2.3-7.3 5 
Y12×BY 
Intermediate dose treatment 
1.9-5.9 40 
Y12×BY 
High dose treatment 
2.3-7.2 59 
 
The number of loci for the L-1374×BY cross fell within the expected range; however for 
the UWOPS87-2421×BY and the Y12×BY crosses the estimates were grossly underestimated. 
One explanation may be that the 1/2n “estimation assay” assumes that the loci have 
approximately equal contribution to the phenotype, which may not be the case for the QTL in 
that study (Wilkening et al., 2014). Another limitation of the “estimation assay” in the current 
dissertation was only a maximum of 308 segregants were used to assess the phenotype fraction, 
while the actual QTL mapping was performed with 100 000 segregants. It is well known that 
the larger the population used, the greater the detection power of the assay (Bloom et al., 2013). 
Thus the “estimation assay” may simply be underpowered to produce an accurate estimation 
of the number of loci involved.   On the other hand, the QTL mapping results may contain false 
positives, thus over-estimating the actual number of QTL responsible (this is discussed in 
greater detail under limitations and future directions). Nevertheless, the 1/2n “estimation assay” 
has been successfully used to determine if a trait was multigenic or monogenic and has been 
instrumental in this study to establish drug response as a multigenic trait as it has in others 
(Deutschbauer et al., 2005; Gerke et al., 2006; Steinmetz et al., 2002; Wilkening et al., 2014). 
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6.2. Potential relation between QTL mapping and chemogenomic 
screening 
A comparison was made between the genes contained within the top-ranking QTL and those 
that were listed in SGD from results of chemogenomic screens (refer to Tables 5.8 and 5.9 for 
the list of genes encapsulated within QTL that were also found in those screens). In such 
screens, the deletion mutant array (DMA; refer to Section 1.3.1) is treated with a low dose of 
the drug of interest. The drug-treated DMA is then observed for hypersensitive or hyper 
resistant null deletion mutants. Drug sensitive mutants typically reveal synthetic enhancement 
interactions between the drug target and the gene product that would otherwise be produced by 
the null mutant. These interactions are thought to arise because the drug target and the other 
gene act in two “redundant” pathways that both contribute to an essential function. 
Alternatively, the gene product of the null mutant may be required to reduce the inhibitory 
effect of the drug (for example, by drug export). On the other hand, drug resistant mutants may 
indicate that their normal gene product is typically   required to enhance the action of the drug—
for instance, by import or activation (Boone et al., 2007; Dekker et al., 2013).  
 
The overlapping findings between QTL genes and genes found as hits in chemogenomic 
screens for benomyl response are shown in Table 6.2. 
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Table 6.2: Genes found within the top-ranking benomyl-response QTL that are reported in chemogenomic 
screens in the literature 
ORF name Gene name 
Benomyl resistance of 
null mutant 
Source 
YAL046C AIM1 Decreased (Brown et al., 2006) 
YOR257W CDC31 Decreased (van Pel et al., 2013) 
YOR244W ESA1 Decreased (van Pel et al., 2013) 
YER110C KAP123 
Decreased 
 
(Dudley et al., 2005; Ptak et al., 
2009) 
Increased (Brown et al., 2006) 
YNL175C NOP13 Decreased 
(Brown et al., 2006; Parsons et 
al., 2004) 
YER007C PAC2 Decreased (Hoyt et al., 1997) 
YOR265W RBL2 Decreased (Brown et al., 2006) 
YAL047C SPC72 Decreased (Parsons et al., 2004) 
YOR256C TRE2 Decreased (van Pel et al., 2013) 
YAL020C ATS1 Increased (Brown et al., 2006) 
YAL040C CLN3 Increased (Brown et al., 2006) 
YAL026C DRS2 Increased (Brown et al., 2006) 
YNL177C MRPL22 Increased (Brown et al., 2006) 
YOL041C NOP12 Increased (Brown et al., 2006) 
YER095W RAD51 Increased (Brown et al., 2006) 
YNL180C RHO5 Increased (Brown et al., 2006) 
YOR234C RPL33B Increased (Brown et al., 2006) 
 
Unfortunately, based on this table, it is difficult to make conclusions about the relationship 
the benomyl-response QTL have to the target of benomyl. The benomyl response QTL genes 
that fall into the processes described in Chapter 5 are more or less evenly distributed between 
the group in which deletion of the gene causes sensitivity (i.e. the potential “redundant 
pathway” genes) and the group in which gene deletion leads to resistance (i.e. genes that may 
mediate the cell inhibitory effects of benomyl). The fact that a large number of genes (804) are 
annotated on SGD as leading to benomyl resistance or sensitivity (upon deletion) may also 
limit this analysis—the fact that the QTL contain such “hits” from chemogenomic screens may 
be coincidental. An extended investigation into additional benomyl response QTL as well as 
further confirmation of causative genes within each QTL interval (discussed later in this 
chapter) could lead to a clearer picture. 
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The overlapping findings between genes within QTL responsible for ketoconazole response 
and genes found as hits in chemogenomic screens for azole response are shown in Table 6.3. 
 
Table 6.3: Genes found within the top-ranking ketoconazole-response QTL that are reported in azole 
response chemogenomic screens in the literature 
ORF name Gene name 
Azole resistance of null 
mutant 
Source 
YLR170C APS1 Decreased (triazoles) (Hoepfner et al., 2014) 
YBR003W COQ1 
Decreased (fluconazole 
and miconazole) 
(Hoepfner et al., 2014) 
YBR041W FAT1 Decreased (miconazole) (Vandenbosch et al., 2013) 
YBR008C FLR1 Decreased (fluconazole) (Broco et al., 1999) 
YML075C HMG1 Decreased (fluconazole) (Hoepfner et al., 2014) 
YJL062W LAS21 Decreased (miconazole) (Vandenbosch et al., 2013) 
YOR231W MKK1 Decreased (fluconazole) (Kapitzky et al., 2010) 
YDR490C PKH1 Decreased (fluconazole) (Kapitzky et al., 2010) 
YDR496C PUF6 Decreased (fluconazole) (Kapitzky et al., 2010) 
YPL002C SNF8 Decreased (miconazole) (Vandenbosch et al., 2013) 
YOL018C TLG2 Decreased (fluconazole) (Kapitzky et al., 2010) 
YDR007W TRP1 Decreased (miconazole) (Thevissen et al., 2007) 
YDR495C VPS3 Decreased (miconazole) (Vandenbosch et al., 2013) 
YDR484W VPS52 Decreased (fluconazole) (Parsons et al., 2004) 
YOR043W WHI2 
Decreased (fluconazole 
and miconazole) 
(Vandenbosch et al., 2013) 
YML071C COG8 Increased (fluconazole) (Kapitzky et al., 2010) 
YML078W CPR3 Increased (miconazole) (Vandenbosch et al., 2013) 
YDR020C DAS2 Increased (miconazole) (Vandenbosch et al., 2013) 
YEL003W GIM4 Increased (fluconazole) (Kapitzky et al., 2010) 
YIL112W HOS4 Increased (fluconazole) (Kapitzky et al., 2010) 
YDR493W MZM1 Increased (miconazole) (Vandenbosch et al., 2013) 
YBR147W RTC2 Increased (fluconazole) (Anderson et al., 2003) 
YML072C TCB3 Increased (fluconazole) (Kapitzky et al., 2010) 
YEL012W UBC8 Increased (fluconazole) (Kapitzky et al., 2010) 
YBR006W UGA2 Increased (miconazole) (Vandenbosch et al., 2013) 
YEL013W VAC8 Increased (fluconazole) (Kapitzky et al., 2010) 
YGL173C XRN1 Increased (fluconazole) (Kapitzky et al., 2010) 
 
Generally, the picture for ketoconazole was as incomplete as the one for benomyl and the 
same discussion points regarding additional analysis and functional confirmation apply. 
However, it is interesting that individual deletion of the two lipid synthesis and transport genes 
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(FAT1 and HMG1) both led to hypersensitivity to azoles. HMG1 is also a precursor in other 
pathways such as protein prenylation and haeme biosynthesis (Callegari et al., 2010) and this 
could have a compensatory function during azole inhibition. Interestingly, azoles and statins 
(which target HMG1 and its homolog HMG2) have synergistic activity on fungal cells when 
they are treated with them in combination (Galgoczy et al., 2011). Furthermore, the two genes 
involved in cell wall integrity (LAS21 and MKK1) have a potential “back up” role that can 
compensate for azole treatment, as their deletion causes azole sensitivity. It should be noted 
that a similar limitation applies here as did for benomyl response, in that a considerable number 
of genes are listed on SGD as being involved in azole response and therefore the occurrence of 
these genes within QTL may be coincidental. 
 
6.3 Limitations  
One finding that may seem initially contradictory was the fact that in spite of attempts to 
eliminate strains whose drug response phenotype was caused by “obvious candidates” (known 
drug targets or efflux pumps of the PDR system) in Chapter 3, several of the QTL uncovered 
harboured drug efflux genes. It should be noted that the elimination tactic used in Chapter 3 
was fairly limited in that it likely only eliminated strains with a global up- or down-regulation 
of the PDR system through Pdr1p and Pdr3p. In a similar fashion, despite efforts to eliminate 
strains whose response was due to drug target alterations, this was only partially successful. 
For example, QTL 8.2 in the Y12×BY cross (within both the intermediate dose and high dose 
sample) and QTL 8.1 in the DBVPG6044×BY cross (intermediate dose sample) contained 
ERG11, the primary target of ketoconazole. These findings may suggest that the PDR analysis 
or the genotype-phenotype correlation analysis performed in Chapter 3 were not sufficient to 
ensure the drug response phenotypes observed did not arise due to “obvious candidates” such 
as changes in the PDR system or the primary drug target. However, it is not possible to 
General Discussion 
 
189 
 
definitively state that the factors described above were the causative ones within their QTL 
without performing further analysis.   
 
A major limitation of this study was that the fact that only a single replicate of the NGS-
BSA experiment was able to be performed (owing to financial considerations). Additional 
replicates would have been beneficial in firmly establishing high-confidence in the QTL. In 
their assessment of NGS-BSA Wilkening et al. determined that although for most phenotypes 
confirmation between replicates was high, some traits were prone to the segregant population 
being taken over by spontaneous mutants (Wilkening et al., 2014); such an occurrence was 
observed within 5-fluorouracil and cantharidin selection in that study. They suggested that their 
use of prolonged growth in drug during the BSA procedure may have contributed to this result.  
Of relevance to the current study the duration of drug treatment was less than half of that used 
by Wilkening et al. (72 h here compared to their 150 h) and furthermore Wilkening et al. used 
drug treatment assays in liquid format which can be susceptible to being overgrown by a single 
mutant. Although the same can occur in agar-based formats, these may be less vulnerable due 
to the fact that the cells are fixed in place and their growth is inhibited due to nutrient 
competition with neighbouring cells.   Performing a replication of the AILs would also have 
given more confidence that the detected QTL did not arise during the long construction 
procedure although that would not be overly expected, as there was no drug selection applied 
during the construction. In particular, replication of Y12×BY cross would have been 
informative because this cross displayed a considerably higher number of QTL than other 
crosses and also there were apparently no allele frequency changes along the entirety of 
chromosome VII under the intermediate-dose ketoconazole treatment. On another point of 
reliability, the very high LOD QTL 2.2 occurred during high-dose treatment but it was 
completely absent during intermediate-dose treatment and repeat determinations may have 
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helped to explain this anomaly. Nevertheless the QTL found here are much more extensive 
than studies published to date and can be further verified through independent methods, thus 
eliminating potential false positives. 
 
6.3. Future directions 
The verification described in the previous section remains the obvious next step for this 
study. Not only would it serve to eliminate false positive QTL hits, but it is also necessary to 
narrow down possible causative genes from an entire QTL locus   to a causative nucleotide 
(quantitative trait nucleotide, QTN) which can be done (Deutschbauer et al., 2005).   
 
The median number of ORFs found within the top ranked set of QTL (as described in 
Section 5.3.6) is 17; theoretically, a QTN (or multiple QTN) could occur within any of those 
ORFs or within intergenic intervals such as in promoter or terminator regions. One step in 
reducing this QTL interval would be to search for variants that are likely to produce a functional 
outcome, such as ones that occur within an ORF or promoter/terminator or variants that may 
cause mutation (Swinnen, Thevelein, et al., 2012). Another approach would be to perform a 
scan of the QTL interval through experimental techniques such as allele swapping or 
hemizygocity analysis (Liti et al., 2012) (Figure 6.1). Allele swapping involves replacing the 
allele of one parent with that of the other and evaluating differences in phenotype.  However, 
allele swapping eliminates strain-specific epistatic interactions that may be required for the 
QTN to exhibit its effect (Sinha et al., 2006) and thus it may not be appropriate, particularly 
since the Y12×BY cross used in this study is likely to exhibit such interactions in its drug 
response. Reciprocal hemizygocity analysis resolves this problem as the functional scan is 
performed in a hybrid background. The basic premise involves making hemizygous deletions 
of either one or the other parental allele and looking for differences in phenotype between the 
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hemizygous hybrids. Potentially the two methods could be combined by performing allele 
swapping in a hybrid background. Once the QTL interval is narrowed down sufficiently, single 
QTN can be verified by site-directed mutagenesis. 
 
Figure 6.1: Methodology for narrowing down the QTL interval and functional verification of QTN. Adapted 
from (Liti et al., 2012).  
 
Another area that remained unexplored in the current study was that of subtelomeric 
variation. Subtelomeres (defined as the region within 30 kb of the end of the chromosome) 
were eliminated from examination due to their high rates of repetitive sequences and genetic 
variability leading to potential error in read mapping (Parts et al., 2011; Treangen & Salzberg, 
2012) in the interest of getting higher confidence QTL. Nevertheless they provide a fertile 
ground for exploration—they frequently harbour non-reference ORFs and copy number 
variants (CNVs), possess an over-representation of missense and frameshift mutations 
compared to the remainder of the genome and play a role in environment-specific gene 
expression and rapid environmental adaptation (Bergström et al., 2014; Brown et al., 2010; Liti 
& Louis, 2005; Liti & Schacherer, 2011; Smith et al., 2011). Furthermore, subtelomeric regions 
were found to have an enrichment of stress-response QTL (Cubillos et al., 2011). The current 
study found at least 19 subtelomeric QTL, which can be explored in greater detail at a later 
point. 
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Because NGS-BSA relied on aligning the segregant population read data to the reference 
S288C genome, there was potential to miss QTL in regions where the SGRP strain had 
structural variation relative to S288C. Previous de novo assembly showed that DBVPG6044, 
L-1374, UWOPS87-2421 and Y12   had 35, 10, 61 and 25 non-reference ORFs respectively in 
addition to various levels of CNVs (Bergström et al., 2014; Liti et al., 2009). One potential 
solution would be to use the de novo assembled genomes of the SGRP strain in each cross and 
repeat the mapping of the segregant population read data to see if any new QTL can be found 
within the non-reference areas. 
 
The identification of QTL regions by BSA could also be further investigated with regard to 
the contribution of the QTL to overall phenotype as well as epistatic interactions between loci. 
Isolating individual segregants from each cross, selectively genotyping them at QTL and 
dissecting the effect of marker genotype to phenotype would allow such an analysis, something 
that could not be done using pooled approaches (Bloom et al., 2013; Ehrenreich et al., 2010; 
Manolio et al., 2009; Wilkening et al., 2014). Estimates of QTL contribution to phenotype 
would provide an estimate of how much of the phenotypic variance can be explained by the 
detected QTL. This would give a reliable indication of whether most or all of the QTL 
responsible for the drug response phenotype in a particular cross have been detected or not. 
Assessment of epistatic interactions would also be fruitful, as the results of Chapter 4 suggested 
that at least the Y12×BY cross was likely to harbour epistatic interactions that contribute to its 
phenotype.  
 
Finally the search for possible candidate genes underlying the drug response phenotype for 
benomyl and ketoconazole (Section 5.3.6) suggested certain genes falling into distinct 
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functional categories—for instance, cell cycle and chromosome division genes contributing to 
benomyl response and mitochondrial function genes or cell wall components for ketoconazole 
response. Assuming such genes are validated in one of the ways described above, further 
functional assays could be undertaken to validate the involvement of those processes in 
response to the respective drugs. Such assays could consist of microscopy investigation with 
fluorescent markers or dyes to investigate the role of these functions in drug response (Hoch et 
al., 2005; Huh et al., 2003; Solaini et al., 2007; Zhang et al., 1997). 
 
6.4. Impact and prospective outcomes of this work 
The current study provides a novel contribution to the literature as the genetic backgrounds 
used here have not been used to study drug response in this level of detail. Y12 was included 
in the association study for ketoconazole response by Strope et al. described in Chapter 5; 
however, the current study has revealed a considerably greater number of QTL because of the 
greater number of segregants used in the current study, which translates to higher detection 
power. Studying additional haplotypes can paint a more complete picture of a phenotype, as it 
allows sampling of new loci that may not have segregated in previous QTL studies Previous 
studies that compared the contributions of genetic background to a phenotype primarily 
focused on selecting parental strains based on genetic diversity instead of phenotypic diversity, 
as was done with the current study (Cubillos et al., 2011; Ehrenreich et al., 2012). The fact that 
the current study found an additional 12 benomyl response QTL even compared to a similarly 
powerful NGS-BSA (Ehrenreich et al., 2012) study supports the fact that the phenotypic 
diversity driven approach is a good one in order to find a rich variety of QTL. Moreover, this 
is the first instance of ketoconazole being studied through such a high-powered technique as 
NGS-BSA. NGS-BSA has been a recent development (Ehrenreich et al., 2010). This means 
that the number of phenotypes explored by this powerful methodology is limited as of the time 
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of this study, although it is continuously increasing (Albert et al., 2014; Clowers et al., 2015; 
Cubillos et al., 2013; Ehrenreich et al., 2012; Parts et al., 2011; Treusch et al., 2015; Yang et 
al., 2013). The increased number of segregants that BSA allows compared to individual 
segregant mapping studies results in considerably more QTL being detected, including minor 
effect QTL (Cubillos et al., 2013; Parts et al., 2011). This is reflected in the fact that the number 
of QTL uncovered for ketoconazole response is much greater than in any previous QTL study 
reported in the literature. 
 
The findings of this thesis have practical application in the clinical setting as it provides 
insight into potential causes of antifungal resistance. Increasing resistance to existing 
antifungals is a growing problem, exacerbated by a lag in the development of novel agents 
(Denning et al., 2015; Kanafani & Perfect, 2008). As ketoconazole is used clinically, the 
findings from this study are directly applicable for development of new combination therapies, 
as described below. Meanwhile, although benomyl is an industrial fungicide whose use has 
been discontinued, the results gained from screening it may still be applicable to other 
antifungals that target microtubules, such as griseofulvin (Odds et al., 2003). Also, the findings 
from this study can be applicable if benomyl or a similar agent is developed further for clinical 
use (Clement et al., 2008; Yenjerla et al., 2009).The identification and confirmation of 
processes involved in off-target effects (for instance confirmation of the recently established 
azole-vacuole link) could lead to combination therapy to improve outcome in cases of drug-
resistant infections (Baddley & Pappas, 2005; Johnson & Perfect, 2007). The fact that the QTL 
mapping has been done in a diploid background makes the results more applicable to general 
eukaryotic cells (Parts et al., 2011) and the common pathogenic fungus Candida albicans 
(Jones et al., 2004). Finally, the more general findings of this thesis suggest that individual 
variation in terms of genetic background can have a significant effect on treatment outcome. 
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Therefore, single-target approaches to drug treatment may be inadequate to achieve optimal 
outcome and a network style treatment approach may present a better alternative (Hopkins, 
2008; Keith et al., 2005). Furthermore, this study indicates that similar genome-wide 
approaches in humans (such as the use of GWAS to elucidate factors that may contribute to 
individual-specific response to medicinal drugs) may be a worthwhile approach to improve 
drug therapy and expand the field of personalised medicine. The system used in the current 
study of yeast strains as models of individuals can furthermore be applied to any human 
therapeutic agents (as long as those agents produce a selectable phenotype in yeast. The yeast 
system can thus be used for simple hypothesis generation to identify QTL and QTN whose 
homologues (if present) can then be tested in human individuals for their contribution to drug 
response. 
 
In summary, this work provided an extensive insight into the factors that can contribute to 
individual strain drug response in S. cerevisiae. This was achieved through the use of the SGRP 
strain collection, which was constructed with the aim of capturing the genotypic diversity of 
the species. The extensive phenotyping studies have provided an in-depth characterisation of 
the variability of antifungal response across the species by drug testing the strains against 
benomyl and ketoconazole. Finally, the application of NGS-BSA concretely revealed the 
genetics of this response and the importance of individual genetic variation in terms of drug 
susceptibility. Overall, this study not only contributed a significant insight into the intellectual 
understanding of what controls phenotypes but also provides practical applications for making 
better medication and antifungal agents. 
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Appendices 
Appendix 7.1 Known variants list 
SGD indels SGD SNPs Ensembl 
BC187 Same as list of SGD indels, 
with the addition of Sigma 
1278b 
SGRP collection 
BY4741 
BY4742 
CEN.PK 
D273 
DBVPG6044 
FL100 
FY1679 
JK9 
K11 
L1528 
RM11_1A 
RedStar 
SEY6210 
SK1 
UWOPS05-217-3 
W303 
X2180 
Y55 
YJM339 
YPH499 
YPS128 
YPS163 
YS9 
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Appendix 7.2 Dose response curves 
Brown boxes are place holders for strains that were not represented in a particular mating 
type in haploid format. 
 
Benomyl initial screen—serial spot dilution; diploid MATa/α SGRP collection 
 
 BY4743 (control) 
 SGRP strain (as named) 
 
 
    
MIC (BY4743) = 125 µM 
MIC (273614N) = 350 µM 
MIC (BY4743) = 125 µM 
MIC (322134S) = ND 
MIC (BY4743) = 125 µM 
MIC (378604X) = 200 µM 
MIC (BY4743) = 125 µM 
MIC (BC187) = 200 µM 
    
MIC (BY4743) = 125 µM 
MIC (DBVPG1106) = 200 
µM 
MIC (BY4743) = 125 µM 
MIC (DBVPG1373) = 200 
µM 
MIC (BY4743) = 125 µM 
MIC (DBVPG1788) = 125 
µM 
MIC (BY4743) = 125 µM 
MIC (DBVPG1853) = 350 
µM 
 
   
MIC (BY4743) = 125 µM 
MIC (DBVPG6040) = 125 
µM 
MIC (BY4743) = 125 µM 
MIC (DBVPG6044) = ND 
MIC (BY4743) = 125 µM 
MIC (DBVPG6765) = 200 
µM 
MIC (BY4743) = 125 µM 
MIC (K11) = 350 µM 
 
   
MIC (BY4743) = 125 µM 
MIC (L-1374) = 87.5 µM 
MIC (BY4743) = 125 µM 
MIC (L-1528) = ND 
MIC (BY4743) = 125 µM 
MIC (NCYC110) = ND 
MIC (BY4743) = 125 µM 
MIC (SK1) = 350 µM 
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MIC (BY4743) = 125 µM 
MIC (UWOPS03-461.4) = 
350 µM 
MIC (BY4743) = 125 µM 
MIC (UWOPS05-217.3) = 
350 µM 
MIC (BY4743) = 125 µM 
MIC (UWOPS05-227.2) = 
350 µM 
MIC (BY4743) = 125 µM 
MIC (UWOPS83-787.3) = 
350 µM 
  
  
MIC (BY4743) = 125 µM 
MIC (UWOPS87-2421) = 
350 µM 
MIC (BY4743) = 125 µM 
MIC (W303) = 20 µM 
MIC (BY4743) = 125 µM 
MIC (Y9) = 200 µM 
MIC (BY4743) = 125 µM 
MIC (Y12) = 200 µM 
 
 
  
MIC (BY4743) = 125 µM 
MIC (Y55) = 350 µM 
MIC (BY4743) = 125 µM 
MIC (YIIc17_E5) = 350 µM 
MIC (BY4743) = 125 µM 
MIC (YJM975) = 125 µM 
MIC (BY4743) = 125 µM 
MIC (YJM978) = 200 µM 
    
MIC (BY4743) = 125 µM 
MIC (YJM981) = 200 µM 
MIC (BY4743) = 125 µM 
MIC (YPS128) = ND 
MIC (BY4743) = 125 µM 
MIC (YPS606) = ND 
MIC (BY4743) = 125 µM 
MIC (YS4) = 125 µM 
 
   
MIC (BY4743) = 125 µM 
MIC (YS9) = 200 µM 
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Benomyl confirmation screen—serial spot dilution assay; haploid SGRP collection 
 
 BY4741 or BY4742 (control) 
 SGRP strain (as named) 
 
MATa MATα MATa MATα 
  
 
 
MIC (BY4741) = 200 µM 
MIC (273614N) = 400 µM 
MIC (BY4742) = 200 µM 
MIC (273614N) = 300 µM 
 MIC (BY4742) = 200 µM 
MIC (378604X) = 200 µM 
    
MIC (BY4741) = 300 µM 
MIC (BC187) = 200 µM 
MIC (BY4742) = 300 µM 
MIC (BC187) = 300 µM 
MIC (BY4741) = 200 µM 
MIC (DBVPG1106) = 400 
µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG1106) = 400 
µM 
    
MIC (BY4741) = 300 µM 
MIC (DBVPG1373) = 300 
µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG1373) = 300 
µM 
MIC (BY4741) = 300 µM 
MIC (DBVPG6044) = ND 
MIC (BY4742) = 200 µM 
MIC (DBVPG6044) = ND 
    
MIC (BY4741) = 300 µM 
MIC (DBVPG6765) = 200 µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG6765) = 300 µM 
MIC (BY4741) = 300 µM 
MIC (L-1374) = 200 µM 
MIC (BY4742) = 300 µM 
MIC (L-1374) = 200 µM 
 
 
  
MIC (BY4741) = 200 µM 
MIC (L-1528) = 400 µM 
MIC (BY4742) = 300 µM 
MIC (L-1528) = 400 µM 
MIC (BY4741) = 200 µM 
MIC (NCYC110) = ND 
MIC (BY4742) = 200 µM 
MIC (NCYC110) = ND 
  
  
MIC (BY4741) = 200 µM 
MIC (SK1) = 400 µM 
MIC (BY4742) = 300 µM 
MIC (SK1) = 400 µM 
MIC (BY4741) = 300 µM 
MIC (UWOPS03-461.4) = 400 
µM 
MIC (BY4742) = 200 µM 
MIC (UWOPS03-461.4) = 400 
µM 
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MIC (BY4741) = 300 µM 
MIC (UWOPS05-217.3) = ND 
MIC (BY4742) = 200 µM 
MIC (UWOPS05-217.3) = ND 
MIC (BY4741) = 300 µM 
MIC (UWOPS05-227.2) = 400 
µM 
MIC (BY4742) = 200 µM 
MIC (UWOPS05-227.2) = 400 
µM 
    
MIC (BY4741) = 200 µM 
MIC (UWOPS83-787.3) = 400 
µM 
MIC (BY4742) = 300 µM 
MIC (UWOPS83-787.3) = ND 
MIC (BY4741) = 300 µM 
MIC (UWOPS87-2421) = ND 
MIC (BY4742) = 200 µM 
MIC (UWOPS87-2421) = ND 
 
 
  
MIC (BY4741) = 300 µM 
MIC (W303) = 100 µM 
 MIC (BY4741) = 300 µM 
MIC (Y12) = 400 µM 
MIC (BY4742) = 300 µM 
MIC (Y12) = 400 µM 
    
MIC (BY4741) = 200 µM 
MIC (Y55) = 400 µM 
MIC (BY4742) = 200 µM 
MIC (Y55) = 400 µM 
MIC (BY4741) = 200 µM 
MIC (YIIc17_E5) = 100 µM 
MIC (BY4742) = 300 µM 
MIC (YIIc17_E5) = 400 µM 
    
MIC (BY4741) = 300 µM 
MIC (YJM978) = 400 µM 
MIC (BY4742) = 200 µM 
MIC (YJM978) = 300 µM 
MIC (BY4741) = 300 µM 
MIC (YJM981) = 400 µM 
MIC (BY4742) = 200 µM 
MIC (YJM981) = 400 µM 
    
MIC (BY4741) = 200 µM 
MIC (YPS128) = ND 
MIC (BY4742) = 300 µM 
MIC (YPS128) = ND 
MIC (BY4741) = 200 µM 
MIC (YPS606) = ND 
MIC (BY4742) = 300 µM 
MIC (YPS606) = ND 
 
   
MIC (BY4741) = 300 µM 
MIC (YS9) = 200 µM 
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Benomyl screen—pinning assay 384 colony format; haploid SGRP collection 
 BY4741 or BY4742 (control) 
 SGRP strain (as named) 
 
MATa MATα MATa MATα 
  
 
 
MIC (BY4741) = 300 µM 
MIC (273614N) = 300 µM 
MIC (BY4742) = 300 µM 
MIC (273614N) = 300 µM 
 MIC (BY4742) = 300 µM 
MIC (378604X) = 200 µM 
    
MIC (BY4741) = 300 µM 
MIC (BC187) = 200 µM 
MIC (BY4742) = 300 µM 
MIC (BC187) = 200 µM 
MIC (BY4741) = 300 µM 
MIC (DBVPG1106) = 300 
µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG1106) = 300 
µM 
    
MIC (BY4741) = 300 µM 
MIC (DBVPG1373) = 300 
µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG1373) = 300 
µM 
MIC (BY4741) = 300 µM 
MIC (DBVPG6044) = 400 
µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG6044) = 400 
µM 
    
MIC (BY4741) = 300 µM 
MIC (DBVPG6765) = 300 
µM 
MIC (BY4742) = 300 µM 
MIC (DBVPG6765) = 250 
µM 
MIC (BY4741) = 300 µM 
MIC (L-1374) = 200 µM 
MIC (BY4742) = 300 µM 
MIC (L-1374) = 150 µM 
    
MIC (BY4741) = 300 µM 
MIC (L-1528) = 350 µM 
MIC (BY4742) = 300 µM 
MIC (L-1528) = 400 µM 
MIC (BY4741) = 300 µM 
MIC (NCYC110) = ND 
MIC (BY4742) = 300 µM 
MIC (NCYC110) = ND 
    
MIC (BY4741) = 300 µM 
MIC (SK1) = 350 µM 
MIC (BY4742) = 300 µM 
MIC (SK1) = 300 µM 
MIC (BY4741) = 300 µM 
MIC (UWOPS03-461.4) = 
400 µM 
MIC (BY4742) = 300 µM 
MIC (UWOPS03-461.4) = 
300 µM 
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MIC (BY4741) = 300 µM 
MIC (UWOPS05-217.3) = 
400 µM 
MIC (BY4742) = 300 µM 
MIC (UWOPS05-217.3) = 
400 µM 
MIC (BY4741) = 300 µM 
MIC (UWOPS05-227.2) = 
400 µM 
MIC (BY4742) = 300 µM 
MIC (UWOPS05-227.2) = 
400 µM 
    
MIC (BY4741) = 300 µM 
MIC (UWOPS83-787-.3) = 
400 µM 
MIC (BY4742) = 300 µM 
MIC (UWOPS83-787.3) = 
400 µM 
MIC (BY4741) = 300 µM 
MIC (UWOPS87-2421)= ND 
MIC (BY4742) = 300 µM 
MIC (UWOPS87-2421) = 
ND 
 
 
  
MIC (BY4741) = 300 µM 
MIC (W303) = 150 µM 
 MIC (BY4741) = 300 µM 
MIC (Y12) = 300 µM 
MIC (BY4742) = 300 µM 
MIC (Y12) = 250 µM 
    
MIC (BY4741) = 300 µM 
MIC (Y55) = 400 µM 
MIC (BY4742) = 300 µM 
MIC (Y55) = 350 µM 
MIC (BY4741) = 300 µM 
MIC (YIIc17_E5) = 75 µM 
MIC (BY4742) = 300 µM 
MIC (YIIc17_E5) = 400 µM 
    
MIC (BY4741) = 300 µM 
MIC (YJM975) = 250 µM 
MIC (BY4742) = 300 µM 
MIC (YJM975) = 200 µM 
MIC (BY4741) = 300 µM 
MIC (YJM978) = 300 µM 
MIC (BY4742) = 300 µM 
MIC (YJM978) = 300 µM 
    
MIC (BY4741) = 300 µM 
MIC (YJM981) = 300 µM 
MIC (BY4742) = 300 µM 
MIC (YJM981) = 250 µM 
MIC (BY4741) = 300 µM 
MIC (YPS128) = 400 µM 
MIC (BY4742) = 300 µM 
MIC (YPS128) = 300 µM 
   
 
MIC (BY4741) = 300 µM 
MIC (YPS606) = 400 µM 
MIC (BY4742) = 300 µM 
MIC (YPS606) = 300 µM 
MIC (BY4741) = 300 µM 
MIC (YS9) = 200 µM 
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Ketoconazole initial screen—serial spot dilution; diploid MATa/α SGRP collection 
 
 BY4743 (control) 
 SGRP strain (as named) 
 
 
 
   
MIC (BY4743) = 120 µM 
MIC (273614N) = 80 µM 
MIC (BY4743) = 120 µM 
MIC (322134S) = ND 
MIC (BY4743) = 120 µM 
MIC (378604X) = 55 µM 
MIC (BY4743) = 120 µM 
MIC (BC187) = 120 µM 
 
  
 
MIC (BY4743) = 120 µM 
MIC (DBVPG1106) = 80 µM 
MIC (BY4743) = 120 µM 
MIC (DBVPG1373) = 55 µM 
MIC (BY4743) = 120 µM 
MIC (DBVPG1788) = ND 
MIC (BY4743) = 120 µM 
MIC (DBVPG1853) = 55 
µM 
 
 
  
 
MIC (BY4743) = 120 µM 
MIC (DBVPG6040) = 55 µM 
MIC (BY4743) = 120 µM 
MIC (DBVPG6044) = ND 
MIC (BY4743) = 120 µM 
MIC (DBVPG6765) = 160 
µM 
MIC (BY4743) = 120 µM 
MIC (K11) = 55 µM 
 
  
 
MIC (BY4743) = 120 µM 
MIC (L-1374) = ND 
MIC (BY4743) = 120µM 
MIC (L-1528) = ND 
MIC (BY4743) = 120 µM 
MIC (NCYC110) = ND 
MIC (BY4743) = 120 µM 
MIC (SK1) = 55 µM 
    
MIC (BY4743) = 120 µM 
MIC (UWOPS03-461.4) = 55 
µM 
MIC (BY4743) = 120 µM 
MIC (UWOPS05-217.3) = 55 
µM 
MIC (BY4743) = 120 µM 
MIC (UWOPS05-227.2) = 
55 µM 
MIC (BY4743) = 120 µM 
MIC (UWOPS83-787.3) = 
80 µM 
  
 
 
MIC (BY4743) = 120 µM MIC (BY4743) = 120 µM 
MIC (W303) = 80 µM 
MIC (BY4743) = 120 µM 
MIC (Y9) = 55 µM 
MIC (BY4743) = 120 µM 
MIC (Y12) = 55 µM 
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MIC (UWOPS87-2421) = 80 
µM 
  
 
 
MIC (BY4743) = 120 µM 
MIC (Y55) = 120 µM 
MIC (BY4743) = 120 µM 
MIC (YIIc17_E5) = ND 
MIC (BY4743) = 120 µM 
MIC (YJM975) = ND 
MIC (BY4743) = 120 µM 
MIC (YJM978) = ND 
 
   
MIC (BY4743) = 120 µM 
MIC (YJM981) = 120 µM 
MIC (BY4743) = 120 µM 
MIC (YPS128) = 80 µM 
MIC (BY4743) = 120 µM 
MIC (YPS606) = 55 µM 
MIC (BY4743) = 120 µM 
MIC (YS4) = 80 µM 
 
   
MIC (BY4743) = 120 µM 
MIC (YS9) = 120 µM 
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Ketoconazole confirmation screen—serial spot dilution assay; haploid SGRP collection 
 BY4741 or BY4742 (control) 
 SGRP strain (as named) 
 
MATa MATα MATa MATα 
  
 
 
MIC (BY4741) = 80 µM 
MIC (273614N) = 100 µM 
MIC (BY4742) = 80 µM 
MIC (273614N) = 40 µM 
 MIC (BY4742) = 100 µM 
MIC (378604X) = 60 µM 
    
MIC (BY4741) = 60 µM 
MIC (DBVPG1106) = 60 µM 
MIC (BY4742) = 100 µM 
MIC (DBVPG1106) = 60 µM 
MIC (BY4741) = 60 µM 
MIC (DBVPG1373) = 80 µM 
MIC (BY4742) = 100 µM 
MIC (DBVPG1373) = 100 
µM 
    
MIC (BY4741) = 60 µM 
MIC (DBVPG6044) = 160 
µM 
MIC (BY4742) = 60 µM 
MIC (DBVPG6044) = 160 
µM 
MIC (BY4741) = 100 µM 
MIC (DBVPG6765) = ND 
MIC (BY4742) = 100 µM 
MIC (DBVPG6765) = ND 
 
 
  
MIC (BY4741) = 100 µM 
MIC (L-1374) = 100 µM 
MIC (BY4742) = 100 µM 
MIC (L-1374) = 100 µM 
MIC (BY4741) = 100 µM 
MIC (L-1528) = ND 
MIC (BY4742) = 100 µM 
MIC (L-1528) = ND 
  
 
 
MIC (BY4741) = 100 µM 
MIC (NCYC110) = 160 µM 
MIC (BY4742) = 100 µM 
MIC (NCYC110) = ND 
MIC (BY4741) = 100 µM 
MIC (SK1) = 40 µM 
MIC (BY4742) = 100 µM 
MIC (SK1) = 20 µM 
    
MIC (BY4741) = 80 µM 
MIC (UWOPS03-461.4) = 20 
µM 
MIC (BY4742) = 80 µM 
MIC (UWOPS03-461.4) = 20 
µM 
MIC (BY4741) = 80 µM 
MIC (UWOPS05-217.3) = 20 
µM 
MIC (BY4742) = 80 µM 
MIC (UWOPS05-217.3) = 20 
µM 
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MIC (BY4741) = 80 µM 
MIC (UWOPS05-227.2) = 20 
µM 
MIC (BY4742) = 80 µM 
MIC (UWOPS05-227.2) = 20 
µM 
MIC (BY4741) = 80 µM 
MIC (UWOPS83-787.3) = 20 
µM 
MIC (BY4742) = 80 µM 
MIC (UWOPS83-787.3) = 20 
µM 
   
 
MIC (BY4741) = 80 µM 
MIC (UWOPS87-2421) = 40 
µM 
MIC (BY4742) = 60 µM 
MIC (UWOPS87-2421) = 40 
µM 
MIC (BY4741) = ND 
MIC (W303) = 15 µM 
 
    
MIC (BY4741) = 80 µM 
MIC (Y12) = 40 µM 
MIC (BY4742) = 100 µM 
MIC (Y12) = 20 µM 
MIC (BY4741) = 60 µM 
MIC (Y55) = 100 µM 
MIC (BY4742) = 60 µM 
MIC (Y55) = 120 µM 
    
MIC (BY4741) = 120 µM 
MIC (YIIc17_E5) = 120 µM 
MIC (BY4742) = 120 µM 
MIC (YIIc17_E5) = 160 µM 
MIC (BY4741) = 60 µM 
MIC (YJM975) = ND 
MIC (BY4742) = 60 µM 
MIC (YJM975) = 60 µM 
    
MIC (BY4741) = 100 µM 
MIC (YJM978) = 20 µM 
MIC (BY4742) = 100 µM 
MIC (YJM978) = 20 µM 
MIC (BY4741) = 80 µM 
MIC (YPS128) = 40 µM 
MIC (BY4742) = 60 µM 
MIC (YPS128) = 40 µM 
  
  
MIC (BY4741) = 80 µM 
MIC (YPS606) = 40 M 
MIC (BY4742) = 60 µM 
MIC (YPS606) = 40 M 
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Ketoconazole screen— pinning assay 384 colony format; haploid SGRP collection 
 
 BY4741 or BY4742 (control) 
 SGRP strain (as named) 
 
MATa MATα MATa MATα 
  
 
 
MIC (BY4741) = 160 µM 
MIC (273614N) = 100 µM 
MIC (BY4742) = 200 µM 
MIC (273614N) = 100 µM 
 MIC (BY4742) = 200 µM 
MIC (378604X) = 100 µM 
    
MIC (BY4741) = 160  µM 
MIC (BC187) = 130 µM 
MIC (BY4742) = 200 µM 
MIC (BC187) = 130 µM 
MIC (BY4741) = 160 µM 
MIC (DBVPG1106) = 130 
µM 
MIC (BY4742) = 200 µM 
MIC (DBVPG1106) = 130 
µM 
 
   
MIC (BY4741) = 160 µM 
MIC (DBVPG1373) = 300 
µM 
MIC (BY4742) = 200 µM 
MIC (DBVPG1373) = 300 
µM 
MIC (BY4741) = 160 µM 
MIC (DBVPG6044) = ND 
MIC (BY4742) = 200 µM 
MIC (DBVPG6044) = ND 
    
MIC (BY4741) = 160 µM 
MIC (DBVPG6765) = 160 
µM 
MIC (BY4742) = 200 µM 
MIC (DBVPG6765) = 160 
µM 
MIC (BY4741) = 160 µM 
MIC (L-1374) = 230 µM 
MIC (BY4742) = 200 µM 
MIC (L-1374) = 230 µM 
    
MIC (BY4741) = 160 µM 
MIC (L-1528) = 200 µM 
MIC (BY4742) = 200 µM 
MIC (L-1528) = 200 µM 
MIC (BY4741) = 160 µM 
MIC (NCYC110) = ND 
MIC (BY4742) = 200 µM 
MIC (NCYC110) = ND 
    
MIC (BY4741) = 160 µM 
MIC (SK1) = 200 µM 
MIC (BY4742) = 200 µM 
MIC (SK1) = 200 µM 
MIC (BY4741) = 160 µM MIC (BY4742) = 200 µM 
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MIC (UWOPS03-461.4) = 80 
µM 
MIC (UWOPS03-461.4) = 80 
µM 
    
MIC (BY4741) = 160 µM 
MIC (UWOPS05-217.3) = 80 
µM 
MIC (BY4742) = 200 µM 
MIC (UWOPS05-217.3) = 80 
µM 
MIC (BY4741) = 160 µM 
MIC (UWOPS05-227.2) = 60 
µM 
MIC (BY4742) = 200 µM 
MIC (UWOPS05-227.2) = 60 
µM 
    
MIC (BY4741) = 160 µM 
MIC (UWOPS83-787-.3) = 
100 µM 
MIC (BY4742) = 200 µM 
MIC (UWOPS83-787.3) = 80 
µM 
MIC (BY4741) = 160 µM 
MIC (UWOPS87-2421)= 100 
µM 
MIC (BY4742) = 200 µM 
MIC (UWOPS87-2421) = 
130 µM 
 
 
  
MIC (BY4741) = 160 µM 
MIC (W303) = 80 µM 
 MIC (BY4741) = 160 µM 
MIC (Y12) = 100 µM 
MIC (BY4742) = 200 µM 
MIC (Y12) = 100 µM 
    
MIC (BY4741) = 160 µM 
MIC (Y55) = 200 µM 
MIC (BY4742) = 200 µM 
MIC (Y55) = 260 µM 
MIC (BY4741) = 160 µM 
MIC (YIIc17_E5) = ND 
MIC (BY4742) = 200 µM 
MIC (YIIc17_E5) = 130 µM 
    
MIC (BY4741) = 160 µM 
MIC (YJM975) = 260 µM 
MIC (BY4742) = 200 µM 
MIC (YJM975) = 160 µM 
MIC (BY4741) = 160 µM 
MIC (YJM978) = 200 µM 
MIC (BY4742) = 200 µM 
MIC (YJM978) = 200 µM 
    
MIC (BY4741) = 160 µM 
MIC (YJM981) = 160 µM 
MIC (BY4742) = 200 µM 
MIC (YJM981) = 160 µM 
MIC (BY4741) = 160 µM 
MIC (YPS128) = 160 µM 
MIC (BY4742) = 200 µM 
MIC (YPS128) = 130 µM 
   
 
MIC (BY4741) = 160 µM 
MIC (YPS606) = 160 µM 
MIC (BY4742) = 200 µM 
MIC (YPS606) = 160 µM 
MIC (BY4741) = 160 µM 
MIC (YS9) = 130 µM 
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Appendix 7.3 Summary results of atorvastatin response screening of 
SGRP collection 
Brown boxes are place holders for strains that were not represented in the testing (either 
because they were not represented in a particular mating type in haploid format in the SGRP 
collection or they were not tested in the specified round of dose responses due to not giving a 
phenotype in the previous round). 
MATa MATα 
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273614N + + + + + + - 273614N + + + + + +  + + + 
BC187 - + + + + BC187 - + + + + 
DBVPG1106 nil  + DBVPG1106 nil  + + + 
DBVPG1373 + + + + + + nil DBVPG1373 + + + + + + + + + 
DBVPG6044 + + + + + + + + + DBVPG6044 + + + + + + + + + 
DBVPG6765 + nil - DBVPG6765 + nil +* 
L-1374 + + + + + + - L-1374 + + + + + + + + + 
L-1528 + + + + + + +* L-1528 + + + + + + nil 
NCYC110 + + + + + + nil NCYC110 + + + + + + + 
SK1 + + + + + + +* SK1 + + + + + + +* 
UWOPS03-461.4 + + + + + + nil UWOPS03-461.4 + + + + + + + 
UWOPS05-217.3 + + + + + + nil UWOPS05-217.3 + + + + + + + 
UWOPS05-227.2 + + + + + + nil UWOPS05-227.2 + + + + + + + 
UWOPS83-787.3 + + + + + + +* UWOPS83-787.3 + + + + + + + 
UWOPS87-2421 + + + + + + +* UWOPS87-2421 + + + + + + nil 
Y12 +  - Y12 + + + + +* 
Y55 + + + + + + + + + Y55 + + + + + + + + + 
YIIc17_E5 + + + + + + + YIIc17_E5 + + + nil + + + 
YJM975 + + + nil +* YJM975 + + + + + + +* 
YJM978 + + + + + + +* YJM978 + + + + + + +* 
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YJM981 + + + + + + - YJM981 + + + + + + +* 
YPS128 + + + + + + nil YPS128 + + + + + + nil 
YPS606 + + + + + + - YPS606 + + + + + + + 
W303 - - - - 378604X + +  + - - - 
YS9 nil  - -  
Represented as diploids only 
322134S + + +  
DBVPG1788 + + + 
DBVPG1853 nil 
DBVPG6040 + + + 
K11 + + + 
Y9 + 
YS4 - 
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Appendix 7.4 AIL segregant pinning with a monogenic trait (clonNAT 
resistance) 
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Appendix 7.5 QTL intervals 
 
UWOPS87-2421×BY, Benomyl treatment intermediate dose (45 µM) 
 
 
 
 
 
 
 
 
 
 
 
UWOPS87-2421×BY, Benomyl treatment high dose (80 µM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Start End Max LOD 
QTL1.1 36,200 151,500 8.59 
QTL 4.1 500,100 549,400 7.33 
QTL 4.2 828,600 843,500 6.34 
QTL 5.1 364,800 405,200 7.43 
QTL 7.1 72,800 93,900 7.13 
QTL 14.1 259,800 298,500 29.03 
QTL 15.1 226,600 253,300 19.12 
QTL 15.2 631,000 659,800 31.28 
QTL 15.3 745,000 829,800 13.91 
 Start End Max LOD 
QTL1.1 35,300 74,700 7.62 
QTL2.1 38,600 62,900 4.27 
QTL2.2 109,900 178,500 4.23 
QTL2.3 520,400 527,900 3.82 
QTL 3.1 14,700 39,700 4.48 
QTL 4.1 503,300 550,900 12.70 
QTL 4.2 1,188,700 1,218,500 4.13 
QTL 5.1 348,200 389,600 10.74 
QTL 7.1 66,900 117,400 5.86 
QTL 10.1 344,900 373,900 4.28 
QTL 10.2 647,700 669,000 4.62 
QTL 12.1 343,100 370,400 25.63 
QTL 14.1 260,100 313,100 19.29 
QTL 15.1 231,800 253,500 35.14 
QTL 15.2 637,200 659,000 67.97 
QTL 15.3 765,200 823,200 18.29 
QTL 15.4 975,300 1,036,300 8.74 
QTL 16.1 876,900 907,400 4.84 
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L-1374×BY, Benomyl treatment intermediate dose (30 µM) 
 
 
 
 
 
L-1374×BY, Benomyl treatment high dose (50 µM) 
 
 
 
 
 
 
 
DBVPG6044×BY, Ketoconazole treatment intermediate dose (25 µM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Start End Max LOD 
QTL1.1 32,700 59,900 14.18 
QTL 5.1 156,100 172,400 47.36 
QTL 15.1 221,600 269,900 7.86 
 Start End Max LOD 
QTL1.1 34,600 60,300 15.66 
QTL 5.1 156,800 171,300 60.08 
QTL 5.2 342,500 388,700 11.85 
QTL 14.1 235,100 292,500 9.47 
QTL 15.1 224,700 260,900 18.95 
 Start End Max LOD 
QTL 2.1 282,700 374,700 10.68 
QTL 2.2 526,900 561,300 29.86 
QTL 4.1 457,600 535,900 12.53 
QTL 4.2 1,028,400 1,091,800 7.14 
QTL 4.3 1,417,800 1,453,500 14.41 
QTL 7.1 178,800 185,600 18.96 
QTL 7.2 287,200 361,600 9.40 
QTL 8.1 88,400 139,700 8.60 
QTL 13.1 104,600 141,700 17.90 
QTL 15.1 928,600 965,600 6.21 
QTL 16.1 636,400 683,900 7.58 
Appendices  
 
216 
 
 
 
DBVPG6044×BY, Ketoconazole treatment high dose (65 µM) 
 
 
 
 
 
 
 
 
 
 
 
Y12×BY, Ketoconazole treatment intermediate dose (11.5 µM) 
 
 Start End Max LOD 
QTL2.1.a 284,000 285,700 6.43 
QTL2.1.b 321,500 379,400 7.18 
QTL2.2 532,600 565,300 25.21 
QTL 4.1a 438,800 488,100 7.53 
QTL 4.1b 488,200 535,600 8.16 
QTL 4.2 1,422,400 1,454,900 7.35 
QTL 10.1 285,300 340,600 7.94 
QTL 12.1 422,600 504,700 7.64 
QTL 15.1 312,100 336,000 6.80 
QTL 15.2 773,400 780,200 18.75 
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 Start End Max LOD 
QTL1.1 33,600 54,000 15.17 
QTL1.2 102,400 150,400 4.28 
QTL2.1 28,700 78,500 25.94 
QTL2.2 217,900 275,600 299.00 
QTL2.3 501,100 533,000 48.70 
QTL 3.1 103,200 147,000 8.63 
QTL 3.2 262,900 294,700 17.75 
QTL 4.1 243,500 298,100 27.51 
QTL 4.2 400,400 522,300 13.21 
QTL 4.3 597,400 671,400 4.71 
QTL 4.4 879,600 1,004,800 4.74 
QTL 4.5 1,057,900 1,101,700 13.66 
QTL 4.6 1,201,700 1,244,500 26.46 
QTL 4.7 1,338,200 1,394,300 21.63 
QTL 5.1 130,300 153,400 93.10 
QTL 5.2 349,400 408,200 20.16 
QTL 6.1 32,800 96,200 22.03 
QTL 6.2 110,100 151,800 18.41 
QTL 6.3 192,500 220,500 11.98 
QTL 7.1 128,200 166,700 19.28 
QTL 7.2 220,600 295,000 9.97 
QTL 7.3 356,700 409,200 6.84 
QTL 7.4 502,100 527,100 3.36 
QTL 7.5 784,500 823,900 48.37 
QTL 7.6 946,600 990,300 11.04 
QTL 7.7 990,400 1,041,300 13.19 
QTL 8.1 116,400 138,500 41.43 
QTL 8.2 183,000 211,000 19.20 
QTL 8.3 343,400 400,300 17.61 
QTL 8.4 470,200 516,300 14.56 
QTL 9.1 148,600 175,600 65.37 
QTL 9.2 291,600 306,400 3.21 
QTL 10.1 176,000 208,700 16.32 
QTL 10.2 272,500 311,300 3.74 
QTL 10.3  389,400 460,500 13.22 
QTL 11.1 326,600 372,500 24.19 
QTL 11.2 532,900 569,600 12.54 
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Y12×BY, Ketoconazole treatment high dose (15 µM) 
 
QTL 12.1 114,300 197,700 5.24 
QTL 12.2 447,200 489,800 29.50 
QTL 12.3 545,100 601,300 21.13 
QTL 12.4 661,000 674,300 7.87 
QTL 12.5 820,000 889,400 21.26 
QTL 13.1 115,800 202,300 40.02 
QTL 13.2 401,000 446,100 20.62 
QTL 13.3 477,100 557,900 15.11 
QTL 13.4 789,900 814,900 12.18 
QTL 14.1 100,000 138,700 11.28 
QTL 14.2 224,500 372,400 15.54 
QTL 14.3 510,900 582,900 16.15 
QTL 14.4 715,200 740,200 30.97 
QTL 15.1 69,900 121,600 8.99 
QTL 15.2 164,800 211,900 4.40 
QTL 15.3 270,800 305,300 19.46 
QTL 15.4 409,800 431,200 103.74 
QTL 15.5 705,200 780,300 13.87 
QTL 15.6 936,800 1,045,000 54.92 
QTL 16.1 161,900 192,900 29.70 
QTL 16.2 324,400 381,700 12.76 
QTL 16.3 544,000 579,500 58.23 
QTL 16.4 684,700 714,200 4.47 
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 Start End Max LOD 
QTL1.1 42,700 52,800 31.29 
QTL 2.1 21,300 84,000 13.32 
QTL 2.2 302,600 325,500 41.72 
QTL 2.3 486,400 524,900 50.04 
QTL 3.1 273,800 300,200 25.49 
QTL 4.1 186,500 368,000 8.96 
QTL 4.2 615,600 665,500 7.67 
QTL 4.3 1,217,500 1,262,800 6.27 
QTL 4.4 1,267,300 1,466,700 13.38 
QTL 5.1 127,200 156,300 76.49 
QTL 5.2 335,000 407,800 20.58 
QTL 6.1 41,600 111,000 16.14 
QTL 8.1 117,800 145,500 30.49 
QTL 8.2 181,200 213,000 17.59 
QTL 8.3 358,700 453,700 16.13 
QTL 8.4 495,700 521,900 34.48 
QTL 9.1 124,400 177,000 24.62 
QTL 10.1 178,000 215,000 11.82 
QTL 10.2.a 352,100 423,000 9.94 
QTL 10.2.b 423,100 509,100 11.05 
QTL 11.1 154,800 238,300 9.45 
QTL 11.2 249,500 388,300 8.21 
QTL 11.3 535,300 563,500 16.03 
QTL 12.1 292,400 485,000 22.90 
QTL 12.2 569,000 605,100 21.39 
QTL 12.3 658,400 672,800 10.43 
QTL 12.4 871,300 1,013,700 12.09 
QTL 13.1 53,900 168,500 25.22 
QTL 13.2 793,500 813,200 17.61 
QTL 14.1 95,300 157,600 8.49 
QTL 14.2 518,900 621,700 7.96 
QTL 14.3 697,500 745,400 15.34 
QTL 15.1 276,500 297,400 48.87 
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QTL 15.2 401,500 423,000 61.99 
QTL 15.3 675,200 732,500 6.86 
QTL 15.4 844,800 932,300 9.12 
QTL 15.5 951,300 991,400 12.83 
QTL 16.1 175,000 207,200 28.75 
QTL 16.2 508,700 588,900 20.28 
QTL 16.3 680,700 699,900 15.71 
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Appendix 7.6 MULTIPOOL raw output—allele frequencies at individual 
markers and LOD scores 
 
Left-hand y-axis of each graph—relative allele frequency of markers used in NGS-BSA 
(blue crosses—control pool markers; red crosses—drug treated pool markers). The parent 
whose allele frequency is described on the axis is specified for each cross. The overall allele 
frequency of all the markers is given by the orange/green line on each graph. This frequency 
calculation is automatically generated by MULTIPOOL; however, because it makes no 
distinction between the control and the drug pools, it should be disregarded. 
 
Right-hand y-axis of each graph—LOD score calculated by MULTIPOOL based in the 
differential allele frequencies of markers at a given locus between the control and the drug-
treated pool. LOD score is described by the green lone on each graph. 
 
Grey regions denote the area of the QTL peak as determined by MULTIPOOL. These should 
be disregarded, as QTL calling was instead performed manually. This is due to the limitation 
imposed by MULTIPOOL in calling only a maximum of one QTL per chromosome. 
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UWOPS87-2421×BY intermediate-dose benomyl treatment (45 µM). 
“Allele frequency” refers to BY allele. 
ChrI ChrII 
  
ChrIII ChrIV 
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UWOPS87-2421×BY high-dose benomyl treatment (80 µM). 
“Allele frequency” refers to BY allele. 
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L-1374×BY intermediate-dose benomyl treatment (30 µM). 
“Allele frequency” refers to L-1374 allele. 
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L-1374×BY high-dose benomyl treatment (50 µM). 
“Allele frequency” refers to L-1374 allele. 
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DBVPG6044×BY intermediate-dose ketoconazole treatment (25 µM). 
“Allele frequency” refers to BY allele. 
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DBVPG6044×BY high-dose ketoconazole treatment (65 µM). 
“Allele frequency” refers to BY allele. 
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Y12×BY intermediate-dose ketoconazole treatment (11.5 µM). 
“Allele frequency” refers to Y12 allele. 
ChrI ChrII 
  
ChrIII ChrIV 
  
ChrV ChrVI 
  
ChrVII ChrVIII 
Appendices 
 
241 
 
  
ChrIX ChrX 
  
ChrXI ChrXII 
  
ChrXIII ChrXIV 
Appendices  
 
242 
 
  
ChrXV ChrXVI 
  
 
  
Appendices 
 
243 
 
Y12×BY high-dose ketoconazole treatment (15 µM). 
“Allele frequency” refers to Y12 allele. 
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